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Abstract 
 
Introduction 
 
Dry eye (DE) disease is characterized by symptoms including, but not limited to, ocular stinging, burning, 
and tearing. The symptoms can range from being mildly irritating, to severely debilitating and negatively 
impacting quality of life. The impairment of the tear film, lacrimal functional unit, and meibomian glands 
(MGs) causes desiccation of the ocular surface, which in turn promotes and exacerbates inflammation. Dry 
eye is a multifactorial disease and the many causative factors can be completely exclusive from each other. 
This necessitates that the management of DE be multi-faceted. Dry eye disease affects millions of people 
around the world and this number will increase as the elderly population rise over the next few decades. 
However, emerging technologies are allowing clinicians and scientists to constantly discover new ways to 
diagnose and manage various aspects of DE. The global aim of this thesis was to evaluate some of the 
contemporary methods used in the diagnosis and management of DE disease.  
The specific aims of each chapter were as follows:  
 Chapter 3: To determine whether an experimental spectral domain ultra-long optical coherence 
tomographer (UL-OCT) can image MGs, and to compare its performance to the Heidelberg Retina 
Tomograph 3 (HRT3) with Rostock Cornea Module (RCM) in vivo laser scanning confocal 
microscope (Heidelberg Engineering GmbH, Heidelberg, Germany) and the Keratograph 5M 
(K5M) (OCULUS, Wetzlar, Germany).  
 Chapter 4: To determine the inter- and intra-observer repeatability in using the Keratograph 4 (K4) 
and K5M to grade MG dropout using meibography grading scales.  
 Chapter 5: To quantify the association of DE diagnostic tests to DE symptoms in an age-matched 
female cohort.  
 Chapter 6: To determine the effectiveness of an eyelid warming device in the management of MG 
dysfunction (MGD). 
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 Chapter 7: To evaluate the effect of lid debridement-scaling (LDS) on DE signs and symptoms in 
individuals with Sjӧgren’s syndrome (SS). 
 Chapter 8: To determine the combined effect of a lubricant eye drop, lid hygiene, and omega 3 fatty 
acids on DE signs and symptoms. 
Methods 
 
 Chapter 3: The superior eyelids of 12 participants were everted and imaged using the UL-OCT. 
The inferior and superior eyelids were then everted and imaged using the K5M. Finally, the inferior 
eyelids were everted and imaged with the HRT3/RCM. 
 Chapter 4: The inferior and superior eyelids of 40 participants were imaged 3 times each on both 
the K4 and K5M. The images were split into one training and two study sets; the latter were graded 
(4-point meibography scale) by two observers on two separate occasions (24hrs apart) to examine 
repeatability. Semi-objective grading of MG dropout was conducted using ImageJ on K4 and K5M 
images. A 7-point meibography scale was used to grade a separate set of K5M images.  
 Chapter 5: Twenty females symptomatic of DE (Ocular Surface Disease Index, OSDI, ≥ 13) were 
age-matched to 20 asymptomatic females (OSDI < 13). Non-invasive tear breakup time (NIBUT), 
ocular staining, meibum quality, number of obstructed glands, lid wiper epitheliopathy (LWE), 
Line of Marx (LOM) placement, eyelid margin score, Schirmer’s test, meibography, and visual 
acuity were compared between the two groups. 
 Chapter 6: This was a prospective, randomized, controlled, single-masked, bilateral eye study that 
enrolled 29 participants. Participants were randomized into either the EyeBag group or the control 
group. Participants in the EyeBag group were instructed to use the EyeBag 10 minutes 2x/day, and 
the control group remained on their own DE treatment regimen (if applicable). All participants 
were seen at baseline, 2 weeks and 4 weeks. At 4 weeks, participants in the EyeBag group were 
asked to stop using the EyeBag. All participants were seen again at the 8 week mark. Primary 
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outcomes were the OSDI, Current Symptoms Questionnaire (CSQ), MG score (MGS), and non-
invasive tear break-up time (NIBUT). 
 Chapter 7: This prospective randomized controlled study enrolled 14 female participants with SS. 
Seven participants were randomized into the treatment group, where they were selected to receive 
LDS, the remainder did not receive LDS and served as controls. Lid debridement-scaling was 
conducted using a stainless steel golf club spud (Hilco Wilson Ophthalmics, Plainville, MA) on 
both the upper and lower eyelids of both eyes. Outcome variables were assessed prior to LDS and 
again 1 month later. The outcome variables were the OSDI, Symptoms iN Assessment of Dry Eye 
(SANDE) visual analogue scores, Sjӧgren’s International Collaborative Clinical Alliance Ocular 
Staining Score (SICCA OSS), fluorescein tear breakup time (FLBUT), MGS, MG yielding liquid 
secretions score (MGYLS), and LOM position. 
 Chapter 8: This prospective study enrolled 28 DE participants. Participants were instructed to use 
the TheraTears® Lubricant Eye Drops at least 2-4x a day, TheraTears® SteriLid 1-2x a day, and 
TheraTears® Nutrition 3 gel caps once a day. Participants were followed up at baseline, 1 month 
and 3 months. Outcome variables were the OSDI, SANDE, NIBUT, osmolarity, number of MGs 
blocked (#MG blocked), meibum quality, eyelid margin features, Schirmer’s test, tear film lipid 
layer thickness (LLT), meniscus height, corneal and conjunctival staining.   
Results 
 
 Chapter 3: All twelve participants (7 female, 5 male) completed the study. The only instrument that 
was able to successfully image MGs was the K5M.  
 Chapter 4: When using the 4-point scale, inter-observer mean difference (MD) was 0.08±0.55 on 
day 1 and 0.13±0.50 on day 2, and the concordance correlation coefficient (CCC) was 0.79 and 
0.81 on days 1 and 2 respectively. Intra-observer MD was 0.04±0.54, CCC=0.79 for observer 1, 
and -0.09±0.60, CCC=0.74 for observer 2. For the 7-point scale, inter-observer MD was 0.05±0.45, 
CCC=0.89 on day 1 and 0.01±0.41, CCC=0.91 on day 2. Intra-observer MD was -0.10±0.35, 
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CCC=0.93 for observer 1 and -0.06±0.30, CCC=0.95 for observer 2. Percentage dropout measured 
between the K4 and K5M images showed lack of agreement, with only a 21.8% coefficient of 
repeatability.  
 Chapter 5: Twenty participant-pairs completed the study. The age (median/interquartile 
range(IQR)) of the symptomatic group was (60/15) and the asymptomatic group was (62/15). The 
diagnostic tests (median/IQR, p-value) that were significantly different between the symptomatic 
group vs. the asymptomatic group were OSDI (35.4/35.4 vs. 3.1/6.7, p < 0.01), NIBUT (2.1s/0.7s 
vs. 3.0s/3.0s, p = 0.01), meibum quality (3.0/0.0 grade units vs. 2.0/1.0 grade units, p < 0.01), 
number of obstructed glands (7.0/2.0 glands vs. 5.0/4.8 glands, p < 0.01), and ocular staining 
(5.5/3.8 grade units vs. 0.5/1.0 grade units, p < 0.01). The diagnostic tests (area under curve (AUC), 
odds ratio (OR)) that were most strongly associated with DE symptoms were ocular staining (0.93, 
5.0), number of glands obstructed (0.79, 2.6), meibum quality (0.76, 2.4), and NIBUT (0.74, 3.2) 
(all p < 0.05). There was no significant difference between the two groups for the other DE 
diagnostic tests (all p > 0.05), and similarly, no significant association to DE symptoms (all p > 
0.05).  
 Chapter 6: Twenty five participants completed the study (mean age 38±15 years, 7 male). There 
was a significant change in OSDI over time for the EyeBag group (mean values±SD, baseline: 
39.1±12.5, week 2: 26.8±11.2, week 4: 26.6±26.6, week 8: 27.7±14.6; p<0.05), but no significant 
change in the control group. There was a significant improvement in symptoms immediately after 
conducting the EyeBag based on at-home CSQ scores (Δ=-5.0 points, p<0.05), but no significant 
change in the control group. There was no significant change in MGS and NIBUT over time for 
either group.  
 Chapter 7: There were 13 participants that completed the study. Data from the right eye only were 
analyzed. For the control group (n=6, mean age=62±12), the pre LDS, post LDS, and significance 
level (pre-mean±SD, post-mean±SD; p-value) were: OSDI (58.3±22.1, 48.3±29.0; p=0.051), 
SANDE (77.4±22.1, 89.6±32.6; p=0.20), SICCA OSS (7.0±4.5, 8.2±3.5; p=0.25), MGS (1.3±1.5,  
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1.0±0.9; p=0.75), MGYLS (0.3±0.5,  0.0±0.0; p=0.50), FLBUT (2.99 ±1.54, 2.85±1.79; p=0.63), 
LOM (2.0±0.0, 2.0±0.0, p=n/a). For the treatment group (n=7, mean age=58±8), the pre LDS, post 
LDS, and significance level were: OSDI (63.2±13.3, 46.9±19.4; p=0.04), SANDE (72.6±17.1, 
77.0±28.0; p=0.54), SICCA OSS (6.6±2.9, 5.0±3.9; p=0.02), MGS (1.0±1.2, 3.1±1.7; p=0.01), 
MGYLS (0.0±0.0, 0.6±1.0; p=0.50), FLBUT (3.13±0.81, 3.45±1.03; p=0.53), LOM (0.9±0.9, 
1.0±1.0, p=1.00).  
 Chapter 8: There were 20 participants (mean age = 43, from 23 to 66, 17F, 3M) that completed the 
study. On average, participants used the Lubricant Eye Drop 2.4x/day, the SteriLid 1.1x/day, and 
the Nutrition 3 gel caps 1x/day. There was a significant change over time (p<0.05) for OSDI (-21.2 
points), SANDE (-32.4 points), NIBUT (+0.43s), eyelid margin features (-1.1 grade), meibum 
quality (-1.0 grade), and #MG blocked (-4.0 glands).  
Conclusions 
 
 Chapter 3: The UL-OCT was unable to image MGs. The HRT3/RCM imaged structures that 
resembled dermal rete pegs and papillae. Of the three methods used in this study, the only device 
that was able to successfully image MGs was the K5M.  
 Chapter 4: Observers graded from -1 to +1 grade units between and within themselves for a 4-point 
scale, 95% of the time. Although the inter- and intra-observer repeatability of the K4 and K5M 
were very similar, a low level of agreement in percentage dropout between K4 and K5M images 
suggests that the two instruments cannot be interchanged. Using a finer scale may be beneficial for 
detecting change over time.   
 Chapter 5: The diagnostic tests that were most strongly associated with DE symptoms in older 
women were ocular staining, meibum quality, number of glands obstructed, and tear film stability. 
 Chapter 6: The MGDRx® EyeBag was effective at relieving symptoms in participants with DE, 
but the effect on MG function and tear stability when used for only 4 weeks was modest.  
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 Chapter 7: This pilot study showed that LDS improved symptoms, ocular staining and MG function 
for the group that received LDS. This indicates that LDS can aid in the management of SS DE.  
 Chapter 8: After using a combination of TheraTears® Lubricant Eye Drop, SteriLid, and Nutrition, 
participants experience significant relief in both DE symptoms and signs. 
This thesis was able to evaluate and suggest improvements to meibography techniques and grading. In 
addition, this thesis was also able to evaluate the effectiveness of various contemporary methods for DE 
treatment. The methods used in this study are clinically accessible and clinicians are free to use these 
findings and apply them directly to their clinical practice.  
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1 Literature Review 
 
1.1 Prevalence and Risk Factors 
 
1.1.1 Prevalence 
 
The prevalence of dry eye (DE), according to the 2007 Report of the International Dry Eye Workshop 
(DEWS I), was reported to be between 5.5% to 33.7% of all participants, 1 with this prevalence being drawn 
from several studies in the US (7.8-14.6%),2-9 Australia (5.5-16.6%),10,11 Taiwan (33.7%),12 and Sumatra 
(27.5%).13 Since 2007, prevalence data have emerged from a number of other countries, including Jordan 
(59%, symptoms only),14 Japan (31.6%-34.1%),15,16 South Korea (8.0%),17,18 Iran (8.7%),19 and mainland 
China (17.0%).20 The data from these studies suggest that Asian populations have the highest prevalence 
of DE. The methods for determining prevalence ranged from measuring DE symptoms only, to being based 
on various batteries of DE clinical tests, to using combinations of both symptoms and signs. As a result, 
prevalence information is dependent on the different methods used to obtain data.  
1.1.2 Risk Factors 
 
One of the goals for the 2007 DEWS I report was to describe the risk factors for DE disease. The report 
found that female sex, older age, hormone replacement therapy, refractive surgery, omega 3 fatty acids 
(O3FA) to omega 6 fatty acids (O6FA) ratio, refractive surgery, vitamin A deficiency, radiation therapy, 
bone marrow transplantation, hepatitis C, and various classes of medications were all strong risk factors for 
DE disease.1 A number of studies conducted after the 2007 DEWS I report supported these findings.   
1.1.2.1 Age 
 
A number studies conducted after DEWS I confirmed aging as a prominent risk factor for DE.21-23 Aging is 
involved in mechanisms that increase oxidative stress in tissues.24-28 Inflammation resulting from oxidative 
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stress has been found to cause a decline in tear production from the lacrimal gland.24 Increase in oxidative 
stress can also be triggered by hyperglycemia,29-31 making diabetes mellitus a further risk factor.  
1.1.2.2 Sex 
 
Females are more likely than males to have DE.2,5,6,14,17,32 Androgens are sex hormones that upregulate 
meibomian gland (MG) function, whereas estrogen and progesterone downregulate sebaceous gland and 
lipid production.33 The production of androgens decline over time in women,33,34 however the level of 
androgens in women remains far less than that of men. This may explain why women are more prone to 
DE than men.33 Furthermore, hormone replacement therapy to help relieve menopausal symptoms has also 
been found to cause DE.35,36  
1.1.2.3 Systemic Conditions and Medications 
 
Numerous systemic conditions and medications can precipitate and exacerbate DE.1 For example, the 
lacrimal gland is often a target in autoimmune diseases such as Sjӧgren’s syndrome (SS),37 systemic lupus 
erythematosus,38 and rheumatoid arthritis.32,39 Parasympathetic input40 is involved in regulating lacrimal 
gland activity and medications that modulate acetylcholine or parasympathetic activity can potentially 
impact the signal for lacrimal secretion. For this reason, anxiolytics,41,42 anticholinergics, 42,43 and 
antihistamines32,42 can downregulate lacrimal gland function. Medications that manage severe acne vulgaris 
(oral isotretinoin, 13-cis-retinoic acid) by inducing apoptosis in sebocytes44,45 can also cause MGs to 
atrophy, since MGs are modified sebaceous glands.46 Without functioning MGs, individuals taking these 
medications are prone to evaporative DE.47-51   
1.1.2.4 Refractive Surgery 
 
Patients who elect to undergo refractive surgery are also at risk for developing DE.52,53 There is a measurable 
loss of corneal sensitivity54,55 from iatrogenic nerve damage, causing a reduction in afferent input (sensory) 
and dampening of the efferent output (tear secretion).53 There is also a loss of conjunctival goblet cell 
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density from the interaction of the suction ring on the eye.56,57 Post-operative inflammation from an increase 
in metalloproteinase-9(MMP-9)58 and inflammatory cytokine levels59 in the tears can trigger symptoms and 
exacerbate pre-existing DE problems.60 The incidence of developing chronic DE from refractive surgery is 
generally low (5.0% for PRK, 0.8% for LASIK), with many patients recovering tear function and symptoms 
12 months after surgery.61 However, individuals presenting with impaired tear film and chronic DE prior 
to surgery generally need a longer recovery time.61 Post-operative DE is not isolated to refractive surgery, 
as it is also a very common side effect following cataract surgery.62,63 
1.1.2.5 Environment Stressors 
 
The environment can play a significant role in precipitating and exacerbating DE disease.1 An increase in 
inflammatory cytokines, osmolarity, corneal staining, and MMP-9 can be observed after spending 2 hours 
in a dry environment.64 An in-flight airplane cabin with low humidity can significantly decrease tear 
stability and tear volume, as well as increase corneal staining.65 In mice, MG basal acinar cell proliferation 
can be triggered by placing the animals in a dry environment. This indicates that the environment can have 
a direct effect on the MGs.66 Long hours of reading (either paper or electronic)67 in a dry environment can 
increase the risk of DE in office employees, especially if they are contact lens (CL) wearers.68 Dry eye test 
values can also be highly dependent on climate, with tear breakup time, corneal and conjunctival staining 
varying significantly between Atlantic and Continental regions.69  
1.1.2.6 Contact Lens Wear 
 
Inserting a foreign object into the tear film, such as a CL for the correction of refractive error or facilitating 
corneal wound healing, disrupts the layers of the tear film and alters the interaction of the tear film with the 
cornea.70 Both conventional and silicone hydrogel CL materials can deposit with tear film components71 
and cause denaturation72 of tear lysozyme and degradation of tear film lipids.73 Deposition of protein and 
lipids can illicit an immune response in the form of giant papillary conjunctivitis.74 Discomfort and dryness 
 
 
4 
 
are primary reasons why patients discontinue CL wear,75 and DE plays a large role in contributing to the 
complex nature of CL discomfort.76 
1.1.2.7 Topical Ophthalmic Medications 
 
Antimicrobial agents are present in topical ophthalmic medication eye drops to preserve and extend their 
shelf-life.77,78 The most common preservative is benzalkonium chloride (BAK).77 It is a quaternary 
ammonium that is cheap to produce and is very effective at reducing microbial loads.79 Unfortunately, BAK 
exacerbates ocular surface disease and DE in a number of ways; it promotes apoptosis in corneal epithelial 
cells,77,80 breaks down tight junctions between epithelial cells,80 reduces surface goblet cell numbers,81 
destabilizes the tear film,82 and increases inflammatory cytokines.83 Consequently, patients who use BAK-
preserved topical ophthalmic medications for extended periods of time (e.g. for intraocular pressure 
management in glaucoma) will often need help with DE and ocular surface disease as well.84 Newer 
formulations of topical medications with less toxic preservative systems may be more appropriate for long-
term use.85,86  
1.2 Etiology and Pathophysiology of Dry Eye 
 
Dry eye is a complex and multifactorial disease. The 2007 DEWS I report defined DE to be  
“… a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, 
visual disturbance, and tear film instability with potential damage to the ocular surface. It is 
accompanied by increased osmolarity of the tear film and inflammation of the ocular surface.”87  
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Figure 1-1: The major etiological categories of DE. Dry eye can be broadly categorized into two major 
etiologies. Within each etiology are sub categories that have potential to cause and exacerbate DE. This 
figure highlights the complex multifactorial nature of DE etiology.  Image from Lemp MA, Baudouin C, 
Baum J, Dogru M, Foulks G, Kinoshita S, Laibson P, McCulley JP, Murube J, Pflugfelder SC, Rolando 
M, Toda I. The definition and classification of dry eye disease: report of the Definition and Classification 
Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5:75-92. 
The etiology of DE can be classified into two broad categories: aqueous deficient and evaporative DE 
(Figure 1-1).87 The aqueous deficient category can be further divided into SS-DE, and Non-SS DE. 
Sjӧgren’s syndrome DE can be further categorized into either primary or secondary. Non-SS DE etiology 
can be further broken down into lacrimal deficiency, lacrimal gland duct obstruction, reflex block, and 
systemic drugs.87  
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The evaporative DE category consists of intrinsic and extrinsic factors. Intrinsic factors that can cause 
evaporative DE include MG oil deficiency, lid aperture disorders, low blink rate, and drug action of 
isotretinoin.87 Extrinsic factors include vitamin A deficiency, topical drug preservatives, CL wear, and 
ocular surface disease.87  
Aqueous deficient and evaporative DE are not necessarily mutually exclusive. A patient could have a 
combination of intrinsic and extrinsic evaporative factors (e.g. lax lids and be using BAK-preserved 
medications), along with several aqueous deficient factors (e.g. primary SS, and on antidepressants). This 
can potentially complicate the diagnosis and management of DE disease.  
1.2.1 Aqueous Deficiency 
 
1.2.1.1 Sjӧgren’s Syndrome 
 
Infiltration of lymphocytes into the exocrine glands is a characteristic of SS,88 and SS is a well-established 
cause for aqueous deficient DE.37,89 Some clinical manifestations of SS include severe DE,90 dry mouth,91 
and dry skin.92 In addition to dryness, individuals with SS often exhibit physical fatigue and mental 
depression as well.93 Like other rheumatic diseases, SS cannot be characterized by a single defining trait. 
The diagnosis is made after an assessment of multiple systems,94 in particular the ocular surface, salivary 
glands, and serum antibodies.95  
The classification of SS first started in 1986,95 and has been revised several times since then. The European 
community had first established a consensus-based criteria in 1993,96 which was subsequently validated in 
1996.97 A revision was conducted in a joint-effort with an American group of experts to improve on 
classifying primary and secondary SS, resulting in the American-European Consensus Group (AECG) 
classification criteria.94 One of the criticisms of the AECG classification criteria was that it included 
subjective patient responses as a criterion, and so the classification criteria were revised once again by the 
American College of Rheumatology (ACR) in 2012.98 The agreement between the AECG and the ACR 
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classification sets is mixed, with one study reporting fairly good concordance,99 but two reporting only 
moderate agreement.100,101  
The AECG and the ACR classification criteria are as follows:  
The AECG classification criteria:94  
 
 I. Ocular symptoms: a positive response to at least one of the following questions:  
1. Have you had daily, persistent, troublesome dry eyes for more than 3 months? 
2. Do you have a recurrent sensation of sand or gravel in the eyes? 
3. Do you use tear substitutes more than 3 times a day? 
II. Oral symptoms: a positive response to at least one of the following questions:  
1. Have you had a daily feeling of dry mouth for more than 3 months? 
2. Have you had recurrently or persistently swollen salivary glands as an adult? 
3. Do you frequently drink liquids to aid in swallowing dry food? 
III. Ocular signs – that is, objective evidence of ocular involvement defined as a positive result for at least one of the 
following two tests:  
1. Schirmer’s I test, performed without anesthesia (≤5mm in 5 minutes) 
2. Rose Bengal score or other ocular dye score (≥4 according to van Bijsterveld’s scoring system) 
IV. Histopathology: In minor salivary glands (obtained through normal appearing mucosa) focal lymphocytic 
sialoadenitis, evaluated by an expert histopathologist, with a focus score ≥1, defined as a number of lymphocytic foci 
(which are adjacent to normal-appearing mucous acini and contain more than 50 lymphocytes) per 4 mm2 of glandular 
tissue.  
V. Salivary gland involvement: objective evidence of salivary gland involvement defined by a positive result for at 
least one of the following diagnostic tests:  
1. Unstimulated whole salivary flow (≤1.5ml in 15 minutes) 
2. Parotid sialography showing the presence of diffuse sialectasias (punctate, cavitary or destructive 
pattern), without evidence of obstruction in the major ducts 
3. Salivary scintigraphy showing delayed uptake, reduced concentration and/or delayed excretion of tracer 
VI. Antibodies: presence in the serum of the following antibodies:  
1. Antibodies to Ro(SSA) or La(SSB) antigens, or both 
The ACR classification criteria:98  
1. Positive serum anti-SSA and/or anti-SSB or (positive rheumatoid factor and ANA ≥1:320) 
2. Ocular staining score ≥3 (using the Sjӧgren’s International Collaborative Clinical Alliance grading scale) 
3. Presence of focal lymphocytic sialadenitis with focus score ≥1 focus/4mm2 in labial salivary gland biopsies.  
In either case, the management of SS-DE often involve a combination of topical and oral anti-
inflammatory agents, immunomodulatory agents, punctal plugs, and topical autologous serum.102  
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1.2.1.2 Lacrimal Gland Deficiency 
 
The lacrimal gland is characterized by tubuloacinar, exocrine cells.103 The entire gland is an almond-shaped 
structure. Within the gland, acini units comprised of pyramid-shaped cells secrete water, electrolytes, 
proteins, and mucins from the apical membrane into the lumen of an excretory duct, and into the tear film.103 
The basolateral membrane of the acinar cells contain receptors for peptides, hormones, and 
neurotransmitters that regulate the secretory processes of the gland.103  
The sensory nerves innervating the ocular surface originates from the ophthalmic branch of the trigeminal 
nerve,104 and the excitation of these nerves results in stimulation of lacrimation.105,106 The cornea is one of 
the most densely innervated surfaces of the human body,107 comprising of mechanoreceptors, mechano-
nociceptors, polymodal nociceptors, and cold receptors.104 Afferent signals from the ocular surface are 
processed in the superior salivary nucleus (lacrimal nucleus) of the facial nerve.108 The superior salivary 
nucleus then supply efferent signals to the lacrimal gland.108 Eliminating sensory input at the trigeminal 
nerve109 and disrupting the efferent pathway 110 reduces lacrimation. This is often the case in refractive 
surgery, where the corneal nerves are often damaged, leading to the loss of corneal sensitivity,54,55 and 
negatively affecting lacrimation.53 
Aging has an impact on the neural regulation of the lacrimal gland. Corneal sensitivity decreases sharply 
after the age of 50,111 and the reduction in sensory input from the ocular surface may be responsible for the 
decreased output of the lacrimal gland. Structural changes to the lacrimal gland,112 decrease in overall 
innervation113,114 and infiltration of mast cells and lymphocytes113,114 are a result of aging in the lacrimal 
gland.115  
Lacrimal deficiency can be due to congenital alacrima, a condition that is characterized by a complete 
absence or underdeveloped lacrimal gland.116 In one case, a 5 year old girl had presented with a lack of 
tearing when crying. Her tear stability was less than 2 seconds, and had corneal epithelial erosions and 
conjunctival epitheliopathy. Magnetic resonance imaging had revealed a complete absence of a lacrimal 
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gland in the left eye, and a severely underdeveloped gland in the right eye.116 She was managed with 
artificial tears and cyclosporine 0.05%.116 Alacrima is also a clinical feature of Allgrove syndrome, an 
autosomal recessive congenital disease additionally characterized by Addison’s disease and achalasia.117,118   
1.2.1.3 Lacrimal Excretory Duct Obstruction  
 
Since the lacrimal gland excretes into the tear film through a lacrimal excretory duct, any obstruction of the 
ducts could result in a decreased supply of tear fluid to the ocular surface. The cauterization of the lacrimal 
excretory duct in rabbits increased tear film osmolarity, decreased goblet cell density and decreased corneal 
epithelial glycogen levels.119 However, this could not be completely attributed to the cautery, since the 
harderian gland and nictitating membranes were also simultaneous excised in this experiment.119  
1.2.2 Evaporative Dry Eye 
 
The second major etiological category relates to evaporative disorders of the tear film. Intrinsic factors that 
can cause evaporative DE include MG oil deficiency, lid aperture disorders, low blink rate, and the reaction 
to taking isotretinoin and its derivatives. Extrinsic factors include vitamin A deficiency, topical drug 
preservatives, CL wear, and ocular surface disease (Figure 1-1).  
1.2.2.1 Lid Aperture Disorders 
 
At this time, there are little to no studies that adequately examine the relationship between aperture disorders 
and DE. Without adequate closure of the eyelids, the ocular surface is exposed to desiccation. Incomplete 
blinking, lagophthalmos, nocturnal lagophthalmos, exophthalmos, ectropion, entropion and facial palsies 
are all sources of incomplete eyelid closure that may precipitate DE symptoms and signs. Additionally, 
without the proper apposition of the eyelids against the eye, the MG orifices are disconnected from the tear 
film, along with a loss of physical support for the inferior tear meniscus.  
Idiopathic facial palsy (Bell’s palsy) may result in the inability of the patient to close their eye completely 
on the affected side.120 The management of Bell’s palsy often involves eye patching and constant lubrication 
 
 
10 
 
to avoid corneal complications.121,122 Other conditions such as lagophthalmos, ectropion, may occasionally 
require additional therapies such as eyelid weight loading, tarsorraphy, taping and lateral canthoplasty to 
restore eyelid structure and function. Patients with more lower lid laxity (but without ectropion, entropion, 
lagophthalmos) tend to be symptomatic for DE.123  
1.2.2.2 Low Blink Rates 
 
Blinking refreshes and redistributes the tear film over the ocular surface.124 Patients with DE generally blink 
more frequently than people without DE.125,126 This is due to the tear film destabilizing faster in DE 
patients,127 which frequently stimulates the blinking reflex. Using a computer reduces the blink rate for both 
DE and normal individuals.128 Also, a separate study found a higher frequency of incomplete blinks when 
using computers as opposed to printed hard copy paper.129 With a reduction in blink rate, the tear film is 
not replenished as frequently and the ocular surface is constantly exposed to desiccating stress. 
1.2.2.3 Meibomian Gland Disease 
 
1.2.2.3.1 Congenital Absence 
 
Meibomian gland disease contributes to MG oil deficiency, resulting in evaporative DE.130 Meibomian 
gland disease can be the result of a lack of MGs from a rare genetic disorder called ectrodactyly ectodermal 
dysplasia cleft lip/palate (EEC syndrome).131 A case report documented a case of EEC syndrome in a 22 
year old Japanese male, in which there were no MG orifices observed at the slit lamp, and an absence of 
MGs upon transillumination.131 This patient had previously managed his DE by using unpreserved artificial 
tears 6x/day and 0.1% vitamin A drops 4x/day, but reported symptoms worsening when viewing a computer 
screening or being in dry, windy, dirty environments.131 
1.2.2.3.2 Meibomian Gland Neoplasia 
 
Meibomian gland neoplasia is another rare aspect of MG disease. Sebaceous gland carcinomas are a group 
of cancers that can arise from the MGs, glands of Zeis or glands associated with the caruncle.132 However, 
 
 
11 
 
tumours of the MGs must not be confused with chalazia – a common localized, lipogranulomatous lesion 
within the MGs.133 
1.3 Meibomian Gland Dysfunction 
 
1.3.1 Etiology and Pathophysiology of Meibomian Gland Dysfunction 
 
The most common contributor to MG disease is MG dysfunction (MGD). The 2011 International Workshop 
on Meibomian Gland Dysfunctional categorized MGD into low (hyposecretory) or high delivery 
(hypersecretory) states.130 Terms such as meibomitis and meibomianitis are no longer used since MGD can 
occur in the absence of inflammation.130,134 Figure 1-2 displays the relationship between MG disease and 
MGD, as well as some of their etiologies.  
Hypersecretory MGD is characterized by an excessive secretion of lipids, and appears to be related to an 
excess of androgens,135 testosterone in particular, as it promotes sebaceous cell proliferation and 
differentiation.136 In contrast, abnormally low delivery of meibum can be secondary to certain types of 
medications that cause MG atrophy.130 As previously discussed, oral isotretinoin for the treatment of acne 
vulgaris induces apoptosis in sebocytes, resulting in a decrease in sebum production.44,45 Since MGs are 
modified sebaceous glands,46 the use of isotretinoin causes MGs to atrophy and reduce meibum output.47-51 
Decreased delivery of meibum can be due to a state of androgen deficiency, which can result from anti-
androgen therapy (as for prostate cancer therapy137 or acne treatment138). Without sufficient androgen 
levels, MG activity is supressed and meibum production is decreased.33 
Low delivery of meibum may also be due to MG obstruction.130 Obstructive MGD is probably the most 
common type of MGD.130 Obstructive MGD can be cicatricial or non-cicatricial in nature. Cicatricial 
obstructive MGD can be secondary to trachoma, ocular pemphigoid, erythema multiforme, and atopy, and 
non-cicatricial MGD include seborrheic dermatitis, rosacea, atopy and psoriasis.130  
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Figure 1-2: The classification of MG disease and MGD. Meibomian gland disease is an umbrella term 
that encompasses MGD. There are three subtypes of MGD; hyposecretory and obstructive both result in 
low-delivery of meibum, hypersecretory refers to high-delivery of meibum. All of these can result in 
alterations to the tear film, causing DE and ocular surface disease. The figure is adapted from Nelson JD, 
Shimazaki J, Benitez-del-Castillo JM, et al. The international workshop on meibomian gland dysfunction: 
report of the definition and classification subcommittee. Invest Ophthalmol Vis Sci. Mar 
2011;52(4):1930-1937. 
 
The most recent definition of MGD by the 2011 International Workshop on Meibomian Gland Dysfunction 
is as follows:130  
“Meibomian gland dysfunction is a chronic, diffuse abnormality of the meibomian glands, 
commonly characterized by terminal duct obstruction and/or qualitative/quantitative changes in the 
glandular secretion. This may result in alteration of the tear film, symptoms of eye irritation, 
clinically apparent inflammation, and ocular surface disease.”  
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1.3.1.1 Anatomy of Meibomian Glands 
 
Meibomian glands are long, modified sebaceous glands imbedded within the tarsal plate.46 There are 
approximately 25 to 40 (median 31) in the superior eyelid, and 20 to 30 (median 26) in the inferior eyelid.46 
The array of glands are arranged vertically, with the closed end positioned most distal to the eyelid margin. 
The opening of the glands are located posterior to Marx’s line. Each single gland consists of a central duct 
with numerous small acini clusters connected to it via small ductules (Figure 1-3). The term “chain of 
onions” has been used to describe the layout of a single gland.46  
 
Figure 1-3: A MG functional unit consists of a central duct, with multiple acini units connected to it. 
Meibum is produced at the acini units, which travels to the central duct, and eventually out the MG orifice 
at the eyelid margin.  
The meibum production begins at the acinus units. The acinus are approximately 150-200μm in diameter 
and consist of secretory cells termed meibocytes. The maturation of meibocytes begin at the basement 
membrane at the periphery of the acinus.46 The basal cells serve as progenitor and proliferates to constantly 
produce new meibocytes. As meibocytes mature they migrate towards the center of the acinus.46 The end 
of maturation is marked with the disintegration of the cell membranes, as they release their contents into 
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the lumen of the ductal system (holocrine secretion).46 The constant replacement of meibocytes ensures this 
process is continuous. In rats, the turnover for meibocytes is approximately 4 days,139 this may be slightly 
different in humans. The regulation of meibocyte proliferation and differentiation appears to be driven in-
part by CD147, a transmembrane protein that also serves to regulate MMP-9s.140  
1.3.1.2 Hormonal Regulation 
 
The production of meibum is regulated by numerous mechanisms. Regulation by androgens and estrogens 
have been studied extensively.141 Some evidence suggests that the MGs are innervated by both the 
sympathetic142 and parasympathetic143 autonomic nervous systems. In mice with ovaries removed, there 
was an increase in expression of neuropeptide Y (associated with the sympathetic system) and decrease in 
vasoactive intestinal polypeptide (associated with the parasympathetic system) in the nerve fibers of the 
MGs.144 This shows that hormones can have an influence on autonomic nervous control of MGs, 
complicating the understanding of its regulation.144  
Secreted meibum travels through the connecting ductules, which are approximately 150μm in length and 
30-50μm in diameter. The connecting ductules transition into the central duct, which is 100-150μm in 
diameter, with the length traversing the length of the eyelid.46 These ducts are characterized by a four-
layered stratified squamous epithelium, containing keratohyalin granules. The excretory duct of the MG is 
the final portion of the gland that meibum travels through before it reaches the opening at the eyelid 
margin.46 The excretory duct differs from the rest of the duct system in that it contains an ingrowth of 
keratinized epithelium from the eyelid margin. This is a key anatomical feature that is responsible for the 
obstruction of the MG orifice when keratinization is upregulated (hyperkeratinization).  
1.3.1.3 Hyperkeratinization 
 
The results of a study by Jester showed that MGs from both humans and rabbits were capable of expressing 
keratin proteins, indicating that keratinization is a process inherent to MGs.145 Hyperkeratinization of the 
eyelid margin and MG orifice epithelium can cause orifice narrowing and create a stenosis that results in 
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decreased delivery of meibum to the tear film. There are several triggers for hyperkeratinization.46 
Hyperkeratinization can be due to anti-androgen therapies,146 CL wear,147 or artificially induced by topical 
epinephrine.148 Furthermore, hyperkeratinization of the eyelid margin epithelium was thought to contribute 
to narrowing and pouting of the MG orifices.149  Obstruction of the orifices have been shown to induce 
atrophic changes in MGs in mice150 and rabbit models.148,151 While hyperkeratinization is a major 
contributor to obstructive MGD, not all MGD arise from obstruction. In a study that compared 2 year old 
versus 5 month old mice,152 Parfitt et al. had found that the lack of meibum production was due to a loss of 
acinar progenitor cells. The keratin markers showed no hyperkeratinization of the excretory duct of the 
MGs.152  
1.3.1.4 Meibum Quality Changes 
 
Change in meibum quality is another characteristic of MGD. The physical quality of meibum can be 
assessed clinically by applying pressure to the eyelid margins (see Figure 1-4). Normal meibum is an 
optically clear and oily fluid, resembling the consistency of cooking oil. As MGD severity progresses, the 
appearance of meibum can take on a thicker, opaque, creamy consistency that is relatively thicker in 
viscosity, resembling toothpaste.   
  
Figure 1-4: Left, upon expression, healthy meibum should appear clear and liquid in consistency. Right, 
altered meibum quality appears white, paste-like and turbid. 
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The collection of meibum is the first step to analyzing meibum lipid composition. Meibum can be collected 
from humans in a number of ways.153 
1) Spatula: pressure is applied to the eyelid margin and a sterile spatula is used to collect the meibum. 
A disadvantage to this procedure is that other extraneous cells and debris may also be collected as 
well.  
2) Microcapillary pipettes: pressure is applied to the eyelid margin to express a small “pool” of 
meibum. A microcapillary tube is positioned on top of the meibum and drawn into the tube. While 
this is one purest ways meibum can be obtained, a disadvantage to this procedure is that very thick 
meibum may be very difficult to collect and then also to remove from the tube.  
3) Paper strips and swabs: pressure is applied to the eyelid margins to express oils and an absorbent 
strip of paper is applied to the eyelid margins to collect it. Lipids can then be extracted from the 
paper. A disadvantage to this technique, due to the large surface area, is that it may also incidentally 
collect lipids from other ocular surface cells.  
4) Chalazion curette: a chalazion curette is able to collect meibum in a manner similar to the spatula 
described above. 
The methods for analyzing meibum are various as well. In general, chromatography (paper, thin layer, gas, 
liquid), mass spectroscopy, spectroscopy, nuclear magnetic resonance, raman spectroscopy, infrared 
spectroscopy, and chemical photometric assays are some methods in which the composition of meibum can 
be derived.153 
It is generally observed that younger individuals have lower meibum viscosity.154 Borchman et al. studied 
the relationship between the physical property of meibum and age using infrared spectroscopy155 and found 
a significant decrease in meibum hydrocarbon chain order, from 48% trans rotamers at birth to 
approximately 30% trans rotamers at approximately 85 years old.  
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The difference in meibum composition may explain the difference in tear film stability observed between 
infants and adults.156 In a separate study, Borchman et al. identified several areas by H-NMR that appear to 
change with age. The amount of -CH3, C=C, and degree of lipid oxidation increased over time. The increase 
in C=C bonds indicated a higher degree of branching in lipid structure. As a result, lipid molecules do not 
stack as close and van der Waal’s forces become diminished, making it easy for lipid-lipid interactions to 
be broken. This was the hypothesized reason for decreased tear stability in adults.156  
Borchman et al. also compared the difference in meibum quality between normal individuals and those with 
MGD.157 The study found that meibum from MGD participants had a higher lipid order than normal 
meibum, which resulted in higher phase-transition temperatures. Lipids that are more tightly packed 
together interact with greater van der Waal’s forces, resulting in higher melting temperature. This is 
clinically relevant as treatment for MGD patients typically involve the application of heat to the eyelid 
margins to melt the meibum.158 An analogy used in this study is that the hydrocarbon stiffness of meibum 
in MGD is somewhere halfway between olive oil and butter.  
A more recent study159 found that meibum from participants with MGD had more insoluble inclusion bodies 
than normals. These inclusion bodies were stainable with Amido Black, suggesting that they were 
composed of proteins. Furthermore, these inclusion bodies also stained with PanCK and CK10 antibodies, 
indicating that they were cytokeratins. Meibum from MGD were also found to be much less mechanically 
resistant than normals. This was shown by mechanically stressing (applying pressure using a coverslip 
against a glass slide) the meibum. Meibum from normals was able to retain its integrity under pressure, but 
meibum from MGD participants disintegrated.159  
Meibum forms the majority of the tear film lipid layer and is thought to prevent evaporation of the tear 
film.160 However, recent evidence suggests that the main function of the lipid layer is to maintain a thin tear 
film while preventing it from collapsing.161 
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1.3.1.5 Non-Obvious Meibomian Gland Dysfunction 
 
As previously discussed, MGD can occur in the absence of inflammation.134  The term non-obvious MGD 
(NOMGD) is used to describe a form of obstructive MGD that is relatively inconspicuous, and is 
characterized by the absence of lid margin notching and inflammation.134 However, after applying pressure 
to the eyelid margins, the orifices may yield solidified meibum plugs or nothing at all. To ensure that 
NOMGD is not missed, diagnostic expression of the MGs is encouraged as part of a regular ophthalmic 
examination.134 Diagnosing NOMGD and managing it early may prevent it from progressing to obvious 
MGD.134  
1.3.1.6 Isotretinoin Use 
 
The use of isotreinoin and their impact on MGs have been discussed in the section on Systemic Conditions 
and Medications.  
1.3.2 Prevalence and Risk Factors for Meibomian Gland Dysfunction 
 
The prevalence of MGD from population studies ranges from 3.5% up to 69.3%.162 The large variation may 
be due to varying definitions of MGD and ethnic groups. Higher prevalence of MGD appears to occur in 
Asian populations.162 The prevalence of evaporative dry eye caused by MGD is higher than dry eye resulting 
from aqueous deficiency.163 The ophthalmic risk factors for MGD previously identified were aniridia, 
chronic blepharitis, CL wear, Demodex blepharitis, eyelid tattooing, floppy eyelid syndrome, giant papillary 
conjunctivitis, ichthyosis, Salzmann’s nodular corneal degeneration, and trachoma.162  
1.3.2.1 Congenital Aniridia 
 
Congenital aniridia is a condition caused by insufficiency of PAX6, a gene responsible for the development 
of various structures of the eye, including the MGs.164,165 As a result, aniridia is often accompanied by 
problems ranging from cataracts, glaucoma, foveal hypoplasia, optic nerve hypoplasia, and ocular surface 
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disease. Ocular surface disease occurs in the form of vascularization and keratinization of the corneal due 
to limbal stem cell deficiency.164 
1.3.2.2 Ichthyosis Follicularis 
 
Ichthyosis follicularis is a condition that is often accompanied by alopecia and photophobia (IFAP).166 This 
is a rare X-linked disease that is associated with MGD.162 One recent case report describes MGD in a father 
and daughter, both with IFAP syndrome.167  
1.3.2.3 Eyelid Tattooing 
 
Eyelid tattooing has a possible association with MGD. This finding is based on a case report published in 
2005 by Kojima et al., describing complete loss of MGs in a 45 year old female who had undergone eyelid 
tattooing.168 A more recent study by Lee et al.169 confirms this association, by showing that tear breakup 
time, fluorescein staining, and MG atrophy was worse in the tattoo group than the control group. The 
authors propose three reasons why tattooing may cause MG atrophy; the needle used to inject tattoo ink 
into the dermis may cause mechanical trauma to the eyelid margins, the ink may contribute to substance 
toxicity, and thirdly, tattoo ink may obstruct the ducts and the gland openings.  
1.3.2.4 Floppy Eyelid Syndrome 
 
Floppy eyelid syndrome is possibly related to MGD, based on a case report published in 1987 by Gonnering 
et al.170 A PubMed search for “meibomian” and “floppy eyelid syndrome” revealed another paper published 
in 1994 by Netland et al.,171 that found MG abnormalities while characterizing tarsal elastin in floppy eyelid 
syndrome.  
1.3.2.5 Contact Lens Wear 
 
Whether or not CL wear causes MGD is still unclear, with many studies yielding conflicting and mixed 
results. Ong et al.172 examined the proportion of individuals with MGD in CL wearers versus non-CL 
wearers and found no significant difference between the two groups. Arita et al.173 compared MG atrophy 
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in CL wearers and non-CL wearers and found that CL wearers had a significantly higher amount of atrophy 
than non-CL wearers. Furthermore, they also found that duration of CL wear and MG atrophy were 
significantly correlated. Marren et al.174 found no correlation between CL wear and MGD. Arita et al.175 
found that CL-induced allergic conjunctivitis caused MG distortion similar to those found in perennial 
allergic conjunctivitis. Machalinksa et al.176 found a significant correlation between meibum quality, 
expressibility and duration of soft CL wear in an age-matched study. A case-control sex-matched study by 
Pucker et al.177 found an inconclusive association between CL wear and MG atrophy. As it stands currently, 
the association of CL wear to MGD remains equivocal.  
1.4 Clinical Tests for Dry Eye 
 
The diagnosis and management of DE frequently involves the assessment of various aspects; patient 
symptoms, the quality of the tear film, and the integrity of the ocular surface. Symptom assessment is 
important, since DE disease is primarily symptom driven. Assessment of the tears and ocular surface is 
important, since chronic desiccation of the ocular surface may result in corneal scarring and loss of visual 
function. However, symptom measurements often do not correlate with objective DE measurements.178-180 
This suggests that symptoms alone are not enough to diagnose and manage DE, and that DE assessment 
must include objective DE measurements.  
1.4.1 Subjective Assessments 
 
Symptom assessment is usually conducted subjectively using questionnaires that may assess purely DE 
symptoms (examples include the Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire 181 
and Symptom Assessment in Dry Eye (SANDE) questionnaire182), a combination of DE symptoms and 
quality of life (Ocular Surface Disease Index, (OSDI)183) or questionnaires that focus mostly on quality of 
life (Impact of Dry Eye on Everyday Life (IDEEL)184). The advantage of using questionnaires is that they 
are non-invasive, and there are no other instruments that can provide a researcher or clinician information 
about a patient’s morbidity or quality of life.185  
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The main problem with using questionnaires is that because they provide a subjective outcome, there is no 
external objective reference.185 Patients’ scores cannot be compared to another, since patients may have 
different sensitivities and perceptions of pain and discomfort.185 Another is that patients are prone to 
psychological bias. Their responses on the questionnaire can be influenced by their mood. Language 
barriers can also be a problem, if a patient is confused or does not understand the questions.  
Questionnaires measure an underlying latent construct. A latent construct is an unobservable trait that is the 
subject of measurement. In this case, the latent construct is DE disease. Latent constructs can be quantified 
by querying the different aspects of the construct, and then analyzing the questions and responses with 
Rasch analysis186 or Item Response Theory to determine how well the items fit the construct. Questionnaires 
must be tested to show that they can accurately and reliably measure the underlying latent construct in a 
unidimensional manner.186 For example, the scale of the instrument should scale linearly with the disease 
so that a high attribute of the latent construct should be reflected as a high measurement on the scale, and a 
low attribute of the latent construct should be reflected as a low measurement on the scale. Incremental 
increase in the latent construct should be reflected with a proportional increment in the scale. In this case, 
DE questionnaires attempt to query the severity of the disease by querying ocular symptoms or quality of 
life measures with dry eye.  
1.4.1.1 Ocular Surface Disease Index (OSDI) 
 
A validated DE questionnaire that is commonly used in clinical research and patient care is the Ocular 
Surface Disease Index (OSDI).183,187 It contains items that queries a combination of DE symptoms and 
quality of life items in the previous week that are relevant to DE disease. The OSDI is one of the few 
questionnaires that meets the Food and Drug Administration (FDA) criteria for patient-reported outcomes 
(PRO) in quality of life measures.188 A composite score is generated based on the responses, with a higher 
score indicating more severe disease. A potential drawback for the OSDI is that categories for each 
individual item may not scale linearly, which can affect the scaling properties of this instrument.189 A search 
for published studies with the terms “Ocular Surface Disease Index” between Jan 01 2015 – Dec 31 2015 
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in PubMed revealed 125 studies. Some of the studies that used the OSDI included one that studied corneal 
and conjunctival sensitivity in rosacea patients (n=92),190 ocular surface disease in diabetic peripheral 
neuropathy patients (n=34),191 and the relationship between DE and depression (n=94).192  
1.4.1.2 Symptom Assessment in Dry Eye (SANDE) 
 
The SANDE questionnaire was developed by Schaumberg et al.182 and is different than the OSDI in that it 
only queries the frequency and severity of symptoms on average using two visual analogue scales. The 
questionnaire also yields a composite score that indicates disease severity. A study by Amparo et al.193 
compared the SANDE to the OSDI and found a significant correlation (R=0.64, p < 0.0001) at baseline and 
follow up (R = 0.47, p < 0.0001). Bland-Altman plots shows bias of -1.5 units at baseline, and 1.8 units at 
followup. The authors conclude that the SANDE is a fast and simple questionnaire to conduct, with 
performance similar to the OSDI.  
1.4.2 Objective Assessments 
 
Following subjective assessments, objective clinical tests are conducted. Some of these tests include 
assessments of tear stability, tear film osmolarity, lipid layer thickness, MG function, ocular surface 
integrity (with vital dyes), tear volume, tear secretion, eyelid margins and the lid wiper region.194  
1.4.2.1 Tear Film Osmolarity 
 
Tear film osmolarity may play a vital role in the pathogenesis of DE disease.87 The increase in concentration 
of solutes creates a hyperosmotic environment for the ocular surface. This increase in tear osmolarity has 
been found to increase the production of inflammatory cytokines in corneal epithelial cells in an in-vitro 
study conducted by Igarashi et al.195 However, the osmolarity values used by Igarashi et al. to induce 
inflammation (400mOsm - 800mOsm) were beyond the range typically measured in vivo, even in SS,196 
where DE disease is severe.  
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There are three different methods for measuring tear osmolarity; freezing point depression,197 vapour 
pressure,198 and electrical impedance.198 Freezing point depression osmolarity is based on the principle that 
the presence of solutes in a solution decreases its freezing point.199 Vapour pressure osmometers is based 
on the principle that vapour pressure is lower in a solution that contains more solutes.200 Electrical 
impedance osmometry measures the electrical conductivity of a solution, which changes based on the ionic 
concentration.199 
Vapour pressure and freezing point depression osmometry can be challenging to conduct in a clinical 
setting. Vapour pressure osmometry requires a relatively large amount of tear fluid for measurement 
(approximately 0.8μL - 2μL),201 and freezing point depression is expensive and requires specialized 
research equipment. An electrical impedance osmometer is commercially available (TearLab® Osmolarity 
System, TearLab® Corporation, San Diego, CA, USA) for clinical DE testing.202 The TearLab® has been 
compared with freezing point depression199 and vapour pressure198 techniques and was found to exhibit 
good correlation with the two osmometers.  
The TearLab® instrument was described to be the “single best test” for the diagnosis of DE.203 Using a 
cutoff of 308 mOsms/L, sensitivity and specificity for mild DE disease was found to be 88% and 75% 
respectively.203 A cutoff of 316 mOsms/L can be used for more moderate/severe patients, with sensitivity 
and specificity of 69% and 92% respectively.204 However, the performance of this instrument for DE 
diagnosis remains mixed. Bunya et al.205 found no significant difference in mean osmolarity between 
participants with SS, blepharitis, and control groups. Variability in osmolarity was increased in the SS and 
blepharitis group compared to the control.205 Tear film osmolarity was found to correlate negatively with 
tear meniscus height,206 but was not impacted by refractive surgery.207 Another study found no correlation 
between tear osmolarity and symptoms,208 and there was no detectable difference in tear osmolarity between 
women using CLs and oral contraceptive pills and those who were not.209  
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1.4.2.2 Tear Film Stability 
 
Tear film stability represents the duration in which the tear film remains spread and fully covers the ocular 
surface. The tear film destabilizes when the most anterior lipid layer collapses onto the corneal surface. A 
summary of various techniques employed in the study of tear film breakup time has been previously 
reported.210 Tear stability can be measured by instilling sodium fluorescein and observing the tear film 
down the slit lamp microscope with cobalt blue light and a Wratten 12 yellow barrier filter. The time for 
when a discontinuity is observed during the interblink interval is reported.210  There are a number of 
methods in which fluorescein can be instilled. One method is to use a standard ophthalmic fluorescein strip, 
where the tip is wetted and instilled into the eye at the inferior fornix. A problem with this method is that 
due to an uncontrolled volume of fluorescein instilled, this method may artificially increase the tear volume 
on the ocular surface, affecting its repeatability.211 To minimize this problem, there are thinner (1mm) 
fluorescein strips (Dry Eye Test, Amcom Laboratories, Saint Louis, MO, USA)212 that limit the amount of 
fluorescein and volume that could be instilled into the eye. Using a pipette to instill a controlled amount of 
fluorescein is another way to improve repeatability of tear breakup time measurements.213  
The addition of sodium fluorescein has also been shown to artificially destabilize the tear film.214 There are 
methods that do not require the addition of fluorescein or extraneous fluids to assess tear film stability (so-
called “non-invasive” methods).215 The procedure generally involves the projection of a mire, grid or 
Placido disk rings onto the anterior tear film, and then observing for when distortions occur in the 
reflection.216 The limitation of this procedure is that bright projections and sustained eye-opening may cause 
reflex tearing.217 A number of other methods using interferometry, confocal microscopy, visual acuity, and 
aberrometry, have been used to study tear film stability.210  
1.4.2.3 Tear Film Lipid Layer Thickness 
 
The majority of the lipids in the tear film originate from the MGs.218 The lipids form a thin layer on top of 
the tear film and act as a “blanket” to stabilize and reduce evaporation of the tear film.219 The lipid layer 
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thickness (LLT) is approximately 100nm and can range from <60nm – 180nm.220 Lipid layer thickness 
correlates significantly with fluorescein tear breakup time, Schirmer’s test,221 and with DE symptoms.222 
One commercially available device for quantifying tear film LLT is the LipiView (TearScience, 
Morrisville, North Carolina, USA). However, the LipiView LLT values showed no significant correlation 
with tear breakup time,223 and was found to thin or not change after receiving a LipiFlow treatment 
(TearScience, Morrisville, North Carolina, USA).224 The inter-observer coefficient of repeatability of the 
LipiView is 13nm, with an inter-observer coefficient of repeatability of 16nm.225 In the same study, LLT 
did not correlate with corneal staining, tear breakup time, and DE symptoms.  
1.4.2.4 Meibomian Gland Evaluation 
 
The MGs are assessed by applying pressure to the eyelid margins and observing the quality of meibum that 
is expressed. Without applying pressure to express the glands, it can be difficult to assess the state of 
obstruction.134 Typically, pressure to the eyelid margins is applied digitally, with the fingertip applied just 
below the base of the eyelash margin (Figure 1-5).   
 
Figure 1-5: A common method to express meibum from MGs is to apply pressure using the leading edge 
of a finger against the base of the eyelashes. Note the paste-like meibum that is being expressed (black 
arrow).  
A potential problem with this technique is that pressure exerted on the eyelids is uncontrolled and can vary 
between individuals. To remedy this, TearScience has developed a small hand held device with a spring 
 
 
26 
 
mechanism (Meibomian Gland Evaluator, MGE) that exerts a pressure of approximately 1.25g/mm2 over 
an area of 40mm2, to simulate the force of blinking on the MGs (Figure 1-6).   
 
Figure 1-6: The MGE consists of a metallic body with a spring-mounted plastic tip. The leading edge of 
the plastic tip is depressed halfway against the inferior eyelid margin, for 10 seconds at the base of the 
eyelashes to express meibum from the MG orifices.  
The leading white tip is approximately 15mm long and the total spring travel is 6mm. To ensure constant 
pressure, the white tip should travel approximately 3mm (or the halfway point) to maintain the pressure of 
1.25g/mm2 and not to exceed 6mm. The white tip should be held for approximately 10 seconds to ensure 
expressible meibum is expressed. 
The MGE can be used to express 5 glands simultaneously and can be used to assess the temporal, central 
and or nasal portion of the eyelids (Figure 1-7).226  
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Figure 1-7: The MGE can be used to express five consecutive glands temporally, centrally, and nasally. 
Image from Blackie CA, Korb DR. The diurnal secretory characteristics of individual meibomian glands. 
Cornea. Jan 2010;29(1):34-38. 
Each single gland can then be evaluated based on the type of meibum secretion that is observed. In the 
study by Friedland et al.,227 secretions were graded from 0 to 3 (0: no secretion, 1: inspissated, 2: liquid 
coloured, 3: clear oil). The grades were then summed for a total out of 15 per each portion of eyelid, for a 
grand total out of 45 for the entire eyelid.228 An additional parameter that can be obtained from this 
measurement is the “Meibomian Glands Yielding Liquid Secretions Score”, where the number of glands 
with secretions of grade 2 or higher is counted.  
Without an MGE, the MGs can still be assessed with digital pressure, but the pressure exerted will vary. A 
study229 found that meibum expressed and graded using a cotton-tipped applicator was not significantly 
different than the MGE in MGD and non-MGD controls. Various grading scales have been used to grade 
the secretions.230-232 
Manipulating the eyelids (e.g. for eyelid eversion) prior to assessing MG expression should be avoided, 
since applying pressure to the eyelids will manually express the contents of the MGs. For this same reason, 
the evaluation of meibum secretion on the superior lid on may be difficult since it typically requires some 
lid manipulation to observe the MG orifices.  
 
 
28 
 
1.4.2.5 Meibography and Meibomian Gland Imaging  
 
(Section adapted from Ngo W, Srinivasan S, Jones L. Historical overview of imaging the meibomian 
glands. Journal of Optometry 2013;6:1-8.)233 
Meibography relates to various methods of visualizing and imaging the MGs, and has become an important 
tool to monitor disease progress. There are a number of methods in which meibography can be conducted. 
The technique has evolved over the past few decades in parallel with advances in medical technology. 
Traditionally, the eyelids were transilluminated with a light source, and the transmitted infrared (IR) rays 
were captured with an IR camera.234-236  
1.4.2.5.1 Lid transillumination 
 
The technique of transilluminating the lid and observing it under the microscope was first described by 
Tapie in 1977,234 by using an illumination probe typically used for intraocular vitreous surgery.230,234,235 The 
tip of the probe was inserted behind the everted eyelid and the silhouette of the MGs was then observed on 
the other side. At the time, this was the only way of obtaining information about the morphology and 
physical characteristics of the MGs. Some major disadvantages of this technique was that the probe tip was 
small and sharp, causing uncomfortable heat, discomfort and pain to patients.237 The transillumination area 
was also small, making it difficult to capture images of the entire length of the lid. Meibomian gland dropout 
in the lid were indicated by decreased transmission of light.  
Fiber optic cables and other devices can be used as light sources for transillumination.230,238-242  As the eyelid 
is everted over the fiber optic cable, it is transilluminated by the light that is conducted through the cable. 
Since fiber optic cables are smaller and thinner, it is more patient-friendly than solid, hand-held probes. 
Once the eyelid is transilluminated, the MGs and acini are revealed. The practitioner can then evaluate and 
record the appearance of the glands using some form of photography. Meiboscopy is the viewing of the 
MGs (using a tool like a Finoff transilluminator) without the use of photography, whereas meibography 
implies visualization and use of photography (film or digital). Photography of MGs can be conducted by 
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combining a photo slit lamp with high speed IR film.236 The process usually requires IR film and the process 
of developing IR film can be very time consuming.  
From the images, the number of MGs can be manually counted and the degree of MG dropout, or area of 
MG loss, can be measured. Lid transillumination has been used to study MG dropout in isotretinoin use for 
acne vulgaris,230 blepharitis,239 chronic blepharitis,230 aging,242 ocular surface disease and MGD,232 and 
SS.238 The practice of lid transillumination remains a key technique in studying MGs, but the use of IR film 
has been overshadowed by more advanced digital video systems. 243  
1.4.2.5.2 Video Meibography Systems 
 
Video-meibography systems have addressed some of the disadvantages with IR photography. In 1994, 
Mathers et al. had developed a video-meibography system which allowed the transilluminated eyelid to be 
viewed in real-time on a computer.243 A VHS recorder was used to record videos and individual frames 
from the video sequence was extracted for analysis.243 The quality of the images was comparable to the 
images captured using IR camera, but without the inconvenience of developing IR film. However, the small 
and localized nature of the light source meant that it still required approximately 5 images to compose the 
entire eyelid.243 This was remedied by fitting custom adaptors onto the transilluminator that allowed a wider 
area of light distribution. Yokoi et al. had designed an oblique T-shaped adaptor with an array of windows 
along the head of the adaptor that simultaneously facilitate eyelid eversion while transilluminating it 
underneath. This reduced the number of images to cover the entire eyelid from 5 to 3.237 Recently, 
improvements in imaging technology have made it possible to conduct meibography without a 
transilluminating device.  
1.4.2.5.3 Non-contact Meibography 
 
Imaging the eyelid with an IR source and then capturing the image using an IR charge-coupled device 
(CCD) is the main principle behind non-contact meibography. Images of the entire eyelid can be obtained 
within a minute. A major advantage with non-contact meibography compared to previous methods is that 
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a transilluminating light source is no longer required, improving patient comfort significantly. Non-contact 
meibography is flexible and can be adapted from a slit lamp,244 a security camera (Figure 1-8),245 or even 
built into multi-purpose devices such as the Keratograph 4 (Figure 1-9)246,247  and 5M (Figure 1-10) 
(OCULUS, Wetzlar, Germany).248  
 
Figure 1-8: Left, an infrared security camera modified for meibography. A ring of infrared LEDs 
illuminate the eye, and the central camera unit captures infrared video to be displayed on a computer 
screen (not shown). Right, this image was captured by the modified security camera. The ring 
configuration of the infrared LEDs of the camera can be seen in the reflection of the cornea. Courtesy of 
Dr. Heiko Pult 
 
Figure 1-9: The OCULUS Keratograph 4 functions primarily as a corneal topographer, however the 
infrared diode intended for pupillometry can be used as an infrared illumination source for meibography 
(left). An everted superior eyelid reveals long thin MGs running vertically on the palpebral side as 
visualized by the OCULUS Keratograph 4 in infrared light (right). 
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Figure 1-10: The entire superior palpebral surface could be imaged using the OCULUS Keratograph 5M 
(left). A processed image of the same eyelid highlights the MGs to make them more visible (right). 
Non-contact meibography has been used to study MG duct distortion in patients with perennial allergic 
conjunctivitis,249 MG dropout in patients with CL wear,173 the difference in dropout between inferior and 
superior eyelids250 and impact of age on MG dropout.244 This method was also used to study the reliability 
of meibography grading scales,241 the diagnostic parameters for obstructive and seborrheic MGD,251,252 and 
the difference between obstructive MGD and aqueous deficient DE.253 
Recently, TearScience has upgraded the LipiView to the LipiView II.254 One of its new functions is 
meibography that features “Dynamic Meibomian Imaging™” technology in which adaptive 
transillumination is combined with dynamic illumination to yield high contrast images of the MGs.254  
Despite the different methods available to undertake meibography, they all provide a gross view of the MGs 
and allow observers to make observations and monitor MG dropout and morphological distortion.  More 
detailed information about MGs and MGD can be obtained by examining them under higher magnification. 
Previously, studying the ultrastructure of MGs required preparing and viewing histological sections 
belonging to animal models or from human exenterations,236,255,256 but with advances in imaging technology 
it is now possible to view the ultrastructure of human MGs in vivo using a variety of anterior segment 
observational instruments.257-263 
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1.4.2.5.4 Confocal Microscopy 
 
The Heidelberg Retinal Tomograph II/III with the Rostock Cornea Module (Heidelberg Engineering 
GmbH, Dossenheim, Germany) uses a 670nm LED light to provide high resolution scans (optical: 4μm 
horizontally, 2μm vertically, digital: 1μm/pixel vertically and horizontally) of the biological tissue of the 
anterior segment. The images generated at 384 x 384 pixels correspond to a 400x400μm field of view, and 
can be analyzed with the built-in software, or with ImageJ (Java software developed by National Institutes 
of Health).258,264,265 The primary advantage of this technique is that it allows in vivo real-time viewing of 
MG acini structures in microscopic detail. 
The first to report on observing MGs with confocal microscopy was perhaps Kobayashi et al.260 in 2005, 
when they used confocal microscopy to observe the cells of the conjunctiva. The “web-like structures” seen 
below the conjunctival layers were presumed to be MGs.260 
Meibomian gland acinar unit density (MGAUD), meibomian gland acinar longest and shortest diameter 
(MGALD, MGALSD) are two metrics that can be used in conjunction with the HRT internal software to 
assess the severity of MGD (Figure 1-11).264,265 In addition, periglandular inflammatory cell density (ICD) 
can also be quantified.264 
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Figure 1-11: A 400μm x 400μm frame of acini clusters as seen with the HRT-II Rostock Cornea Module. 
Acini units (cyan) and inflammatory cells (magenta) are manually marked, and density for each is 
automatically calculated using the Cell Count® software (Heidelberg Engineering GmbH, Germany). 
Courtesy of Dr. Murat Dogru. 
Confocal microscopy can assess the effectiveness of various MGD treatment strategies,266 the effect of 
aging on conjunctival and MG structures,267 the difference in morphology of gland structures between non-
CL and CL wearers,268 and reveal MG morphological changes in patients with SS.269  
1.4.2.5.5 Optical Coherence Tomography 
 
Imaging the MG structures with optical coherence tomography (OCT) for clinical management of dry eye 
is also not common, but has been shown to be feasible. Hwang et al. had used a fourier domain OCT with 
center wavelength of 1310nm (bandwidth = 100nm) to generate 3D images of MGs.270 Images of MGs 
captured with OCT have greater detail than those observed by infrared meibography,271 but do not surpass 
the theoretical limits of confocal microscopy.272 Three dimensional image reconstructions of MGs have 
also been accomplished using a polarization sensitive OCT to study age-related changes to the MGs.273 
1.4.2.5.6 Meibography Grading Scales 
 
Currently, there has been no consensus on grading MG dropout, and thus several grading scales have been 
devised and used to assess MG dropout. 
Mathers et al.50: The central 10 glands of the inferior tarsus were photographed and graded based on how 
much light was transmitted through the gland.  
Jester et al.236 found that more severe dropout corresponded with decreased transmission of light, due to 
increased thickness of the keratinized epithelium.  
 Grade 1: Normal gland 
 Grade 2: Gland visible with decreased absorption 
 
 
34 
 
 Grade 3: Acini of gland severely atrophic with duct still visible 
 Grade 4: No gland structures visible 
Den et al.242 :   
Grade 0: absent 
Grade 1: present (more than half of lower lid) 
Arita et al.244 :   
Grade 0: no dropout 
 Grade 1: dropout of less than <1/3 of total area of glands  
 Grade 2: dropout of more than 1/3, but less than 2/3 of total area of glands 
 Grade 3: dropout of more than 2/3 of total area of glands 
McCulley et al.54 and Aronowicz et al.274,275:   
The central 7 glands of the tarsal plate were examined. Each gland is given a score from 0 to 4, 
where 0 represents no dropout, and 4 is complete dropout of that single gland. The score from each 
gland is summed up as a total out of 28. 0/28 would represent no dropout whereas 28/28 is complete 
dropout. 
Shimazaki et al.15 and Goto et al.238,276:   
Grade 0: no dropout 
 Grade 1: loss of less than half the glands in inferior tarsus 
 Grade 2: loss of more than half the glands in inferior tarsus 
McCann et al.239:  
Grading was based on the percentage of glands that were absent. For example, if 50% of glands 
had dropped out, dropout would be graded as 0.5.  
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Pult et al.245 :  
Using ImageJ to analyze photos, the area of dropout was subjectively defined and expressed as a 
percentage of the total area of the tarsal plate. The angles at which the glands are bent are also 
analyzed.  
Srinivasan et al.244,245,277 : indicated the presence or absence of white patches and gland tortuosity while 
using the grading by Arita et al. and ImageJ.  
Ngo et al.248 :  
 Grade 0: 0% dropout 
 Grade 0.5: 1 to 16% dropout 
 Grade 1.0: 17% to 33% dropout 
 Grade 1.5: 34% to 50% dropout 
 Grade 2.0: 51% to 67% dropout 
 Grade 2.5: 68% to 84% dropout 
 Grade 3.0: 85% to 100% dropout 
Currently there is no consensus on the number of increments that should be present in a grading scale for 
meibography. Bailey et al. has recommended that a scale of fine clinical sensitivity should not exceed one-
third of the standard deviation of the discrepancy, using scales with smaller increments to increase the 
ability to detect clinical changes.278,279 
1.4.2.6 Corneal and Conjunctival Staining 
 
Corneal and conjunctival staining allows for the assessment of ocular surface integrity through the use of 
vital dyes. Despite its common use, the mechanism for damaged cells to take up the stain is still unknown.280 
The interpretation of corneal and conjunctival staining depends on the grading scale that is used. The 
staining is usually located at the inferior third of the ocular surface, representing the palpebral fissure where 
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desiccation occurs. Four ocular staining grading scales (Oxford scheme,281 National Eye Institute-
recommended system,282 area-density combination index,283 and the Sjogren’s International Collaborative 
Clinical Alliance284) were compared by Sook and Park.285 They found excellent inter-observer repeatability 
and reliability.285 While these scales use subjective grading methods, automated and objective methods of 
grading also exist.286,287  
1.4.2.7 Schirmer’s Test 
 
Schirmer’s test is used to quantify tear and volume production. This is conducted by inserting a sterile 
standardized paper strip into the inferior lid margin. The strip is allowed to soak up tears for 5 minutes, and 
the amount of wetting represents the volume and production of tears. The test can be conducted with or 
without anesthesia of the ocular surface. The use of anesthesia (Schirmer II) reduces lacrimation input from 
the ocular surface and measures basal lacrimal secretion, and was reported to generally be more reliable.288 
There is currently no consensus as to where on the inferior lid margin the Schirmer’s strip should be placed, 
which gaze direction to be held,289 and whether the eyes should be open or closed.290  
1.4.2.8 Lid Margin Evaluation 
 
The eyelid margin is assessed using a biomicroscope. The eyelid margin may exhibit changes including the 
presence of irregularity,231 erythema,291 telangiectasia, and increased vascularity of the posterior margin. 
These signs are associated with MGD.292 How these changes occur remains unknown. Some other important 
eyelid margin features that may be related to DE include the position of the Marx’s line, and lid wiper 
epitheliopathy.  
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Figure 1-12: An irregular Marx’s line with varying thicknesses is highlighted with lissamine green.  
Marx’s line is an anatomical feature, a demarcation representing the junction between the keratinized 
cutaneous skin of the face and the mucous epithelium of the conjunctiva. Marx’s line is thought to originate 
from hyperosmolar stress at the leading edge of the peripheral tear meniscus, creating a region that is 
susceptible to vital dye staining.293 In normal patients, Marx’s line is straight, regular, and runs posterior to 
the MG orifices. In CL wearers294 and MGD,295 Marx’s line appears to be irregular, thickened, and may 
shift anteriorly and bypass the MG orifices. Lissamine green can be used to stain and visualize Marx’s line 
(Figure 1-12).296 There are currently two different methods of grading Marx’s line.  
Kim et al.294 grades of Line of Marx (LOM) as follows:  
 Grade 0: LOM mostly (>75%) posterior to the orifices 
 Grade 1: LOM mostly bisecting the orifices 
 Grade 1: LOM mixed posterior and bisecting the orifices 
 Grade 2: LOM mostly anterior 
 Grade 2: Mixed posterior, bisecting and anterior to the orifices 
 Grade 2: LOM mixed bisecting and anterior to the orifices 
Yamaguchi et al.295 grades Marx’s line as follows:  
 Grade 0: the line runs entirely on the conjunctival side of the MG orifices 
 Grade 1: parts of the line arch forward to touch the MG orifices 
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 Grade 2: the line runs through the MG orifices 
 Grade 3: the line lies on the skin side of the MG orifices 
Yamaguchi grades the line on the central, nasal and temporal thirds of the eyelid, for a total score out of 9 
per each eyelid.  
The debridement, or the mechanical removal of debris using a golf club spud, of Marx’s line was found to 
improve signs and symptoms in individuals with evaporative dry eye297 and SS-DE.298  
1.4.2.9 Lid Wiper Epitheliopathy 
 
The lid wiper is an epithelial ridge located in both the superior and inferior eyelid, just posterior to the MGs. 
A number of different cell types make up this area (stratified epithelium, cuboidal cells, goblet cells, 
parakeratinized cells).299 Without proper ocular surface lubrication, mechanical trauma from friction may 
induce cellular changes.299 This could be observed with the instillation of ophthalmic dyes (Figure 1-13). 
A higher prevalence of lid wiper epitheliopathy was found in dry eye participants,300 and correlated with 
dry eye symptoms.178  
 
Figure 1-13: Lid wiper epitheliopathy can be observed with lissamine green. In this photo, the entire 
sagittal width of the lid wiper has been stained. Courtesy of Jalaiah Varikooty, Centre for Contact Lens 
Research. 
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1.5 Management of Dry Eye 
 
1.5.1 Tear Supplementation 
 
Artificial tears are a mainstay in DE management.301 Artificial tears can range widely in composition and 
viscosity, 302 allowing them to target specific tear film or ocular surface deficiencies. For example, some 
artificial tears contain lipids303,304 to supplement a deficient lipid layer, and some contain hyaluronic acid (a 
glycosaminoglycan) for water retention and to promote recovery of the ocular surface.305,306 Some artificial 
tears have higher viscosities, allowing them be retained on the ocular surface for a longer period of time, 
but at the cost of visual quality.307 Other artificial tears may contain a preservative-free formulation, which 
allow the drops to be instilled more frequently or used along-side other topical ophthalmic medication to 
relieve ocular surface disease.308   
1.5.2 Warm Compresses 
 
The delivery of heat (with or without mechanical pressure) to the eyelid comes in a variety of forms and 
can range from simple towel compresses, 309 to steam-emitting devices,310 microwaveable heat-retaining 
bags311 and electronically-controlled eye-mounted actuators.312 The application of heat and pressure 
decreases the viscosity of meibum within the MGs, promoting increased delivery of meibum into the tear 
film.313 Since heat is required to melt meibum, heat retention is an important aspect of therapy. Rapid 
dissipation of heat on the eyelid can be attributed to the dense vasculature of the skin,314 where blood flow 
can quickly remove heat from the area. This may be counter-acted by applying some pressure around the 
eyelid to slow down blood flow.314 Additionally, moistened towels tend to cool off quickly, therefore a 
device that retains heat well over the eyelids will be beneficial. A study of heat retention across several 
eyelid warming devices has been previous studied,315 and there are currently multiple studies310,311,316-319 
that assess their efficacy in the treatment of MGD.  
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1.5.3 Omega-3 Fatty Acids 
 
Omega-3 fatty acids (O3FAs) are essential fatty acids that can be acquired through a diet consisting of 
fish.320 These oils play a role in modulating inflammation in many systemic diseases, such as bipolar 
depression,321 diabetes mellitus,322 and cardiovascular disease, 323,324 osteoarthritis,325 and other autoimmune 
conditions.326  Two types of O3FAs, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are 
incorporated into cell membranes for cell signalling and communication.327 Specifically, O3FAs have 
antagonistic effects to pro-inflammatory Omega-6 fatty acids (O6FAs).328 One such O6FA is arachidonic 
acid, a key molecule responsible for initiating the inflammatory cascade which results in the production of 
various inflammatory cytokines.328 Various studies have found that a lower O3FA:O6FA ratio was not only 
associated with cardiovascular disease,329-331 but also with a higher incidence of DE.332  
Inflammation is a core component of DE.333 Omega 3 fatty acid supplementation was shown to have an 
effect on the metabolic profile of the tear film,334 and was found to improve various signs and symptoms in 
DE.335-342 To-date, there is still no consensus as to the appropriate dosage for a therapeutic effect.343 Some 
previous studies that reported successful DE outcomes have used at least 1000mg of combined EPA and 
DHA.336,344-346  
1.5.4 Eyelid Hygiene 
 
Microbial bioburden can adversely affect the ocular surface environment in a number of ways. Bacteria 
may use components of the tear film as food source,347 thereby metabolizing and changing the tear film 
composition. The breakdown of meibum by staphylococcal lipases was previously confirmed.348 Bacterial 
toxins can also trigger an immune reaction and exacerbate inflammation.347 A common type of blepharitis 
is staphylococcal blepharitis, which can be diagnosed by observing the eyelashes for misdirection, eyelash 
loss, injection and/or the presence of matted/hard scales on the lashes.349 
Another common type of blepharitis is Demodex blepharitis,350 and this can be diagnosed by looking for 
waxy, cylindrical dandruff “cuffs” at the base of the eyelash (Figure 1-14).351 A strain of bacteria (Bacillus 
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oleronius) isolated from Demodex may be responsible for triggering an inflammatory response within the 
surrounding tissue.352,353  
 
Figure 1-14: Two Demodex tails can be seen protruding from the lash follicle when the cylindrical 
dandruff is cleaned off and the lash is pulled aside.  
Eyelid hygiene is a standard for the treatment of blepharitis.354 The purpose of eyelid cleansing is to reduce 
microbial burden on the eyelids.354 Decreasing microbial burden reduces the source of toxins and improves 
the environment of the ocular surface. Eyelid cleansing products can come in various forms. They may take 
the form of pre-moistened cotton pads,355,356 foam-dispensing bottles,357 spray bottles,358 or an electronic 
rotary brush.359 These products typically contain detergents or antimicrobial substances, and when 
combined with mechanical action, can be effective at removing bioburden and biofilms from the eyelid 
margins. Eyelid cleansing has been shown to improve symptoms of discomfort.355,356  
Overall, DE is a multifactorial condition that requires a careful assessment of patient risk factors, symptoms 
and signs for an accurate diagnosis and management plan. There are a number of DE diagnostic tools and 
treatment strategies that have been recently developed, but their role in DE management is still unknown. 
Further investigation into these new technologies and treatments will allow researchers and clinicians to 
better understand their impact on DE disease.  
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2 Rationale 
 
Dry eye (DE) is a multifactorial disease1 that affects millions of individuals around the world.2 This 
condition inflicts symptoms of ocular burning, stinging, and tearing, which can severely impact quality of 
life.3  
The assessment of DE is conducted with a variety of clinical tests.4 A thorough assessment consists of 
several aspects; a detailed history to evaluate DE risk factors, symptom assessment to evaluate subjective 
morbidity; and a battery of clinical tests to assess the function of the lacrimal functional unit and accessory 
glands.4 One part of a routine DE assessment involves the examination of the meibomian glands (MGs). 
These glands produce and secrete meibum (lipids) into the tear film to reduce its surface tension, and reduce 
its rate of evaporation.5  
One of several clinical tests that is used to examine the MGs is meibography. Meibography is a set of 
techniques that facilitates the viewing of MGs.6,7 From viewing the MGs, the extent of MG atrophy can be 
observed and quantified. Meibomian gland atrophy is commonly graded using clinical grading scales, of 
which a wide variety exists.8 There are numerous existing instruments that have been adapted to conduct 
meibography.9-11 Chapter 3 explores some of the capabilities of MG imaging using infrared meibography, 
optical coherence tomography, and confocal microscopy. Currently, there is no consensus and set standards 
on MG imaging. A possible reason for this is that there is a current lack of sufficient evidence and 
knowledge to build these standards. One unknown aspect of grading MGs is whether meibography 
instruments can be used interchangeably (e.g. using instrument “A” on day 1, and instrument “B” on day 
2). A second aspect is that the inter- and intra-observer variability for grading MG atrophy is not well 
studied. To address these knowledge gaps, Chapter 4 examines the repeatability and inter- and intra-
observer variability when using the Keratograph 4 and K5M (OCULUS, Wetzlar, Germany) for MG 
imaging.   
 
 
43 
 
In addition to MG atrophy, two eyelid margin features (lid wiper epitheliopathy and Marx’s line placement) 
have recently been associated with symptomatic DE12 and meibomian gland dysfunction (MGD).13 
Mechanical trauma to the eyelid wiper region as a result of insufficient ocular lubrication has been 
hypothesized to cause DE symptoms in individuals with no other apparent DE signs,14 and the anterior shift 
in Marx’s line placement may be correlated with MGD.13 To gain a better understanding of these two eyelid 
margin features, Chapter 5 investigates an age-matched female cohort to study these features in the context 
of symptoms and other DE signs.  
New methods for the treatment of MGD are constantly emerging. Warm moist towel compresses have been 
a mainstay for MGD treatment, however they lack efficacy due to rapid cooling.15,16 The MGDRx EyeBag 
(The EyeBag Company Ltd., Halifax, UK)17 is a recently developed eyelid warming device that has been 
designed to retain heat longer than conventional warm moist towels. There is only one prior study that 
examined the efficacy of the EyeBag,18 but that was based on a contralateral eye design, which made it 
difficult to accurately assess the impact of the device on symptoms. To address this limitation, Chapter 6 
examines the efficacy of the EyeBag in a bilateral randomized controlled trial.  
Lid debridement-scaling (LDS) is also a relatively newly reported clinical procedure, which functions to 
mechanically remove eyelid margin debris that obstruct the MG orifices.19 This procedure was previously 
shown to be effective at improving MG function and symptoms in individuals with evaporative DE.19 It is 
currently unknown whether this procedure could be extended to individuals with Sjӧgren’s syndrome (SS), 
and how efficacious this procedure would be if used in such patients. To further understand the effectiveness 
of LDS, Chapter 7 examines the potential benefit of LDS in individuals with SS in a randomized controlled 
study.  
The management of DE typically involves the use of artificial tears,20 eyelid hygiene,21 and supplementation 
with omega 3 fatty acids.22,23 Although many studies examine the efficacy of each of these single 
components, very few have quantified the efficacy that can be achieved when all these products are used in 
combination. In Chapter 8, the efficacy of a combination of DE products is assessed over a duration of 3 
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months. Quantifying the effect of combined therapy will allow clinicians and researchers to further 
understand the impact of combination DE therapies.  
In the concluding chapter, Chapter 9, a summary of the work and suggestions for future direction is 
presented.  
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3 Imaging Meibomian Glands using Optical Coherence Tomography 
and Confocal Microscopy 
 
3.1 Overview 
 
PURPOSE: To determine whether an experimental spectral domain ultra-long optical coherence 
tomographer (UL-OCT) can image meibomian glands (MGs) and to compare its acquired MG images with 
the Heidelberg Retinal Tomograph 3 (HRT3) with Rostock Cornea Module (RCM) in vivo laser scanning 
confocal microscope (Heidelberg Engineering GmbH, Heidelberg, Germany) and the Keratograph 5M 
(OCULUS, Wetzlar, Germany).  
METHODS: Twelve healthy participants (7F, 5M) were enrolled in this study. The superior eyelids of 
participants were everted and imaged using the UL-OCT. Participants then had both the inferior and 
superior eyelids everted and imaged using the Keratograph 5M. Finally, the inferior eyelids were everted 
and imaged with the HRT3/RCM.   
RESULTS and CONCLUSION: The UL-OCT was unable to image MGs. The HRT3/RCM imaged 
structures that resembled dermal rete pegs and papillae. Of the three methods used in this study, the only 
device that was able to successfully image MGs was the Keratograph 5M.  
3.2 Introduction 
 
The secretions of the meibomian glands (MGs) play a vital role in maintaining the stability of the tear film.1 
These modified sebaceous holocrine glands are located within the tarsal plate of the eyelids, and produce 
meibum (lipids) that travel out of the gland orifices at the eyelid margin, and into the tear film.2 Meibum 
reduces the rate of tear film evaporation,3 and functions to keep the tear film spread thinly without 
collapsing onto the cornea.4 A lack of meibum delivery to the tear film could be due to several factors,5 one 
of which is thought to be due to atrophy of the MGs.6 With an unstable tear film, the ocular surface is 
repeatedly desiccated, which can potentially cause symptoms of ocular dryness, burning, and irritation.7   
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Imaging the MGs is a way to assess the severity of MG atrophy and it is facilitated with a group of 
techniques collectively known as meibography.8 An overview of meibography techniques have been 
discussed elsewhere.8,9 Generally, MGs can be observed by transilluminating the eyelid, or by illuminating 
the palpebral conjunctiva with infrared light.10,11 The Keratograph 5M (OCULUS, Wetzlar, Germany) has 
a dedicated meibography function that use 840nm LED bulbs to illuminate the palpebral conjunctiva.12  
Imaging the ultrastructure of MGs using confocal microscopy (CM)13-23 and optical coherence tomography 
(OCT)24-28 have also been reported, but their use in dry eye management is not as common, despite their 
wide range of use in medical applications.29,30  
Optical coherence tomography images biological tissue in vivo in real-time31 and is similar in principle to 
ultrasound imaging.32 Instead of using sound energy, a low coherence light source is directed at biological 
tissue and a computer interprets the reflecting light by comparing it against a reference beam.32 Various 
structures at different depths generate unique interference signals and a computer uses this information to 
calculate the depth of the structures.32 The axial resolution of an OCT is highly dependent on the wavelength 
and bandwidth of the light source.32 A shorter wavelength is more resolving, but a longer wavelength 
penetrates deeper tissue.32 A larger bandwidth yields shorter coherence length and higher axial resolution.32 
A reconstructed image of MGs imaged with OCT is displayed in Figure 3-1.26 Optical coherence 
tomography transverse sections of the superior eyelid have revealed that MGs are approximately 0.45mm 
in width, and are located approximately 0.4mm below the apical surface of the palpebral conjunctival 
epithelium (Figure 3-2).25  
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Figure 3-1: A) Meibomian gland imaged from an FD-OCT, compared with B) the infrared meibography 
image. Image from: Hwang HS, Shin JG, Lee BH, Eom TJ, Joo CK. In Vivo 3D Meibography of the 
Human Eyelid Using Real Time Imaging Fourier-Domain OCT. PLoS One. 2013;8(6):e67143. 
 
Figure 3-2: A) Infrared meibography image is compared to B) a transverse section of the superior 
palpebral conjunctiva. The white line indicates the location of the section. Image from: Hwang HS, Park 
CW, Joo CK. Novel noncontact meibography with anterior segment optical coherence tomography: Hosik 
meibography. Cornea. Jan 2013;32(1):40-43. 
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Confocal microscopy (CM) differs from OCT in that CM does not depend on interferometry to image axial 
structures.32 Instead, scattering and reflectance of the laser by the specimen provides information at the 
plane of focus.33 The depth of field in confocal microscopy is shallow and utilizes pinholes along the optical 
path to attenuate non-planar photon noise.33 Although CM can generally achieve higher resolution scans 
than OCT,32 one limitation is that tissue depth penetration is very limited.34 An image of MG acini taken 
with CM is displayed in Figure 3-3.17  
The Centre for Contact Lens Research (CCLR) have an experimental custom-built spectral domain ultra-
long OCT (UL-OCT) (University of Waterloo, Ontario, Canada) that was used to successfully fit scleral 
lenses35 and study various tear meniscus parameters.36 It is currently unknown whether or not the UL-OCT 
is capable of imaging tarsal plate structures, in particular the MGs.   
The purpose of this study was to determine whether the UL-OCT was capable of imaging MGs, and to 
compare them to images captured by the Heidelberg Retinal Tomograph 3 (HRT3) with Rostock Cornea 
Module (RCM) in vivo laser scanning CM (Heidelberg Engineering GmbH, Heidelberg, Germany), and the 
Keratograph 5M.  
 
Figure 3-3: Meibomian gland acini structures from a healthy 26 year old male obtained using the 
HRT3/RCM confocal microscope. Image from: Fasanella V, Agnifili L, Mastropasqua R, et al. In Vivo 
 
 
49 
 
Laser Scanning Confocal Microscopy of Human Meibomian G lands in Aging and Ocular Surface 
Diseases. Biomed Res Int. 2016;2016:7432131. 
3.3 Methods 
 
The study was conducted at the Centre for Contact Lens Research at the University of Waterloo. The study 
was conducted in conformance with the ethical principles of the Declaration of Helsinki, the ICH guidelines 
for Good Clinical Practice, and the UW Guidelines for Research with Human Participants. Informed 
consent was obtained from all participants prior to enrollment in the study. Ethics clearance was obtained 
through a UW Research Ethics Committee prior to commencement of the study.  
3.3.1 Participants 
 
This was a single-visit study that enrolled 12 healthy participants (7 female, 5 male). To be eligible for the 
study, participants indicated that they were willing to undergo eyelid eversion and must not have worn 
contact lenses for at least 12 hours prior to the study visit. This was to minimize the occurrence of any 
inflammatory events.  
3.3.2 Ultra Long Optical Coherence Tomography  
 
The superior eyelid of the right eye was everted and imaged using the UL-OCT (Figure 3-4). The 
specifications of the UL-OCT and the settings used for imaging the meibomian glands can be found in 
Appendix 1. The area for scanning was selected to be at the horizontal midpoint, and one-quarter from the 
everted eyelid margin. The focal plane of the UL-OCT was adjusted so that the transverse section of the 
palpebral conjunctiva was clearly visualized. A horizontal scan capturing 30 images across an area of 
4.96mm x 4.93mm was initiated using a foot pedal. This was repeated for the left eye.  
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Figure 3-4: The UL-OCT is mounted onto a slit lamp platform, which allowed participants to remain 
stable during eyelid eversion.   
3.3.3 Infrared Meibography 
 
Participants were then imaged on the Keratograph 5M. The inferior and superior eyelids of the right eye 
was everted using a cotton-tipped applicator and imaged using the meibo-scan tool. This involved using 
infrared light-emitting diodes (LEDs) at a wavelength 840nm to illuminate the everted eyelids.12 This was 
repeated with the left eye. Meibomian gland dropout of each eye was graded by using the grading method 
described in Arita et al.11 (Grade 0: No dropout, Grade 1: up to 1/3 of the lid, Grade 2: 1/3 to 2/3 of the lid, 
Grade 3: More than 2/3 of the lid). Meibomian gland dropout was reported as an average between the two 
eyes.  
3.3.4 Confocal Microscopy 
 
The lower eyelids of each participants were then imaged using the HRT3/RCM.37 A drop of proparacaine 
hydrochloride ophthalmic solution 0.5% (Alcaine, Alcon Canada, Mississauga, Ontario, Canada) was 
instilled in both eyes. An optical coupling gel (GenTeal, Novartis, Dorval, Quebec, Canada) was applied 
between the microscope lens and the Tomocap. The imaging plane of the HRT3/RCM was zeroed at the 
anterior surface of the Tomocap. Another application of the coupling gel was applied to the anterior surface 
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of the Tomocap. Participants were asked to position their eyes in superior gaze while the right inferior 
eyelid was everted. The Tomocap was applanated onto the surface of the palpebral conjunctiva. The focus 
plane was adjusted using the fine focus knob until MG structures could be visualized. A volumetric scan 
was conducted to obtain a tomogram of the region of interest. This was repeated with the left eye. The full 
specifications of the HRT3/RCM is listed in Appendix 2.  
3.4 Results 
 
The mean±SD age of the participants (7F, 5M) was 36±13 years old, ranging from 20 to 56 years old.  
3.4.1 Infrared Meibography 
 
Meibomian gland images were successfully obtained in all participants. A typical image of the MGs imaged 
with the Keratograph 5M is shown in Figure 3-5. The mean±SD meiboscore of this sample was 1.5 ± 1.4. 
 
Figure 3-5: An image of the meibomian glands captured with the Keratograph 5M. Meibomian glands 
appear as an array of bright threads that vertically traverse the eyelids.  
3.4.2 Ultra Long Optical Coherence Tomography 
 
The images generated by the UL-OCT were 2048 x 2048 pixel slices, with 72dpi resolution. The instrument 
was unable to penetrate deep enough to detect the MGs. Figure 3-6 is a typical transverse  section generated 
from a UL-OCT scan. ImageJ38 was used to adjust brightness and contrast to bring out details of the glands, 
but was unsuccessful.  
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Figure 3-6: Typical UL-OCT of a transverse section of the superior palpebral conjunctiva. The horizontal 
width of the image corresponds to a length of 4.96mm. No meibomian glands could be detected.  
3.4.3 Confocal Microscopy 
 
The images generated from the HRT3/RCM were 384 pixel x 384 pixel slices, which corresponded to a 
400μm x 400μm field of view. The manipulation and eversion of the eyelid induced tissue strain and 
distortion. This made it very difficult to maintain stability for imaging, and also made it impossible to 
determine the precise location and depth of the imaging plane. However, the observed structures appeared 
to be very superficial, located immediately below the basal epithelium of the eyelid margin, at a depth 
between 10μm - 100μm. The CM images of presumed MG acini structures were divided into two categories. 
The structures were round with either a hyper-reflective border or a hypo-reflective border. Four of the 12 
participants had hyper-reflective circular structures, 7 participants had hypo-reflective circular structures, 
and images could not be obtained from the one remaining participant. Figure 3-7 contrasts and compares 
the two different types of circular structures that were observed in this study.  
 
 
53 
 
     
Figure 3-7: Left, HRT3/RCM image of presumed MG acini structures from a 20 year old Asian male. 
Hyper-reflective circular structures could be observed. Right, HRT3/RCM image from a 25 year old 
Caucasian female. Ringed structures were also present, but the borders were relatively hypo-reflective.  
The hyper-reflective structures were observed only in participants with darker pigmented skin and the hypo-
reflective structures were observed only in participants with lighter skin. Table 3-1 compares these 
structures across heavily-pigmented (HP) and lightly-pigmented (LP) skin types.  
Table 3-1: Representative confocal images from participants with HP or LP skin types.  
HP 
  
   
LP 
     
 
Acini structures that were previously described as “age-related atrophic changes” in a separate publication18 
were observed in relatively young participants in this study. These “age-related atrophic changes” were 
found in a 30 year old male with extensive MG atrophy (Figure 3-8), and also in a 25 year old female, with 
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relatively little MG atrophy (Figure 3-9). It appeared in the sample examined in this cohort that these “age-
related atrophic changes” were independent of age and extent of MG atrophy.  
 
Figure 3-8: Left, presumed age-related atrophic structures imaged with HRT3/RCM. Right, Keratograph 
5M infrared meibography image of atrophic meibomian glands in a 30 year old male.  
 
Figure 3-9: Left, presumed age-related atrophic structures imaged with HRT3/RCM. Right, Keratograph 
5M infrared meibography image of intact meibomian glands in a 25 year old female. 
A volumetric scan from one participant consisting of 40 images over a depth of 80 μm was stacked and 
stabilized using the Template Matching and Slice Alignment (TMSA) plugin39 for ImageJ. The TMSA 
plugin consisted of two functions, the first (cvMatch_Template) allowed the user to select a region of 
interest (ROI) and the software would search the entire image stack that resembled the ROI. The second 
function (Align_stack) aligned the stack of images centered at the ROI.39  
The resulting tomogram showed how the morphology of the MG acini changed with depth. Figure 3-10 is 
a montage view of the stacked and stabilized tomogram. Note that signal loss began very early on at a depth 
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of approximately 30μm (Figure 3-10) into the section. Beyond this depth, the laser was not able to penetrate 
any deeper into the tissue.  
  
Figure 3-10: A montage of a 400 μm x 400 μm x 80 μm tomogram of the eyelid margin, starting from just 
below the basal epithelium of the epidermis. Each subsequent slice is 2μm deeper than the previous slice. 
The presumed MG structures merged together as depth increased. Signal to noise ratio depreciated 
considerably after 30 μm (slice 16).  
3.5 Discussion 
 
The UL-OCT was unable to obtain images of MGs and there may be a number of reasons why this was the 
case. A possible explanation is that the wavelength of 840nm may not have been able to penetrate through 
the tarsal plate deep enough to yield MG structures. The incident photons may have been scattered or 
absorbed. In either case, the lack of spatial and coherence information returning to the OCT detector means 
that no data could be used to generate depth information. A previous discussion on the relationship between 
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wavelength and penetration depth in a separate study40 essentially stated that longer wavelengths are less 
attenuated than shorter wavelengths in deeper tissue. All previous studies that were successful in imaging 
meibomian gland structures using an OCT had used a wavelength of least 1300nm.26-28 Furthermore, a 
recent study showed that OCT was able to detect acini structures in areas of the eyelid that was not 
detectable with infrared meibomian gland imaging,41 suggesting that missing or truncated glands seen in 
infrared imaging could be misinterpreted as MG atrophy.   
If the wavelength of 840nm was not appropriate for imaging MGs, then it may be interesting to investigate 
why the Keratograph 5M (also with 840nm light) was able to image the MGs. The reason may be based on 
the difference of the two imaging technologies. The Keratograph 5M was able to image the glands because 
the infrared detector depended on MG tissue light scattering to “see” the physical form of the gland. If the 
MG tissue was non-scattering and purely reflective, then the MGs would act as a mirror and appear as the 
LED light source illuminating them. Using an analogy, consider the reason why the moon is visible at night. 
The Moon is a matte object that scatters the photons of the sun in every direction and allows our eyes to 
receive the photons and discern the details of the moon. Similarly, MGs scatter light that allow the infrared 
detector to see the MGs. However, for interferometric-based imaging technologies such as the OCT, 
photons deflected off tissue must return on a certain path (spatial) and must contain useful interferometric 
information (coherence) for the computer to process depth information. Excessive scattering of photons in 
this case becomes detrimental to signal detection. This may explain why photon scattering in MG tissue 
allowed one type of technology to image MGs whereas another could not.  
The images of MG acini structures imaged using the HRT3/RCM in this study closely resembled structures 
that appeared in various publications claiming to be MGs.19,21 However, there were physical features that 
these structures exhibited that may indicate that they were not MG acini at all. Whether or not they were 
truly MG acini or not is worthy of discussion.  
The CM images of MG acini depicted in the literature were often round and with bright or dark borders. 
This characterization is also consistent with cross-sections of dermal rete pegs. The rete pegs are finger-
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like projections that anchor the epidermis to the dermis.42 A cross-section of these rete pegs would thus 
yield a field of round structures. A cross-sectional histology and CM study of the eyelid by Knop et al.43 
described the presumed MG structures to be rete pegs and skin papillae (Figure 3-11). Furthermore, the 
previously mentioned “age-related atrophic changes”18 were considered to be goblet cells imbedded within 
the epithelium.43   
 
Figure 3-11: Rete pegs and papillae form undulating, finger-like projections into the epidermis (2A). A 
cross sectional view yielded bright circular structures as depth increased (2C). Image from Knop E, Knop 
N, Zhivov A, et al. The lid wiper and muco‐cutaneous junction anatomy of the human eyelid margins: an 
in vivo confocal and histological study. J Anat. Apr 2011;218(4):449‐461. 
A separate dermatology article using CM to image skin nevi lesions showed that they contain circular 
features very similar to the questionable MG structures.44 It appeared that the hyper-reflective border 
observed surrounding these structures may be related to pigmentation of skin – since it was only in 
pigmented skin that these hyper-reflective borders were observed. Meibomian gland epithelial cells were 
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not known to express melanin and the only case that reported on MG pigmentation was a case related to 
cosmetics contaminating the MGs.45 Figure 3-12 shows a CM section of a nevus lesion.   
 
Figure 3-12: Confocal microscopy of the nevus yields hyper-reflective circular structures that are similar 
to the presumed MG structures. Image from: Pellacani G, Scope A, Ferrari B, et al. New insights into 
nevogenesis: in vivo characterization and follow-up of melanocytic nevi by reflectance confocal 
microscopy. J Am Acad Dermatol. Dec 2009;61(6):1001-1013. 
To settle the discussion, a HRT3/RCM scan of the skin on a volunteer’s forearm was obtained and it also 
appeared to be very similar to the presumed MG structures (Figure 3-13).  
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Figure 3-13: Left, presumed MG structures from the eyelid. Right, an image obtained from imaging skin 
on forearm of a pigmented individual.  
Finally, the montage (Figure 3-10) showed how the shape of these presumed MG structures changed as a 
function of depth. As tissue depth was increased, the structures appeared to merge together and it could be 
seen that these structures do not at all resemble MGs.  
3.6 Conclusions 
 
The experimental UL-OCT was unable to obtain images of meibomian glands. We propose that the 
HRT3/RCM images of MGs were actually rete pegs and papillae of the dermis that were enhanced with the 
deposition of melanin. Of the three imaging devices used in this study, only the Keratograph 5M was able 
to successfully image the meibomian glands.  
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4 Repeatability of Grading Meibomian Gland Dropout using Two 
Infrared Systems 
 
This chapter is published as follows: 
Ngo W, Srinivasan S, Schulze M, Jones L. Repeatability of grading meibomian gland dropout using two 
infrared systems. Optom Vis Sci. Jun 2014;91(6):658-667. 
Reprinted with permission. 2014 Wolters Kluwer Health Lippincott Williams & Wilkins © 
 Concept & Design Recruitment 
Acquisition of 
Data Analysis 
Write-
up/publication
Ngo Y  Y Y Y 
Srinivasan Y  Y  Y 
Schulze Y   Y Y 
Jones Y    Y 
Table detailing role of each author in this publication (Y denotes significant contribution).  
4.1 Overview 
 
PURPOSE: To determine the inter/intra-observer repeatability in using the OCULUS Keratograph 4 (K4) 
and 5M (K5M) to grade meibomian gland (MG) dropout using meibography grading scales.  
METHODS: The inferior and superior eyelids of 40 participants (35F, 5M, mean age 32yrs) were imaged 
3 times each on both instruments. The images were split into one training and two study sets; the latter were 
graded (4-point meibography scale) by two observers on two separate occasions (24hrs apart) to determine 
repeatability. Semi-objective quantification of percentage MG dropout was conducted using ImageJ on K4 
and K5M images. A finer 7-point meibography scale was used to grade a separate set of K5M images.  
RESULTS: For the 4-point scale, inter-observer mean difference (MD) was 0.08 ± 0.55 on day 1 and 0.13 
± 0.50 on day 2, and the concordance correlation coefficient (CCC) was 0.79 and 0.81 on days 1 and 2 
respectively. Intra-observer MD was 0.04 ± 0.54, CCC = 0.79 for observer 1, and -0.09 ± 0.60, CCC = 0.74 
for observer 2. For the 7-point scale, inter-observer MD was 0.05 ± 0.45, (CCC) = 0.89 on day 1 and 0.01 
± 0.41, CCC = 0.91 on day 2. Intra-observer MD was -0.10 ± 0.35, CCC = 0.93 for observer 1 and -0.06 ± 
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0.30, CCC = 0.95 for observer 2. Percentage dropout measured between the K4 and K5M images showed 
lack of agreement, with 21.8% coefficient of repeatability. There was no significant correlation (r<0.2; 
p>0.05) between meibography score and clinical signs (corneal staining, gland expressibility, 
telangiectasia, vascularity, lash loss), however there was a high correlation (r=0.77; p<0.05) between 
meibography score with percentage dropout.   
CONCLUSION: Observers graded from -1 to +1 grade units between and within themselves for a 4-point 
scale, 95% of the time. Although the inter/intra-observer repeatability of the K4 and K5M were very similar, 
a high rate of disagreement in percentage dropout between K4 and K5M images suggests that the two 
instruments cannot be interchanged. MG dropout scores did not correlate significantly with clinical signs. 
Using a finer scale may be beneficial for detecting change.   
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4.2 Introduction 
 
Meibomian glands (MGs) are modified sebaceous glands that are embedded within the tarsal plate. These 
glands consist of a long central duct surrounded by secretary acini units, with orifices terminating posterior 
to the mucocutaneous junction of the eyelid.1 An oily secretion, termed meibum, is produced from these 
glands, which serves to stabilize the tear film and slow its evaporation rate.2 Obstruction of these glands 
can cause changes to the MG tissue and lead to a decreased production or stasis of the oils within the glands. 
This results in a condition termed meibomian gland dysfunction (MGD).3 The International Workshop on 
Meibomian Gland Dysfunction recommends MGD to be defined as:  
“Meibomian gland dysfunction is a chronic, diffuse abnormality of the meibomian glands, commonly 
characterized by terminal duct obstruction and/or qualitative/quantitative changes in the glandular 
secretion. This may result in alteration of the tear film, symptoms of eye irritation, clinically apparent 
inflammation, and ocular surface disease.”3 
MGD is a condition with a reported prevalence ranging from 3.5%4 to 69.3%.5 This wide range in reported 
prevalence is due to a number of factors, including ethnic differences in study participants and the 
classification of MGD adopted for each study.6 MGD is believed to be the leading cause of evaporative 
DE,7 which is a major cause for contact lens discontinuation.8  Some clinical tests used to diagnose and 
assess MGD include biomicroscopy of the eyelid margin,9 observation of MG expressibility10 and expressed 
meibum quality,11 in conjunction with other tests such as tear film break-up time,12,13 tear film lipid layer 
thickness,13,14 symptom assessment,10 and meibography.3,15,16  
Meibography relates to the technique of imaging the MGs (either with infrared film17 or digital capture18) 
and is a method that allows the appearance of the glands to be characterized. Traditionally, this technique 
was performed by everting the eyelids over a white light transilluminator, which revealed the MGs through 
the lid and allowed the examiner to view them.16,19,20 With advancements in imaging technology, the more 
recent practice is to use infrared (IR) light to illuminate the everted eyelid to reveal the MGs for digital 
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capture with an IR-sensitive camera. The MGs can be physically characterized as an array of “string-like” 
structures that traverse the palpebral surface vertically.21 Partial loss or truncation of these structures is 
presumed to represent MG “dropout” or atrophy. To assess the degree of MG dropout, a number of different 
clinical grading methods have been reported,21-23 however the most appropriate procedure for tracking the 
course of dropout has yet to be determined. 
The OCULUS Keratograph 4 (K4; OCULUS, Wetzlar, Germany) is primarily a corneal topographer that 
includes an IR camera (for pupillometry) that has been adapted for meibography.24 The OCULUS 
Keratograph 5M (K5M; OCULUS, Wetzlar, Germany) is a more recent model that was developed to be 
used as a “true” meibography device. It has been optimized for meibography by increasing the field of 
view, modifying the position of the IR diodes to minimize interfering reflections, and generating post-
processed images that highlight the MGs (Figure 4-1).  
 
Figure 4-1: The K4 (left) and K5M (right) images show a marked difference in appearance. K5M images 
are brighter, show high contrast, and a larger field of view. 
The purpose of this study was to assess the inter- and intra-observer repeatability of two observers when 
grading images obtained with these two instruments, to determine if they are interchangeable in a clinical 
setting, where patients may return often and see different practitioners or be imaged on either instrument. 
In addition, a grading scale with more scale steps is introduced, to investigate its effect on user repeatability. 
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4.3 Methods 
 
Ethics clearance was obtained through the Office of Research Ethics at the University of Waterloo prior to 
commencement of the study and all procedures adhered to the tenets of the Declaration of Helsinki. 
Informed consent was obtained from all participants prior to enrolment in the study.  
4.3.1 Participants 
 
Forty participants (35 female, 5 male, mean age = 32.2 ± 11.9 yrs, age range = 19 to 62) without any 
uncontrolled systemic conditions, and without any history of ocular disease in which lid eversion would 
cause unacceptable discomfort (i.e. recent blepharoplasty, refractive surgery) were enrolled in this 
prospective, single visit study. Participants were not permitted to wear contact lenses on the day of the 
appointment. Thirteen of the 40 were contact lens wearers.  
The appointment consisted of a brief case history to obtain demographic information, followed by a visual 
acuity measurement and biomicroscopy of the anterior eye and eyelid margins. The following clinical 
parameters were recorded: corneal staining, eyelid telangiectasia, lash loss, vascularity, and degree of MG 
orifice obstruction of the inferior central 8 MG orifices. The scores pertain to the eye that was selected 
randomly for meibography. A table displays more information on the specific clinical techniques conducted 
(see Appendix 1, which is a summary of clinical tests and grading scales). 
After a 10 minute break, meibography was conducted with both the K4 and K5M.  
4.3.2 Meibography 
 
The participant was seated and their head positioned comfortably on the K4. Both the inferior and superior 
eyelid of one randomly selected eye were imaged sequentially. The participant was then asked to withdraw 
their head from the instrument for approximately 5 seconds, and then repositioned their head on the K4 
again, and images of the inferior and superior eyelid of the same eye were obtained again in an identical 
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fashion. This was repeated so that a total of 6 images were acquired (3 superior, 3 inferior). This process 
was repeated with the K5M.  
A total of 480 images were acquired from the 40 participants. The images were sorted into 3 sets (each set 
contained 1 superior and 1 inferior eyelid image from both the K4 and K5M of all participants, for a total 
of 160); one set was used to train two observers, and the remaining two sets were presented to the same two 
observers for grading on two separate occasions (24 hours apart) to determine inter- and intra-observer 
agreement.  
All images from each set were randomized and then sequentially presented to the two observers on a 50” 
high definition television screen, in a darkened room. Each image was displayed for 15 seconds. No 
communication between the two observers was permitted. MG dropout was assessed using both a subjective 
grading scale and a semi-objective computer based image analysis method.  
4.3.3 Subjective dropout grading with a 4 point scale 
 
The areas of partial or complete MG dropout of the upper and lower lids were assessed using the 4 point (0 
– 3) grading scale described by Arita et al.21 The grading steps are as follows: Grade 0: no dropout, Grade 
1: less than 1/3 total area dropout, Grade 2: 1/3 to 2/3 total area dropout, Grade 3: more than 2/3 total area 
dropout. The grading number assigned is termed the “meiboscore”.21  
4.3.4 Semi objective digital grading 
 
MG dropout from images used on the first day of subjective grading was digitally quantified using ImageJ 
1.46r (Wayne Rasband, National Institutes of Health, Bethesda, MD, USA; http://imagej.nih.gov/ij),25 an 
open source image analysis software. A total of 160 images consisting of 80 K4 images, and 80 K5M 
images were ordered randomly. Areas of MG loss in those images were measured by manually outlining 
the regions on the everted eyelid where MGs were not detected. This value was then divided by the total 
area of the everted eyelid to calculate percentage area loss, as previously reported by Srinivasan et al.24 
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4.3.5 Subjective dropout grading with a 7 point scale 
 
A second repeatability experiment was conducted using a 7 point scale. This scale was derived by adding 
half-steps to the Arita 4 point scale. The resulting scale steps were: Grade 0: 0% dropout, 0.5: 1 to 16%, 1: 
17 to 33%, 1.5: 34 to 50%, 2.0: 51 to 67%, 2.5: 68% to 84%, 3.0: 85 to 100%. A set of 42 K5M (21 superior, 
21 inferior) images were obtained from the Centre for Contact Lens Research (CCLR) archives. The images 
were selected by a third investigator and images were deliberately selected such that the set would contain 
a balanced distribution of MG dropout across the scale. The images were then presented to both observers 
for visual grading on two separate occasions (24 hours apart) to determine inter- and intra-observer 
agreement.  
4.3.6 Statistical Analysis 
 
Inter- and intra-observer repeatability was calculated using mean differences and concordance correlation 
coefficient (CCC). Grading repeatability for superior and inferior eyelids for each device were also 
calculated using mean differences and CCC. Concordance correlation coefficient evaluates how well a pair 
of observations fall along a 45 degree line from the origin.26 To help interpret CCC values, McBride27 
interpreted CCC values as follows:  
 CCC  < 0.90 = poor. 
 CCC 0.90-0.95 = moderate. 
 CCC 0.95-0.99 = substantial. 
 CCC > 0.99 = almost perfect. 
Correlation of clinical signs to meibography scores was determined using Pearson’s r. Paired t-test was 
used to determine percent MG dropout difference between K4 and K5M images analyzed with ImageJ. 
Data analyses were conducted using Statistica 7.1 (StatSoft Inc. Tulsa, OK, USA), MedCalc 12.3 (MedCalc 
Software bvba, Broekstraat 52, 9030 Mariakerte, Belgium), and GraphPad Prism (GraphPad Software, Inc., 
La Jolla, CA, USA). Level of statistical significance was set at p < 0.05. 
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4.4 Results 
 
4.4.1 Clinical outcomes 
 
The clinical findings are reported in Table 4-1, and a summary of the meiboscores when using the Arita 4 
point grading scale from the two observers over the two days are displayed in Table 4-2.  
There was no significant difference (p > 0.05) in average meiboscore given by the two observers, nor over 
the two different days (p > 0.05) on which grading occurred.  
The meiboscores from observer 1 on the first day from the K5M were used to calculate Pearson’s 
correlations with the clinical signs. The results are displayed in Table 4-3. There were no statistically 
significant correlations between clinical signs and meiboscore, or clinical signs with percentage dropout 
(Pearson’s r < 0.2; all p > 0.25). However, there was a high correlation between meiboscore with percentage 
dropout (Pearson’s r = 0.77; p < 0.05).  
Table 4-1: Summary of clinical test results. 
Technique Mean ± SD Range 
Corneal Staining 38.75 ± 77.09 0 – 400 
Telangiectasia 0.100 ± 0.38 0 – 2 
MG orifice obstruction (of the inferior central 8 orifices) 1.85 ± 1.00 0 – 4 
Vascularity 1.05 ± 0.85 0 – 3 
Lash loss 0.28 ± 0.55 0 – 2 
 
Table 4-2: Summary of meiboscores (mean ± SD, medians and quartiles) from each observer on both 
days. 
 Observer 1 Day 1 Observer 1 Day 2 Observer 2 Day 1 Observer 2 Day 2 
Mean ± SD 0.77 ± 0.85 0.73 ± 0.83 0.70 ± 0.85 0.60 ± 0.81 
Low  0 0 0 0 
1st Quartile 0 0 0 0 
Median 1 0 1 0 
3rd Quartile 1 1 1 1 
High 3 3 3 3 
 
 
 
 
 
68 
 
Table 4-3: Pearson’s r correlation of clinical signs to meiboscore for observer 1 on day 1.  
 
 Corneal Staining Telangiectasia MG orifice obstruction Vascularity Lash loss 
Pearson’s r 
correlation to 
meiboscore  
r = 0.03 
p = 0.87 
 
r = -0.03 
p = 0.85 
r = 0.18 
p = 0.26 
r = -0.06 
p = 0.71 
r = 0.03 
p = 0.83 
 
Raw data of both observer 1 and observer 2 on both days are listed in a table (see table, Appendix 2, 
which is the raw grading scores for both observers on both days) and a histogram displays the grading 
distribution (meiboscores) for both observers on day 1 (Figure 4-2).  
 
Figure 4-2: This histogram outlines the grading distributions of the 2 observers on day 1. A total of 160 
images from the K4 and K5M were graded by two observers on day 1. The frequency of each grade 
assigned by each observer was tallied and summarized in this histogram. The possible grades for each 
image was 0 to 3 (for both the superior and inferior eyelid separately).  
4.4.2 Inter-observer repeatability of grading with the Arita 4 point scale. 
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Limits of agreement plots for the inter-observer mean difference, with 95% upper and lower limits of 
repeatability between the two observers are shown in Figure 4-3. The 95% limits of agreement spanned 
from -1.00 to +1.16 on day 1, and -0.85 to +1.11 on day 2.   
The inter-observer mean difference and CCCs on day 1 and day 2 were similar. On day 1, mean difference 
± SD was 0.08 ± 0.55 grade units, with CCC = 0.79. On day 2, mean difference ± SD was 0.13 ± 0.50 grade 
units, with CCC = 0.81. There was an agreement of 110/160 (69%) images on day 1, and 121/160 (76%) 
images on day 2.  
 
Figure 4-3: Data were pooled from both the K4 and K5M. Left: limit of agreement plot showing day 1 
inter-observer repeatability. Right: limits of agreement plot showing day 2 inter-observer repeatability. 
Numbers at each point indicate the number of overlapping points. 
4.4.3 Intra-observer repeatability of grading with the Arita 4 point scale. 
 
Limits of agreement for the intra-observer mean difference were similar for observer 1 (95% upper and 
lower limits of agreement: -1.02 to +1.10) and observer 2 (-1.27 to +1.09). The limits of agreement plots 
are shown in Figure 4-4. 
The intra-observer mean differences and CCC were also similar for both observers. The intra-observer 
mean difference ± SD for observer 1 was 0.04 ± 0.54 grade units, with CCC = 0.79. For observer 2, the 
intra-observer mean difference was -0.09 ± 0.60 grade units, with CCC = 0.74. There was an agreement of 
116/160 (73%) images for observer 1 and 121/160 (76%) for observer 2.  
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Figure 4-4: Data were pooled from both the K4 and K5M. Left: limit of agreement plot showing intra-
observer repeatability of Observer 1 between day 1 and day 2. Right: limits of agreement plot showing 
intra-observer repeatability of Observer 2 between day 1 and day 2. Numbers at each point indicate the 
number of overlapping points. 
The inter- and intra-observer mean differences ± SD and CCC for both observers, subdivided by device, is 
displayed in Table 4-4. The inter- and intra-observer repeatability when grading images from either 
instrument were similar, however, based on CCC scores there was slightly better intra-observer 
repeatability when the observers were grading images obtained with the K5M than with the K4. This slight 
difference is may not be clinically significant, as the intra-observer mean differences remained similar.  
Table 4-4: Summary of observers’ inter- and intra-observer mean differences ± SD grade units and CCC 
on each individual device when grading with the Arita 4 point scale.  
K4 K5M 
Inter-observer Intra-observer Inter-observer Intra-observer 
Day 1 Day 2 Observer 1 Observer 2 Day 1 Day 2 Observer 1 Observer 2 
0.01 ± 0.58 
CCC = 0.78 
0.08 ± 0.52 
CCC = 0.80 
-0.08 ± 0.49, 
CCC = 0.76 
-0.09 ± 0.51, 
CCC = 0.68 
-0.16 ± 0.51, 
CCC = 0.79 
0.18 ± 0.47, 
CCC = 0.81 
-0.01 ± 0.85, 
CCC = 0.82 
-0.10 ± 0.68, 
CCC = 0.80 
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4.4.4 Superior and inferior eyelid repeatability for the Arita 4 point scale   
 
The limits of agreement for superior and inferior eyelids were separately analyzed on each device. Data 
from an arbitrary observer were used. On the K4, intra-observer mean difference with the 95% upper and 
lower limits of agreement, and CCC were 0.15 (-1.36 to 1.66), CCC=0.61 for the inferior eyelid, and 0.05 
(-1.12 to 1.22), CCC=0.72 for the superior eyelid. On the K5M, intra-observer mean difference with the 
95% upper and lower limits of agreement were 0.10 (-1.06 to 1.26), CCC=0.76 for the inferior eyelid, and 
0.08 (-0.74 to 0.89), CCC=0.84 for the superior eyelid. In all cases, the grading of the superior eyelid was 
more repeatable than grading the inferior eyelid, and grading with the K5M was more repeatable than the 
K4. Figure 4-5 and Figure 4-6 compares the limits of agreement between superior and inferior eyelids 
conducted across the K4 and K5M.  
 
Figure 4-5: Left: limit of agreement plot showing intra-observer repeatability of observer 1 grading the 
superior eyelid with the K4. Right: limit of agreement plot showing intra-observer repeatability of 
observer 1 grading the inferior eyelid with the K4.  Numbers at each point indicate the number of 
overlapping points. 
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Figure 4-6: Left, limit of agreement plot showing intra-observer repeatability of observer 1 grading the 
superior eyelid with the K5M. Right, limit of agreement plot showing intra-observer repeatability of 
observer 1 grading the inferior eyelid with the K5M. Numbers at each point indicate the number of 
overlapping points. 
4.4.5 Second repeatability experiment 
 
As can be seen from the results presented above, the majority of images in this study belonged either to the 
Grade 0 or Grade 1 category, with a lack of images representing the higher end of the scale. Furthermore, 
the high rate of agreement between the two observers indicated that the scale used may be too coarse. These 
two issues were addressed by running a second repeatability experiment using a 7-point scale to grade a set 
of K5M images. The distributions of grades given by the 2 observers are shown in Figure 4-7.  
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Figure 4-7: This histogram outlines the grading distributions of the 2 observers on day 1, using the new 7 
point scale. A total of 42 K5M images were presented to the two observers for grading on day 1. The 
grades that each observer assigned was tallied and summarized in this histogram. The possible grades 
were from 0.0 to 3.0 in 0.5 steps (for both the superior and inferior eyelid separately).  
 
On day 1, inter-observer mean difference ± SD was 0.05 ± 0.45 grade units with CCC = 0.89. On day 2, 
inter-observer mean difference ± SD was 0.01 ± 0.41 grade units with CCC = 0.91. The rate of perfect 
agreement was 22/42 (52%) and 24/42 (57%) on day 1 and day 2 respectively. The 95% limits of agreement 
spanned from -0.84 to +0.94 on day 1, and -0.78 to +0.80 on day 2 (Figure 4-8).  
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Figure 4-8: Left: limit of agreement plot showing day 1 inter-observer repeatability using the new 7 point 
scale. Right: limit of agreement plot showing day 2 inter-observer repeatability using the new 7 point 
scale. Numbers at each point indicate the number of overlapping points. 
Intra-observer mean difference ± SD was -0.10 ± 0.35 grade units, with CCC = 0.93 for observer 1, and -
0.06 ± 0.30 grade units, with CCC = 0.95 for observer 2. The rate of agreement was 26/42 (62%) for 
observer 1, and 27/42 (64%) for observer 2. The 95% limits of agreement spanned from -0.79 to +0.60 for 
observer 1, and -0.51 to +0.62 for observer 2 (Figure 4-9).  
 
Figure 4-9: Left: Limit of agreement plot showing intra-observer repeatability of observer 1 using the new 
7 point scale. Right: limit of agreement plot showing intra-observer repeatability of observer 2 using the 
new 7 point scale. Numbers at each point indicate the number of overlapping points. 
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4.4.6 Superior and inferior eyelid repeatability for the new 7 point scale.  
 
The mean difference, with 95% limits of agreement, and CCC for the superior eyelid was -0.02 (-0.60 to 
0.55), CCC=0.94. For the inferior eyelid, the mean difference, 95% limits of agreement were 0.14 (-0.41 to 
0.69), with CCC=0.96. The repeatability for the superior and inferior eyelids were approximately the same. 
Figure 4-10 compares the repeatability of grading superior and inferior eyelids in the K5M with the new 7 
point scale.  
 
Figure 4-10: Left, limit of agreement plot showing intra-observer repeatability of observer 1 using the 
new 7 point scale to grade the superior eyelid with the K5M. Right: limit of agreement plot showing intra-
observer repeatability of observer 1 using the new 7 point scale to grade the inferior eyelid with the K5M. 
Numbers at each point indicate the number of overlapping points. 
4.4.7 Semi-objective digital grading 
 
Semi-objective digital image analysis (Figure 4-11) was conducted by a single observer on the images from 
the first grading experiment. The mean percentage dropout (mean ± SD) in K4 and K5M images were 
27.5% ± 17.6% and 29.5% ± 16.7% respectively.  
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Figure 4-11: The free-hand tool in ImageJ was used to quantify gland dropout in K4 (left) and K5M 
(right) images. The K5M images appeared brighter, with better contrast and larger field of view than the 
K4 images.  
Despite a statistically significant correlation between the measured dropout between the K4 and K5M 
(Pearson’s r = 0.80, p < 0.001), a method comparison plot reveals the inconsistencies and variability in 
measured percentage dropout of the K4 and K5M images. The coefficient of repeatability is 21.8%, and the 
95% limit of agreement interval spanned from -19.8% to +23.8 (Figure 4-12).  
 
Figure 4-12: A method comparison plot showing variability between percent area dropout measured on 
K4 versus K5M images. A scale unit of 0.2 corresponds to 20%.  
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4.5 Discussion 
 
Both the inter- and intra-observer mean difference was <<1 grade points for the K4, K5M and both K4 and 
K5M together (all ≤ 0.18; Table 4-4), which could be rounded to 0 since the meibography grading scale 
consisted of only integers. This indicated that the inter- and intra-observer mean difference for the two 
observers was negligible when using this Arita 4 point integer scale, and that the responses from the two 
observers were similar (Figure 4-3).   
The standard deviation of the mean differences was approximately ±0.50 for both inter- and intra-observer 
differences, resulting in a coefficient of repeatability of approximately: 
(1.96)(0.50) = 0.98 
If µ represents the inter-(or intra-)observer mean difference, then a 95% confidence interval for limits of 
agreement can be expressed as:  
[µ – 0.98, µ + 0.98] 
Since µ ≈ 0 as discussed before, this indicates that on this Arita 4 point meibography scale, 95% of the time 
both observers will grade within -1 to +1 grade units of each other and against themselves.   
Concordance correlation coefficient is a measure of repeatability and can be used to quantify agreement of 
observers and devices.26 The CCC of inter-observer repeatability of the K4 was very similar to the K5M, 
but the K5M showed a slightly higher intra-observer CCC than the K4. Despite the higher intra-observer 
CCC of the K5M over the K4 (Table 4-4), this was not clinically significant, as the observers still graded 
within -1 to +1 grades against themselves, 95% of the time (Figure 4-4). 
The limits of agreement spanning -1 to +1 covered 3 units of the Arita 4 point scale, which made both 
grades 1 and 2 very convenient choices if the observer was in doubt. Considering that the eyelids have 
approximately 26 glands each and that 1 unit of progression is 1/3 of total area MG loss, it would require 8 
– 9 glands to drop out before the unit of progression can be increased. This suggests that the Arita 4 point 
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scale is insensitive to MG dropout progression. Bailey et al.28 proposed that a clinical grading scale of 
moderate sensitivity should have a paired comparison concordance of no more than 37%, meaning that two 
observers should not agree more than 37% of the time, and no more than 13% for a scale of fine sensitivity. 
In this study, it was found that the two observers agreed 69-76% of the time with each other, and against 
themselves which indicated that the sensitivity of this Arita 4 point meibography scale could be improved. 
It is also important to note that a majority of participants in this study had either grade 0 or 1 level dropout, 
which caused the grading distribution to take on a binary (and coarser) characteristic. With the digital 
imaging capabilities of the K4 and K5M, it should not be unreasonable for the observers to detect changes 
smaller than 1/3 total area dropout. It was unlikely that the observers would fail to discriminate between 
dropout of, for example, 7 MGs versus 2 MGs. Therefore, to maximize the potential of digital imaging, a 
meibography scale of finer sensitivity (e.g. incorporate 0.5 unit steps) was considered.   
When the second repeatability experiment was conducted with a finer scale (7 point scale), the maximum 
rate of agreement had reduced slightly from 76% to 64%. Although the 95% limits of agreement intervals 
had narrowed, the inter-observer repeatability was still within 0.5 to 1.0 grades of each other (Figure 4-8). 
It is also important to note that the CCC values had also increased (from ~0.78 to ~0.92) using this new 
scale, indicating an improvement over the Arita 4 point scale. The 95% limits of agreement intervals for 
intra-observer repeatability may be small enough that observers could grade within 0.5 points against 
themselves (e.g. intra-observer repeatability of observer 2, Figure 4-9). While this suggests that the 7 point 
scale may have some utility, this grading method is still not a very sensitive method. A precision of ±0.5 
grade points would still not be able to discriminate a dropout of, for example, 2 whole MGs, but will still 
allow better discrimination of severity of MG dropout than the Arita 4 point scale.   
While the inter- and intra-observer repeatability of each device had been established, using ImageJ to 
measure percentage area dropout revealed that there was a considerable lack of agreement between the K4 
and K5M images (Figure 4-12). As a result, although both devices are suitable as stand-alone device for 
MG imaging, we recommend that patients be followed up on any one device only, and that clinicians should 
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not interchange devices to monitor MG dropout. While digital analysis might have the potential to be more 
discriminatory, grading scales are more likely to be used in clinical practice.  
A possible factor that contributed to the variable nature of the data may be difference in quality of image. 
The K5M had been optimized for meibography with optimal IR diode positioning, increased working 
distance and enhanced image views. This allows the K5M to generate images that have improved exposure 
and are clearer to observe. In contrast, the IR illumination system in the K4 was not intended for 
meibography, but instead for pupillometry. As a result, gland borders on the K4 appear fuzzy, and appear 
to blend into the background and are not easily distinguishable (Figures 4-1 & 4-11). There is also 
uncertainty in defining the borders of the tarsal plate, which is compounded by the fact that the K4 has a 
more restricted field of view. These uncertainties make it difficult to select areas of interest to calculate 
dropout.   
It is also important to note that the ImageJ percentage dropout is derived from selecting areas where glands 
are absent and is not a real measure of MG dropout. To measure actual gland shortening and dropout the 
position of pre-atrophied MGs would have had to be measured, but since this is not a longitudinal-type 
study, atrophic changes cannot be quantified in this case. Also, atrophied gland structures are not detected 
by IR light, and therefore it is impossible to determine the amount atrophied by the time imaging was 
performed. 
Although the method of eyelid eversion was kept consistent for each participant as they were being imaged 
across each device, it was not possible to perfectly evert an eyelid to expose identical areas each time. This 
resulted in inconsistency in exposing glands, which may have contributed to variability to the data. A direct 
consequence of this was the consistently better repeatability in superior eyelid grading compared to the 
inferior eyelid. The eversion of the superior eyelid was more consistent possibly because the eyelashes of 
the everted eyelid could be pinned to the orbital bone. In the inferior eyelid, the eversion is facilitated by a 
“rolling” motion that could expose a variable amount of palpebral conjunctiva each time. Furthermore, the 
larger surface of the superior eyelid surface allowed the observer to see where the termination of the glands 
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were, and allowed for easier interpretation of dropout. In the inferior eyelid, there were occasions 
encountered during this study where the termination of the glands could not be observed despite the best 
efforts to evert them. This may explain why grading the superior eyelid was more repeatable than the 
inferior eyelid.  
Therefore, everting the participants’ eyelids once, and then imaging them 3 times consecutively may result 
in lower variability, but repositioning the participant’s head in-between imaging was an attempt to mimic 
real-world practice. For example, a patient imaged on one occasion may return in a month to be imaged 
again, and the positioning of their head and eyelid eversion will be slightly different each time. Therefore 
it was decided to have the patient retract and reposition their head in the instrument for every subsequent 
image.   
4.6 Conclusion 
 
Although there is a difference in image quality between the K4 and K5M, inter- and intra-observer 
repeatability was found to be very similar for each device separately. When using the instruments to take 
meibography images and grading them with the linear Arita 4 point integer scale, it can be expected that 
two observers will grade within -1 to +1 grade of each other and within themselves. Due to differences in 
image quality and properties between the two devices, it is recommended that patients be imaged on only 
one device. To take advantage of the benefits of digital imaging, a grading method with higher sensitivity 
(e.g. a 7 point scale) should be used with these two instruments.  
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5 A Comparison of Dry Eye Diagnostic Tests between Symptomatic 
and Asymptomatic Age-Matched Females 
 
5.1 Overview 
 
PURPOSE: To determine the strength of association of dry eye (DE) diagnostic tests to DE symptoms in 
an age-matched female cohort.  
METHODS: Twenty females symptomatic of DE (Ocular Surface Disease Index, OSDI, ≥ 13) were age-
matched with 20 asymptomatic females (OSDI < 13) in this cross-sectional study. Non-invasive tear 
breakup time (NIBUT), ocular staining, meibum quality, number of glands obstructed, lid wiper 
epitheliopathy (LWE), Marx’s line placement, eyelid margin score, Schirmer’s test, meibography, and 
visual acuity were compared between the two groups.  
RESULTS: The symptomatic group showed significantly poorer NIBUT, meibum quality, number of 
obstructed glands, and ocular staining than the asymptomatic group. The diagnostic tests (area under curve, 
odds ratio) most strongly associated with DE symptoms were ocular staining (93, 5.0), number of glands 
obstructed (79, 2.6), meibum quality (76, 2.4), and NIBUT (74, 3.2). Marx’s line placement, LWE, eyelid 
margin score, Schirmer’s test, meibography, and visual acuity were not significantly different between the 
two groups (p > 0.05) and were not significantly associated with DE symptoms. 
CONCLUSION: The diagnostic tests most strongly associated with symptoms in older women were ocular 
staining, meibum quality, number of glands obstructed, and tear film stability.  
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5.2 Introduction 
 
Dry eye (DE) disease is a prevalent condition affecting millions around the world.1-5 The disease can be 
broadly categorized  based on two different etiologies – due to lack of aqueous tear production (aqueous 
deficient DE), or due to increased tear film evaporation (evaporative DE).6 Some of the risk factors 
associated with DE include age,7,8 female sex,9 asian ethnicity,10 use of various medications,11-13 and certain 
health conditions (e.g. rheumatoid arthritis14 and Sjӧgren’s Syndrome15).  
Dry eye causes symptoms of discomfort that are typically described as burning, stinging, tearing and or 
itching.16 These symptoms, if severe enough can become bothersome and can be destructive towards quality 
of life and work productivity.17 In the United States, the economic burden of DE is estimated to cost $55.4 
billion to society, with an average DE patient spending approximately $783 yearly for DE  management 
alone.18 
The definition of DE disease was revised several times, with the most recent definition by the 2007 
International Dry Eye Workshop to be “…a multifactorial disease of the tears and ocular surface that results 
in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular 
surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface.”6 
This definition highlights the vague and elusive nature of the disease.  
The assessment of DE disease is conducted using a wide variety of clinical tests.16 Ocular staining,19,20 tear 
film stability,21 Schimer’s test,22 eyelid margin examination,23 and meibomian gland (MG) function24 are 
tests that are commonly used to assess the severity of DE disease. These tests are usually combined with a 
subjective symptom measurement (e.g. Ocular Surface Disease Index (OSDI),25 Symptom Assessment iN 
Dry Eye (SANDE),26 Standard Patient Evaluation of Eye Dryness (SPEED))27 to obtain information on 
patient morbidity and quality of life. Monitoring changes in these test results over time provides information 
about how the disease or therapy is progressing.  
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Recently, Marx’s line placement28-30 and lid wiper epitheliopathy (LWE)31-34 were found to play a role in 
DE disease.35 Marx’s line is a junction where the keratinized epithelium of the eyelids meets the epithelium 
of the conjunctiva.36 This junction is located at the eyelid margin, posterior to the MG orifices and pinned 
at the leading edge of the tear meniscus.29 The anterior migration of the Marx’s line was thought to be due 
to cellular changes of the epithelium.28 The cause for this was not entirely known, however the anterior 
migration of Marx’s line appeared to be associated with meibomian gland dysfunction (MGD).37 The 
mechanical debridement of Marx’s line was found to improve signs and symptoms of DE.35,38   
The eyelid wiper is an epithelial ridge located posterior to the MGs, underneath the superior eyelid. This 
area is characterized by a combination of stratified epithelium, cuboidal cells, goblet cells and 
parakeratinized cells.39 The lack of lubrication and increased mechanical friction at the lid wiper and corneal 
interface was thought to cause the epithelia of the eyelid wiper to undergo cellular changes.39 These changes 
could be readily observed with topical ophthalmic dyes.32 A recent study found a higher prevalence of LWE 
in DE participants,32 and another study found that LWE is correlated with DE symptoms.40  
Since DE disease is associated with both age7,8 and sex,9 it is not clear whether or not the presence of LWE 
and a thickened Marx’s line is due to DE disease, or as a result of confounding factors from older age and 
female sex. No previous studies that examined LWE and Marx’s line placement have used an age-matched 
case-control study design. The purpose of this study was to firstly, compare LWE and Marx’s line 
placement in an age-matched design between symptomatic and asymptomatic females. Secondly, this study 
also aimed to place LWE and Marx’s line placement in the context of other diagnostic tests for DE disease.  
5.3 Methods 
 
The study was conducted at the Centre for Contact Lens Research (CCLR), at the University of Waterloo 
(UW). The study was conducted in conformance with the ethical principles of the Declaration of Helsinki, 
the ICH guidelines for Good Clinical Practice, the UW Guidelines for Research with Human Participants.  
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Informed consent was obtained from all participants prior to enrollment in the study. Ethics clearance was 
obtained through a UW Research Ethics Committee prior to commencement of the study.  
5.3.1 Participants 
 
This was a cross-sectional, age-matched study that enrolled 40 females. Twenty females with OSDI score 
≥ 13 were enrolled, and were age-matched (±3 years) with asymptomatic females (OSDI < 13). All 
participants who were on ocular lubricants were asked to abstain from using them on the day prior to the 
visit appointment, and participants taking systemic medications were required to have used the same dosage 
and regimen for at least 3 months. The inclusion and exclusion criteria for study entry is outlined in Table 
5-1.  
Table 5-1: Criteria for study entry. 
Inclusion Exclusion 
Participants must have read an information 
consent letter. 
Has any active ocular disease, infection, or 
allergies.  
Must be at least 17 years of age and has full legal 
capacity to volunteer. 
Has a systemic condition or on systemic 
medications that may affect an outcome variable. 
For the symptomatic group, participants must 
have OSDI ≥ 13 and be female.  
Has undergone refractive error surgery. 
For the asymptomatic group, participants must 
have OSDI < 13, and can be age-matched (±3 
years) to a participant in the symptomatic group.  
Has worn contact lenses within the past 5 years. 
Participants must be willing and able to follow 
instructions to maintain the appointment schedule. 
Has known sensitivity to diagnostic 
pharmaceuticals to be used in the study. 
 Is pregnant, lactating, or planning a pregnancy at 
the time of enrolment.  
 Is participating in any concurrent clinical or 
research study.  
  
 
5.3.2 Clinical Methods 
 
All clinical tests were conducted by one investigator, in the order they appear below. The clinical grading 
scales for meibum quality (Table A1),41 eyelid margin score (Table A2), LWE (Table A3),34 Marx’s line 
placement (Table A4),42 and MG dropout (Table A5)43 are listed in the Appendix.  
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At the beginning of each visit, demographic information was collected and was followed by a symptom 
assessment using the OSDI.25 The OSDI is a validated questionnaire that queried 3 aspects of DE: vision-
related aspects, ocular symptoms, and environmental triggers.25 Based on a previous study that investigated 
clinically minimal differences,44 participants who scored higher than 12 were considered to be symptomatic.  
Visual acuity was assessed using a computerized high contrast chart at a distance of 6 meters. Participants 
were instructed to read rows consisting of 5 letters that progressively decreased in size until they could no 
longer distinguish the letters on the screen. Visual acuity was recorded in logMAR form.  
Non-invasive tear breakup time (NIBUT) was assessed by projecting illuminated Placido disks onto the 
anterior tear film.45 Participants were asked to blink several times before holding their eyes open for as long 
as they could. The time in seconds from eye opening to the first disruption of the Placido rings to occur was 
recorded. Three measurements were taken from each eye and averaged.   
Meibum quality was assessed by applying firm digital pressure to the inferior eyelid margin for 
approximately 8 seconds to express the central 8 MGs. The quality of expressed meibum was graded using 
the scale described in Mathers et al.41 (Table A1). The number of glands that did not express meibum when 
digital pressure was applied was counted. 
Ocular staining was assessed with a fluorescein strip (Fluorets, Bausch & Lomb Canada Inc., Markham, 
Ontario, Canada) wetted with saline (Bausch & Lomb Sensitive Eyes® Saline Plus, Rochester, New York, 
USA). With the excess shaken off, the moistened strip was touched to the inferior fornices of both eyes. 
The van Bijsterveld grading scale46 was used to grade the extent of ocular surface staining (both corneal 
and conjunctival) and the full scale from 0-9 was utilized. Fluorescein was used in place of Rose Bengal as 
it was not permitted for use in Canada. Despite this, there was no difficulty in assessing conjunctival 
staining.   
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The eyelid margin was examined under slit lamp biomicroscopy. The degree of erythema, lash loss, edema, 
and lid margin telangiectasia were each graded separately. The eyelid margin score was derived from the 
sum of the grades of all these features.  
Lid wiper epitheliopathy, as well as Marx’s line placement was assessed as follows. Fluorescein was 
instilled twice, one minute apart, in both eyes. After an additional 3 minutes had elapsed, the superior 
eyelids of both eyes were everted and fluorescein LWE was graded. A Lissamine green strip (GreenGlo™, 
HUB Pharmaceuticals, Rancho Cucamonga, California, USA) was wetted with saline, and with the excess 
shaken off, instilled in the inferior fornices of both eyes. The inferior eyelids were everted to grade Marx’s 
line placement using the scale described in Kim et al.42 
After a minute had elapsed from the previous Lissamine green instillation, another Lissamine green strip 
was instilled. Then, after 3 minutes had elapsed, the superior eyelids of both eyes were everted to grade 
Lissamine green LWE staining. The final LWE grade was the average of the fluorescein and the Lissamine 
green LWE grade. 
Meibomian gland atrophy was assessed using the Keratograph 5M (OCULUS, Wetzlar, Germany).47 The 
superior and inferior eyelids were everted and the meibo-scan tool was used to capture images of the MGs. 
Meibomian gland dropout was graded with the Arita scale. 43 The score for both the superior and inferior 
eyelid were summed to generate the “meiboscore” for each eye. 
Schirmer’s test was conducted by inserting a Schirmer’s tear strip (TearFlo™, HUB Pharmaceuticals, 
Rancho Cucamonga, California, USA) in both eyes at the junction between the temporal third and central 
third of the eyelid margin.48 Participants were instructed to close their eyes during the test. The tear strips 
were removed after 5 minutes and the length of wetting was measured. No anesthesia was used.  
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5.3.3 Statistical Analysis 
 
Data from only the right eye were analyzed. Statistical analyses were conducted using GraphPad Prism 6.05 
(GraphPad Software, California, USA). Normal data distribution testing was conducted using the Shapiro-
Wilk test at the level of α=0.05.  
Paired t-test or Wilcoxon signed-rank test (depending on the data distribution) was used to determine the 
significance of the difference of means of the diagnostic tests between the two groups. Similarly, Pearson’s 
or Spearman’s rho was used to determine the linear correlation between diagnostic tests. Receiver operator 
characteristics (ROC) were used to determine sensitivity and specificity of the diagnostic tests, and their 
corresponding cut-offs for classifying symptomatic and asymptomatic participants. Level of statistical 
significance was set at p < 0.05. 
5.4 Results 
 
5.4.1 Participants 
 
A total of 40 women (20 matched pairs) completed the study. In the symptomatic group, participants 
reported being symptomatic for DE for at the past 3 years. Six of the 20 women in the symptomatic group 
verbally expressed that they had Sjӧgren’s Syndrome, but this was not medically confirmed at the visit 
appointment. The median age (interquartile range, IQR) of the symptomatic group was 60 (15) and 
asymptomatic group was 62 (15). The age range of this sample was 46 to 73 years old inclusive.  
5.4.2 Clinical Outcomes 
 
The clinical results are summarized in Table 5-2. The symptomatic group showed significantly higher 
ocular staining (+5.0 grade points), lower NIBUT (-0.9s), poorer meibum quality (+1.0 grade points), and 
had a higher number of obstructed MGs (+2.0 glands) than the asymptomatic group (all p ≤ 0.01 by 
Wilcoxon signed-rank test). Furthermore, the symptomatic group also showed greater amount of MG 
atrophy (+0.5 grades) and a more anteriorly placed Marx’s line (+1.0 grades), however these differences 
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were not statistically significant (all p > 0.06 by Wilcoxon signed-rank test).  Eyelid margin score and LWE 
were similar in both groups (both p > 0.57 by Wilcoxon signed-rank test). Schirmer’s test was higher in the 
symptomatic group but this difference was not statistically significant (p = 0.87 by Wilcoxon signed-rank 
test).  
The linear correlations between all DE diagnostic tests are displayed in Table 5-3. Symptoms did not 
significantly correlate with any diagnostic tests (all p>0.05). Marx’s line placement correlated significantly 
with eyelid margin score and ocular staining, but lid wiper epitheliopathy did not significantly correlate 
with other diagnostic tests.  
The ROC values of diagnostic tests are shown in Table 5-4. The diagnostic tests that showed a significant 
association (p < 0.05) to symptoms were ocular staining (odds ratio, OR: 5.0), number of glands obstructed 
(OR: 2.6), meibum quality (OR: 2.4) and NIBUT (OR: 3.2), with area under curve (AUCs) of 93, 79, 75, 
and 74 respectively. Meibography and Marx’s line placement were similar in AUCs (64) but was not 
significantly associated with symptoms. Lastly, LWE, eyelid margin score, Schirmer’s test, and visual 
acuity were all weakly associated with symptoms (Table 5-4).  
Table 5-2: Summary of clinical findings (first quartile, median, third quartile). All comparisons were 
conducted using the Wilcoxon signed-rank test.   
 Symptomatic Group Asymptomatic Group p value 
Age 51, 60, 66 52, 62, 67 0.43 
OSDI (0-100) 21.3, 35.4, 56.7 0.0, 3.1, 6.7 <0.01 
Visual Acuity (logMAR) -0.08, 0.04, 0.10 -0.08, 0.02, 0.12 0.86 
Ocular staining (0-12) 3.2, 5.5, 7.0 0.0, 0.5, 1.0 <0.01 
Meibum quality (0-3) 3.0, 3.0, 3.0 2.0, 2.0, 3.0 <0.01 
Number of glands obstructed (0-8) 6.0, 7.0, 8.0 2.0, 5.0, 6.8 <0.01 
NIBUT (seconds) 1.9, 2.1, 2.6 2.3, 3.0, 5.3 0.01 
Eyelid margin score (0-13) 4.2, 7.0, 8.0 6.0, 8.0, 9.0 0.58 
Meiboscore (0-6) 1.0, 2.0, 3.0 1.0, 2.0, 2.0 0.09 
Lid wiper epitheliopathy (0-3) 0.0, 0.0, 1.0 0.0, 0.0, 0.4 0.71 
Marx’s line placement (0-2) 0.0, 1.0, 2.0 0.0, 0.0, 1.0 0.06 
Schirmer’s Test (0-30) 3.5, 11.0, 15.8 3.2, 8.5, 14.0 0.87 
Bold represents p < 0.05 
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Table 5-3: Correlation matrix showing the linear relationship between diagnostic tests with Spearman’s rho 
correlation coefficient. 
 OSD
I 
score 
Meibum 
quality 
Number of 
glands 
obstructed 
Meibography NIBU
T 
Eyelid 
margin score 
Ocular 
Staining 
Visual 
Acuity 
Schirmer's 
test 
Marx's line Lid wiper 
OSDI score  -0.12 -0.10 0.30 -0.18 0.09 0.34 0.33 -0.11 0.24 -0.28 
Meibum 
quality 
  0.57 -0.47 -0.42 0.25 0.39 0.32 0.10 0.25 0.33 
Number of 
glands 
obstructed 
   -0.06 -0.33 0.18 0.17 0.29 0.31 0.13 0.16 
Meiboscore     -0.25 0.11 0.15 0.12 -0.32 0.01 -0.32 
NIBUT      -0.46 -0.68 -0.60 0.27 -0.31 -0.43 
Eyelid 
margin score 
      0.58 0.34 -0.27 0.60 0.16 
Ocular 
Staining 
       0.46 -0.56 0.58 0.29 
Visual 
Acuity 
        -0.05 0.06 0.04 
Schirmer's 
test 
         -0.36 -0.12 
Marx's line           0.04 
Lid wiper             
Bold represents p < 0.05 
 
Table 5-4: Area under ROC curves for diagnostic tests.  
Diagnostic Test Area Under Curve Sensitivity Specificity Cutoff Odds Ratio 
Ocular staining (0-12) 0.93 100 80 >1.5 5.0 
Number of glands obstructed (0-8) 0.79 90 65 >5.5 2.6 
Meibum quality (0-3) 0.76 85 65 >2.5 2.4 
NIBUT (seconds) 0.74 80 75 <2.6 3.2 
Meiboscore (0-6) 0.64 47 84 >2.5 3.0 
Marx’s line placement (0-2) 0.64 30 90 >1.5 3.0 
Eyelid margin score (0-13) 0.56 80 40 <8.5 1.3 
Lid wiper epitheliopathy (0-3) 0.54 40 70 >0.12 1.3 
Schirmer’s test (0-30) 0.53 40 80 >14.5 2.0 
Visual acuity (logMAR) 0.51 90 25 <0.11 1.2 
Bold represents p < 0.05  
 
5.5 Discussion 
 
By controlling for age and sex, this study allowed for the examination of DE diagnostic tests in the absence 
of two well-known confounding factors. Despite having controlled for age and sex, this study did not find 
a linear correlation between symptoms and signs and reinforced the findings of previous studies.49,50 
However, based on odds ratios and AUCs, the tests that were relatively strongly associated with symptoms 
were ocular staining, number of central obstructed glands, meibum quality, and NIBUT. In contrast, eyelid 
margin score, LWE, Schirmer’s test, and visual acuity each had very low AUCs and did not appear to be 
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associated with symptoms. Overall, the symptomatic group exhibited worse physical features of DE disease 
than the asymptomatic group.  
The placement of Marx’s line was found to be more shifted anteriorly in the symptomatic group than the 
asymptomatic group, but this difference was not significant. A previous study37 had found an association 
between an anteriorly shifted Marx’s line with MGD, however the grading scale used in that study was 
much more sensitive than the one used in this present study. Yamaguchi assigned a score to the Marx’s line 
at each third of the eyelid and summed them, yielding a total score out of 9. The grading scale used in this 
study had only 3 grades and each of these grade units also represented more than one clinical feature. This 
made the current scale less sensitive and less discriminative and may explain why a difference between the 
two groups was not detected.  
One of the major differences between the two groups was the quality of meibum, with the symptomatic 
group showing significantly poorer meibum quality than the asymptomatic group. Increased viscosity of 
meibum is partly responsible for driving MG obstruction.51 The obstruction of MGs would then cause the 
tear film lipid layer to become deficient, leading to the rapid collapse and destabilization of the tear film 
onto the ocular surface.52 With decreased tear film stability, the ocular surface is repeatedly exposed and 
desiccated, resulting in constant stimulation of the ocular surface and driving discomfort symptoms.53 The 
repeated desiccation of the ocular surface also results in the increased uptake of ophthalmic vital stains.54 
This mechanism may be an over-simplification of the disease pathophysiology, but treatment in DE that 
aimed to decongest the MGs and improve meibum quality have resulted in substantial improvements in DE 
symptoms and signs.55-57  
The meibum quality and the degree of gland obstruction were unusually poor in this sample. In this 
relatively older age group this could be plausible as changes in meibum quality were found to be related to 
aging.58 The poor NIBUT in both groups may have been a direct consequence of this. There may be other 
etiological factors that have contributed to the severity of MGD, but this was not investigated in this study.  
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Since the function of MGs was to produce meibum, the atrophy of the MGs would therefore result in 
decreased production of meibum. This study did not find a correlation between gland dropout and number 
of obstructed glands. Furthermore, this study unexpectedly found an inverse relationship between meibum 
quality and gland dropout, suggesting that participants with worse MG atrophy were producing relatively 
healthier lipids. This finding is contradictory to the findings from another study.59 
Only one investigator conducted all the clinical tests in this study. While this eliminated the possibility of 
inter-observer variabilities, this also meant that it was impossible to mask participant grouping. 
Consequently, the results may show some bias. Additionally, the enrollment of participants were based only 
on symptoms and not on any of the diagnostic tests for DE. This was necessary to evaluate how well 
diagnostic tests discriminate symptomatic from asymptomatic participants. If certain diagnostic values were 
required for entry, then the ROC analyses would show an artificially high ability for those tests to 
distinguish the two groups. 
Since this study observed a sample of women in the age range between 46 and 73, the results of the study 
may not be valid for younger women or males. However, the findings are still valuable, as the elderly 
population is expected to rise globally over the next few decades,60 and consequently the prevalence of DE 
as well.7,8 In addition, post-menopausal women form a substantial proportion of the sufferers of DE.61 For 
future work, it would be valuable to conduct a similar study in a different age group, in males, or even with 
contact lens wearers. By examining the strength of associations of diagnostic tests with symptoms, it may 
provide some information about the underlying pathophysiology.  
5.6 Conclusion 
 
The DE tests that were strongly associated with DE symptoms in older women in this study were ocular 
surface staining, meibum quality, number of obstructed glands, and NIBUT.  
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6 The Effect of an Eyelid Warming Device on Meibomian Gland 
Dysfunction 
 
6.1 Overview 
 
PURPOSE: To determine the effectiveness of the MGDRx® EyeBag in the management of meibomian 
gland dysfunction. 
METHODS: This was a prospective, randomized, controlled, single-masked, bilateral eye study that 
enrolled 29 participants. Participants were randomized into either the EyeBag group or the control group. 
Participants in the EyeBag group were required to use the EyeBag 10 minutes 2x/day, and the control group 
remained on their own dry eye treatment regimen (if applicable). All participants were seen at baseline, 2 
weeks and 4 weeks. At 4 weeks, participants in the EyeBag group were asked to stop using the EyeBag. 
All participants were seen again at the 8 week mark. Primary outcomes were the Ocular Surface Disease 
Index (OSDI), Current Symptoms Questionnaire (CSQ), meibomian gland score (MG score), and non-
invasive tear breakup time (NIBUT). 
RESULTS: Twenty five participants completed the study (mean age 38±15 years, 7 male). There was a 
significant change in OSDI over time for the EyeBag group (mean values, baseline: 39.1, week 2: 26.8, 
week 4: 26.6, week 8: 27.7; p<0.05), but no significant change in the control group. There was a significant 
improvement in symptoms immediately after conducting the EyeBag based on at-home CSQ scores (Δ=-
5.0 points, p<0.05), but no significant change in the control group. There was no significant change in MG 
score and NIBUT over time for either group.  
CONCLUSIONS: The MGDRx® EyeBag was effective at relieving symptoms in participants with dry eye, 
but the effect on meibomian gland function and tear stability when used for only 4 weeks was modest.  
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6.2 Introduction 
 
Meibomian glands (MGs) are modified sebaceous glands imbedded within the tarsal plate.1 The glands 
consist of multiple acini which manufacture and secrete meibum (oils) into a central duct. The duct 
terminates in an orifice at the eyelid margin posterior to Marx’s line. Meibum released at the orifice serves 
to mix and stabilize the tear film.2  
When the gland orifices becomes obstructed, the delivery of meibum onto the tear film is reduced.1 The 
primary mechanism of gland orifice obstruction appears to be driven by hyperkeratinization and thickening 
of the MG ductule epithelium.3,4 This results in a loss of tear film stability2 and brings about symptoms of 
dry eye (burning, stinging, foreign body sensation).5 Symptoms of dry eye range from mild to severe6 and 
can potentially have a large impact on economic burden7 and quality of life of the patient.8 This condition 
is termed meibomian gland dysfunction (MGD).6 As per the 2011 International Workshop on Meibomian 
Gland Dysfunction, the recommended definition of MGD is:   
 “… a chronic, diffuse abnormality of the meibomian glands, commonly characterized by terminal 
duct obstruction and/or qualitative/quantitative changes in the glandular secretion. This may result in 
alteration of the tear film, symptoms of eye irritation, clinically apparent inflammation, and ocular surface 
disease.”9 
Meibomian gland dysfunction is thought to be the leading cause of dry eye.6 The prevalence of MGD ranges 
widely and have been reported to be from 3.510 to 69.3%,11 depending on ethnicity and the working 
definition of MGD used for study inclusion.12 The condition appears to be associated with, but not limited 
to, aging,13,14 taking certain medications (e.g. retinoids),15-18 androgen deficiency,19-21 and possibly contact 
lens wear.12,22  
One of the mainstay treatments for MGD involves warm compresses.23 The application of heat and pressure 
to the eyelid margin melts the meibum plugging the gland orifices and facilitates delivery of meibum from 
the gland into the tear film. One standard recommendation is to wet a face towel with hot water and apply 
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the towel to the eyelid margins.24 This procedure has limitations, such as the inconvenience of constantly 
holding the towel against the face, rapid heat loss from the towel, and the constant need to replace and 
reheat the towel.25,26   
Recently, a number of commercial products were developed with the same principle of delivering either 
moist or dry heat to the eyelids and all serve to retain heat better than a face towel.25,27-30 The MGDRx® 
EyeBag (The EyeBag Company Ltd, Halifax, UK) is one such product31 and is essentially a cotton/silk 
pouch filled with flax and linseed.32 The product retains heat well and can be easily fitted over the closed 
eyes without difficulty.25 
At the time of conducting this study, a PubMed search using the terms “mgd” and “eyebag” revealed only 
one other study examining the treatment effect of the EyeBag on MGD.28 The previous study examined the 
effectiveness of the EyeBag using a contralateral eye design and found a large improvement in symptoms 
and modest improvement in MG function in the eye receiving treatment. The purpose of this current study 
is similar, in that it examines the effectiveness of the EyeBag in improving MG function and symptoms, 
however the main difference is in the study design (bilateral) which we feel allows for more accurate 
representation of symptom change.   
6.3 Methods 
 
6.3.1 Participants 
 
This study was conducted in conformance with the ethical principles of the Declaration of Helsinki, the 
ICH guidelines for Good Clinical Practice, and the UW Guidelines for Research with Human Participants.  
Informed consent was obtained from all participants prior to enrollment in the study. Ethics clearance was 
obtained through a UW Research Ethics Committee prior to commencement of the study.  
This was a prospective, randomized, controlled, single-masked, bilateral eye study that enrolled 29 
participants.  
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The sample size was determined using G*Power 3.1 (Universität Kiel, Kiel, Germany).33,34 To detect a 3.0 
mean difference in MG score (1.0 effect size) at 90% power at 0.05 level of significance, a minimum sample 
size of 24 is required. The 3.0 mean difference was chosen since it was a modest value compared to the 
reported 7.0 mean difference previously reported with another device that has been developed for the 
management of MGD, the TearScience® LipiFlow.35  
The inclusion and exclusion criteria are outlined in Table 6-1. 
Table 6-1: Criteria for study entry 
Inclusion Exclusion 
Has read and signed an information consent letter. Is currently participating in any concurrent 
clinical or research study. 
At least 17 years of age. 
Has a systemic condition or on medication that 
may affect an outcome variable (e.g. previous 
refractive and/or cataract surgery, glaucoma 
medications, Sjӧgren’s syndrome, rheumatic 
disease). 
Ocular Surface Disease Index ≥ 23. Hypersensitivity to EyeBag components.
Meibomian Gland Score ≤ 9 (see below in 
Methods). 
Is pregnant, lactating or planning a pregnancy at 
the time of enrolment, as determined verbally. 
Not a contact lens wearer. Has undergone refractive error surgery. 
Is on a stable dry eye regimen (if applicable) within 
the past 4 weeks, and is willing to maintain this 
regimen. 
Has significant discomfort and or inducible 
seizures from rapid blinking lights. 
Agree to use the MetricWire app for online data 
entry.  
  
 
6.3.2 Visit Schedule 
 
This study consisted of 4 visits. At the initial visit, participant eligibility was determined and baseline data 
were collected. Participants were randomized into either the EyeBag (treatment) or control group. 
Participants in the control group were asked to remain on their current dry eye regimen and keep 
medications steady for the duration of the study period. Participants in the EyeBag group were provided 
the EyeBag and instructed to use them 10 minutes twice daily. All participants returned at 2 weeks and 4 
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weeks for follow-up assessments. After 4 weeks, participants in the EyeBag group ceased EyeBag use and 
all participants returned for a final assessment at the 8 week mark.  
6.3.3 Clinical Methods 
 
At the beginning of each follow-up study visit, a research assistant asked participants how often they had 
used the EyeBag at home. Participant compliance information regarding frequency and duration of use was 
documented. Changes to health or medications were also documented. All clinical tests were conducted by 
one investigator (WN) and in the same order each time as they appear below. 
Dry eye symptoms were measured using the Ocular Surface Disease Index (OSDI)36 and the Symptom 
Assessment iN Dry Eye (SANDE)37 questionnaires. The OSDI is a questionnaire that assessed severity of 
dry eye by querying symptoms, difficulties with certain tasks, and comfort in different environments.36 The 
SANDE consisted of visual analogue scales that queried severity and frequency of dry eye symptoms.37 
Tear film lipid layer thickness was conducted using the LipiView (TearScience®, Morrisville, North 
Carolina, USA) in primary gaze.38 
High and low contrast visual acuity was assessed using an electronic computer LogMAR chart at an optical 
length of 6 meters. Participants were asked to read rows of letters that decreased in size until no more letters 
could be read.  
Non-invasive tear breakup time was assessed by using the Humphrey Atlas® Topographer 991 (Zeiss, 
California, USA). The topographer projected illuminated Placido discs onto the cornea39 and the time for 
distortion to appear on the Placido disks during the interblink interval was recorded 3 times and averaged.  
Corneal staining and conjunctival staining was assessed by wetting a fluorescein strip with a few drops of 
sterile saline, shaking off the excess, and instilling it in both eyes. Corneal and conjunctival staining was 
assessed using the CCLR scale (corneal: 0 to 100 for type, extent, and depth; conjunctival: 0 to 100),40 both 
with cobalt blue illumination through a Wratten no. 12 barrier filter.  
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Meibomian gland assessment was conducted using the Meibomian Gland Evaluator (TearScience®, 
Morrisville, North Carolina, USA).41 The leading edge was applied against the central inferior eyelid, 
exerting a pressure of 1.25g/mm2. The Meibomian Gland Score (MG score) is the grade of the appearance 
of meibum expressed from the 5 central glands:35  
 Grade 0: No secretion 
 Grade 1: Inspissated 
 Grade 2: Coloured liquid 
 Grade 3: Clear oil 
The Meibomian Glands Yielding Liquid Secretions (MGYLS) variable is a count of the number of glands 
with MG score 2 or higher.  
Meibography was assessed using the meibography feature on the Keratograph® 5M (OCULUS, Wetzlar, 
Germany).42 Both the inferior and superior eyelids of both eyes were everted and imaged. Gland dropout 
was graded using the Arita scale43 and the final score for each eye was obtained by summing the grade from 
the upper and the lower eyelids.   
During the study visit, participants in the EyeBag group received an EyeBag treatment. The EyeBag was 
heated in a 900W microwave (RCA, New York, USA) on high power for 30 seconds and then placed over 
the participants’ closed eyes (silver side against the eyes) for 10 minutes, according to manufacturer 
recommendation.31 The temperature profile of an EyeBag heated for 30 seconds in a 900W microwave is 
detailed in the Appendix. Digital massage of the eyelids was then conducted according to manufacturer 
instructions (i.e. a gentle sweeping motion across the eyelids in a nasal to temporal motion for 10 cycles). 
The Current Symptoms Questionnaire (CSQ) was conducted before and after the EyeBag treatment. The 
Current Symptoms Questionnaire is a subset of the Dry Eye Questionnaire and had been modified to assess 
immediate symptoms.44,45 Participants randomized into the control group did not receive the EyeBag 
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treatment and was asked to complete the CSQ twice, 10 minutes apart, with no intervention in between. 
Both high and low contrast visual acuity was recorded again immediately after EyeBag treatment. 
At the end of the baseline visit, participants in the EyeBag group were provided the EyeBag to use at home. 
They were instructed to heat the EyeBag in a microwave oven for 30s before placing it over their eyes for 
10 minutes. Participants were also instructed to conduct digital massage immediately after the 10 minutes 
had elapsed. They were not restricted to when they were required to use the EyeBag at home, however they 
must use it twice a day. Participants in the control group did not receive an EyeBag and were asked to 
remain on their own dry eye regimen (if applicable) for the duration of the study.  
The CSQ was also administered at home via smartphone using the MetricWire app (Kitchener, Ontario, 
Canada).46 This app enabled participants to receive notifications and fill out the CSQ on their smartphone. 
Similar to above, participants who were randomized into the EyeBag group were instructed to fill in the at-
home CSQ via smartphone prior to using the EyeBag and then immediately after using the EyeBag. 
Participants in the control group were asked to fill out the at-home CSQ via smartphone twice, 10 minutes 
apart, with no intervention in between. Participants were only required to do this once during weeks 1 and 
3, so that there would be 2 pairs of pre/post at-home CSQ values per participant.  
6.3.4 Statistical Analysis 
 
Statistical analyses were conducted using GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA, USA). 
Normal data distribution testing was conducted using the Shapiro-Wilk normality test at the level of α=0.05. 
Parametric data is presented as mean±SD, whereas nonparametric data is presented as medians and inter-
quartiles (Q1 and Q3).  
To determine statistically significant change over time, repeated measures ANOVA with Bonferroni 
correction and Friedman test with Dunn’s multiple comparisons test were used. Paired t-test and Wilcoxon 
test were used to determine differences between pre and post EyeBag CSQ, and HCVA/LCVA values.  
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Level of statistical significance was set at p < 0.05. Data from only the left eye (where applicable) were 
analyzed.   
6.4 Results 
 
6.4.1 Participants 
 
Twenty five participants completed the study (mean age 38 ± 15 years, 7 male). Twelve were randomized 
into the EyeBag group (mean age 38 ± 15 years, 3 male), 13 were randomized into the control group (mean 
age 37 ± 15 years, 4 male). Four participants were found to be ineligible for the study at the screening visit. 
Their data were not used in the analysis.  
6.4.2 Adherence to Therapy 
 
Participants were instructed to use the EyeBag twice daily for 10 minutes each. On average, participants in 
the EyeBag group reported having used the EyeBag 1.9 times a day, for 9.6 minutes each, from baseline to 
week 2. From weeks 2 to 4, participants used the EyeBag 1.7 times per day for 9.6 minutes each. Overall, 
participants in the EyeBag group reported having used the EyeBag 1.8 times per day for approximately 9.6 
minutes for the duration of the treatment period. 
6.4.3 Clinical Results 
 
There was a significant change in OSDI over time for the treatment group (Figure 6-1, left). For the EyeBag 
group, the mean score at baseline was 39.1, which decreased significantly (-12.3 points, p = 0.03) to 26.8 
at week 2 and remained lowered for the duration of the study (change of -12.5 at week 4, p = 0.03; and -
11.4 at week 8, p = 0.06). For the control group, the OSDI score was 41.3 at baseline and did not change 
significantly over time. Symptom reduction was also reflected in the SANDE score (Figure 6-1, right). The 
EyeBag group showed a reduction over time from baseline, with the maximum reduction observed at week 
4 (-12.9 points). The control group also showed change over time, however in the opposite direction. 
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Baseline control SANDE score was 52.4 and increased to 63.0 over the duration of the study. None of these 
changes were statistically significant.  
 
Figure 6-1: Summary (mean±SD) of OSDI (left) and SANDE (right) changes over time. The OSDI scores 
in the EyeBag group was significantly different than baseline at weeks 2 (-12.3, p = 0.03) and 4 (-12.5, p = 
0.03), but not 8 (-11.4, p = 0.06). There was no significant change over time for the control group. There 
was no significant difference over time in either the EyeBag or control group for the SANDE scores. 
The median MG score for the EyeBag group increased from 4.0 to 6.0 points from baseline to week 2, 5.0 
at week 4, and returned to 4.0 at week 8. None of these changes were statistically significant. For the control 
group, the median MG score stayed at 3.0 from baseline to week 2. This decreased to 1.0 at weeks 4 and 8. 
The changes were also not statistically significant (Figure 6-2, left). The median EyeBag MGYLS count 
increased from 1.5 at baseline to 2.0 at weeks 2 and 4, and decreased to 0.0 at week 8. In the control group, 
median MGYLS count stayed at 0.0 for the entire study duration (Figure 6-2, right). None of the changes 
in either group were statistically significant.  
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Figure 6-2: Box-and-whisker plots summarizing change in MG score (left) and MGYLS (right). An 
overall improvement in median meibum quality and glands yielding liquid secretions was observed by 4 
weeks relative to baseline (+1.0 units, +0.5 glands, respectively) and appeared to return to baseline levels 
at week 8. None of these changes were statistically significant. There was no significant change over time 
in the control group. 
For NIBUT, a gradual increase was observed in the EyeBag group. At baseline, NIBUT was observed to 
be 2.9s. This value increased to 3.1s at 2 weeks, and 3.4s at 4 weeks, before decreasing to 3.0s at week 8. 
In the control group, NIBUT decreased from 3.1s at baseline to 2.7s at week 2, 2.3s at week 4 and 3.1s at 
week 8. Neither groups showed significant changes (p > 0.07). Figure 6-3 summarizes the change in 
NIBUT.  
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Figure 6-3: Non-invasive tear breakup time (mean±SD) in the EyeBag group increased gradually from 
baseline to 4 weeks (+0.5s, p > 0.05) but returned to baseline levels at week 8. None of the changes in the 
EyeBag or control group were statistically significant. 
There was a statistically significant difference detected in conjunctival staining over time, however it is not 
likely to be clinically significant. A reduction of 4.0 points on a scale of 100 was relatively minor. 
Furthermore, there was no significant change in corneal staining, lipid layer thickness, and meibography 
for both the EyeBag and control group. Tables 6-2 and 6-3 summarize the clinical results for the EyeBag 
group and control group respectively. 
The pre and post EyeBag CSQ scores conducted at CCLR were pooled from all study visits for analysis 
(n=48 for the EyeBag group, n=52 for the control group). The EyeBag and control group both showed a 
significant decrease in CSQ scores (-5.5 points for the EyeBag, -2.5 points for the control, both p < 0.01 by 
Paired t-test) over the course of 10 minutes. The decrease in symptoms in the control group was likely 
describing recovery from discomfort induced by clinical testing. After applying an offset (+2.5 points) to 
the post-EyeBag CSQ values to correct for clinically induced discomfort, the decrease in symptoms 
detected in the EyeBag group was still statistically significant (p < 0.01). There was no change for both 
HCVA and LCVA in both groups (Table 6-4).   
 
 
103 
 
Participants in the EyeBag group were instructed to complete the at-home CSQ immediately prior to and 
after the EyeBag treatment (10 minutes). With n=12 in the EyeBag group we had expected a total of 24 
pairs (pre/post) of responses (12 pairs for week 1, and another 12 for week 3). Due to some participants 
who had not completed the at-home CSQ properly, only 19 pairs of data were useable (9 pairs from week 
1, 10 pairs from week 3). The median time between the submission of the first at-home CSQ, and the 
initiation of the second at-home CSQ was 22.6 minutes (Q1: 13.5 mins, Q3: 61.6 mins), ranging from 0.6 
mins to 289.1. The median reduction in at-home CSQ scores reported was 5.0 (Q1: 0.0, Q3: 9.0), ranging 
from -1.0 to 21.0. There was no significant correlation between treatment time and CSQ score reduction 
(Spearman’s rho = 0.14, p = 0.55).  
In the control group, of the 26 pairs of responses, only 13 pairs of data were usable. The median time 
between at-home CSQ submissions was 13.5 minutes (Q1: 9.1 mins, Q3: 22.7 mins) ranging from 1.3 mins 
to 37.4 mins. The median reduction in at-home CSQ scores reported was 0.0 (Q1: -3.0, Q3: 1.0), ranging 
from -6.0 to 3.0.  
The mean reduction in at-home CSQ scores in the EyeBag group was significantly greater than the control 
group (p < 0.05 by Mann Whitney test).  
Table 6-2: Summary of clinical changes for the EyeBag group (n = 12). 
 Baseline 2 weeks 4 weeks 8 weeks p value 
Parametric (mean ± SD) 
OSDI  39.1 ± 12.5 26.8 ± 11.2* 26.6 ± 15.9* 27.7 ± 14.6 0.02 
SANDE 58.7 ± 14.5 50.1 ± 25.5 45.8 ± 27.1 49.4 ± 31.7 0.25 
LLT  68.7 ± 16 68.2 ± 14 64.4 ± 11 64.0 ± 13 0.13 
NIBUT  2.9 ± 1.2 3.1 ± 0.8 3.4 ± 0.8 3.0 ± 0.9 0.46 
Meibography  2.2 ± 1.4 2.3 ± 1.5 2.2 ± 1.3 2.2 ± 1.4 0.53 
Non parametric (Q1, median, Q3) 
MG Scoreα  2.0, 4.0, 6.0 3.0, 6.0, 8.0 3.2, 5.0, 6.8 2.2, 4.0, 6.0 0.21 
MGYLSα  0.0, 1.5, 3.0 1.0, 2.0, 3.0 1.0, 2.0, 3.0 0.0, 0.0, 2.0 0.14 
Corneal stainingα  3.0, 11.2,107.5 2.5, 25.0, 87.5 2.5, 62.5, 137.5 0.0, 62.5, 118.8 0.95 
Conjunctival stainingα 2.6, 4.0, 10.4 0.0, 0.0, 1.1* 3.8, 6.3, 13.4 0.0, 0.0, 2.2* <0.01 
α indicates Friedman Test 
* indicates p < 0.05 from baseline 
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Table 6-3: Summary of clinical changes for the control group (n = 13). 
 Baseline 2 weeks 4 weeks 8 weeks p value 
Parametric (mean ± SD) 
OSDI 41.3 ± 15.4 39.0 ± 17.8 35.8 ± 20.7 35.6 ± 23.2 0.23 
SANDE 52.4 ± 15.6 57.9 ± 19.6 62.9 ± 23.1 63.0 ± 30.7 0.15 
NIBUT 3.1 ± 1.3 2.7 ± 0.9 2.3 ± 0.7 3.1 ± 1.0 0.08 
Meibography 2.2 ± 1.6 2.2 ± 1.6 2.2 ± 1.4 1.8 ± 1.4 0.16 
Non Parametric (Q1, median, Q3) 
MG Scoreα 0.5, 3.0, 6.0 2.0, 3.0, 4.5 0.5, 1.0, 3.5 0.5, 1.0, 5.5 0.16 
MGYLSα 0.0, 0.0, 2.5 0.0, 0.0, 2.0 0.0, 0.0, 1.5 0.0, 0.0, 1.0 0.40 
LLTα 43.5, 65.0, 76.0 49.0, 59.0, 71.0 51.0, 52.0, 56.0 48.0, 51.0, 56.5 0.07 
Corneal stainingα 0.0, 10.0, 25.0 0.0, 25.0, 50.0 0.0, 0.0, 25.0 0.0, 0.0, 37.5 0.37 
Conjunctival stainingα 0.0, 1.2, 5.2 0.0, 0.0, 1.9 0.6, 2.2, 13.8 0.0, 0.0, 1.2 <0.01 
α indicates Friedman Test 
* indicates p < 0.05 from baseline 
 
Table 6-4: Paired t-test comparison of pooled visual acuities and at-CCLR CSQ scores immediately pre 
and post EyeBag (after offset) application.  
 EyeBag group (n = 48)  Control group (n = 52) 
 HCVA LCVA CSQ  HCVA LCVA CSQ 
Pre Eyebag -0.04±0.10 0.21±0.10 15.0±8.0  0.00±0.12 0.31±0.17 17.3±8.4 
Post Eyebag -0.05±0.10 0.19±0.12 12.0±6.2  0.01±0.12 0.29±0.17 17.3±8.4 
p value 0.11 0.11 <0.01  0.82 0.09 1.00 
 
 
6.5 Discussion 
 
The results from this study suggest that the changes in terms of measurable signs from using the EyeBag 
are modest. A one point increase in MG score from baseline to the second week suggests that, on average, 
one of five glands showed an improvement in meibum grade. This change is maintained up to the fourth 
week but returned to baseline after discontinuing the EyeBag. This trend is also observed with NIBUT, 
where an improvement was observed during the period in which the EyeBag was used, returning to baseline 
where it was discontinued. This suggests that the EyeBag needs to be used continuously to maintain the 
improvement in MG function and NIBUT. The potential changes in such clinical measures after extended 
use remains unknown.  
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The statistically non-significant findings with MG score and NIBUT was likely due to an over-estimation 
of the impact of the EyeBag when calculating sample size. A post-hoc analysis showed that the effect size 
of the MG score in this study was actually around 0.4, which was much less than what the study was 
powered to detect (1.0). One reason that may explain a depressed effect size could be related to the dry 
winter environment during which this study was conducted. Therefore, to detect a statistically significant 
difference, future studies using this same study design and analysis would require at least n=52 per group. 
The other EyeBag study28 that found a statistically significant improvement with the EyeBag with sample 
size of n=25 had used a contralateral-eye design which allowed for more statistical power to detect smaller 
differences.  
Despite modest changes in MG score and NIBUT, both short (CSQ) and long-term (OSDI) symptoms 
improved significantly after using the EyeBag. Long-term improvement was noticed as soon as week 2, 
and the OSDI remained decreased for the duration of the study, even after the EyeBag was discontinued. It 
is not clear why this is the case, since both MG score and NIBUT appeared to return to baseline after 
discontinuing use. Perhaps there exists a lag period after which symptoms are reflected in the change in 
function. Alternatively, there may exist a placebo effect,47 in which participants believe they feel better 
after having undergone the EyeBag therapy. In either case, the OSDI score reduction was not as high as 
reported by the previous study28 and we believe the difference is due to bias inherent with a contralateral 
design and the application of the questionnaire in a unilateral manner.   
Short term symptom reduction measured with the CSQ was also considered to be minor. A 3.0 point (at-
CCLR) and 5.0 point (at-home) CSQ score reduction corresponds to a 6% and 10% improvement. It was 
also not possible to predict symptom improvement as there appears to be no observable correlation between 
treatment time and CSQ symptom reduction.   
Meibomian gland atrophy did not change significantly throughout the study. This was not surprising, since 
it takes many years for MG atrophy to occur.43 Due to this fact, we also cannot conclude whether or not the 
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EyeBag prevents or reverses atrophy. Furthermore, we did not find any clinically meaningful changes with 
corneal staining, conjunctival staining and lipid layer thickness.  
Due to the importance of adherence in medical therapy48 this study had attempted to quantify EyeBag use 
with two methods (self-reporting to research assistant, and via MetricWire app). Although participants self-
reported using the EyeBag 1.8 times a day for 9.6 minutes, the timestamps from the CSQs administered via 
the MetricWire app suggested differently. We could only conclude that participants were either not 
completing the CSQs in the instructed manner or they were using the EyeBag differently from what they 
reported. At the end of the study, some participants mentioned they had fallen asleep while using the 
EyeBag, while some others mentioned that 10 minutes was too time consuming. Without any more 
information, it is not possible to make any further conclusions with EyeBag compliance.  
All participants have different microwave ovens so it was difficult to determine if all EyeBags were heated 
to the same extent. There also appears to be variation in EyeBag temperature retention between EyeBags 
(Appendix) after being heated with the same amount of power. The difference in temperature profiles may 
be due to differences in which the EyeBag was positioned in the microwave. There may also have been 
residual heat on the table after a previous measurement that may have impacted overall temperatures.  
The EyeBag is aimed towards managing obstructive MGD by melting and softening meibum obstructing 
the MGs. However, various forms of MGD exist, and not necessarily all driven by obstruction49 and it is 
currently unclear whether or not atrophied glands may benefit from the EyeBag treatment. This may be an 
area for future research. Additionally, in severe cases of MGD, eyelid warming devices may not be enough 
for treatment. Blepharitis is often associated with MGD50 and it may be beneficial to study the combined 
effect of an eyelid warming device with antibiotics or anti-inflammatory therapies. Additionally, since there 
are many emerging eyelid warming devices, it may also be beneficial to compare their efficacies in the 
management of MGD.   
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6.6 Conclusion 
 
There was a considerable improvement in long and short term symptoms after using the MGDRx® EyeBag, 
with only modest improvement in MG function and tear breakup time. The continued use of the Eyebag is 
required to sustain improvement, but given that symptoms did improve, then compliance may be helped by 
the fact that subjects do seem to appreciate a reduction in symptoms.  
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7 The Effect of Lid Debridement-Scaling in Sjӧgren’s Syndrome Dry 
Eye 
 
This chapter is published as follows: 
Ngo W, Caffery B, Srinivasan S, Jones LW. Effect of Lid Debridement-Scaling in Sjogren Syndrome Dry 
Eye. Optom Vis Sci. Sep 2015;92(9):e316-320. 
Reprinted with permission. 2015 Wolters Kluwer Health Lippincott Williams & Wilkins © 
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up/publication
Ngo Y Y Y Y Y 
Caffery  Y   Y 
Srinivasan Y    Y 
Jones Y    Y 
Table detailing role of each author in this publication (Y denotes significant contribution).  
 
7.1 Overview 
 
PURPOSE: To evaluate the effect of lid debridement-scaling (LDS) on dry eye signs and symptoms in 
individuals with Sjӧgren’s Syndrome (SS).  
METHODS: This prospective randomized controlled study enrolled 14 female participants with SS. Seven 
participants were randomized into the treatment group where they were selected to receive LDS, the 
remainder did not receive LDS and served as controls. LDS was conducted using a stainless steel golf club 
spud (Hilco Wilson Ophthalmics, Plainville, MA) on both the upper and lower eyelids of both eyes. 
Outcome variables were assessed prior to LDS and again 1 month later. The outcome variables were the 
Ocular Surface Disease Index (OSDI), Symptoms iN Assessment of Dry Eye (SANDE) visual analogue 
scores, ocular staining (SICCA OSS) fluorescein tear breakup time (FLBUT), meibomian gland score (MG 
score), meibomian glands yielding liquid secretions (MGYLS), and Line of Marx’s (LOM) position.  
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RESULTS: Thirteen participants completed the study. Data from the right eye only were analyzed. For the 
control group (n=6, mean age=62.3±11.6), the pre LDS, post LDS, and significance level (pre mean±SD 
vs post mean±SD; p-value) were: OSDI (58.3±22.1 vs 48.3±29.0; p=0.051), SANDE (77.4±22.1, 
89.6±32.6, p=0.20), SICCA OSS (7.0±4.5 vs 8.2±3.5; p=0.25), MG score (1.3±1.5 vs 1.0±0.9; p=0.75), 
MGYLS (0.3±0.5 vs 0.0±0.0; p=0.50), FLBUT (2.99 ±1.54 vs 2.85±1.79; p=0.63), LOM (2.0±0.0, 2.0±0.0, 
p=n/a).  
For the treatment group (n=7, mean age=58.0±8.1), the pre LDS, post LDS, and significance level were: 
OSDI (63.2±13.3 vs 46.9±19.4; p=0.04), SANDE (72.6±17.1, 77.0±28.0; p=0.54), SICCA OSS (6.6±2.9 
vs 5.0±3.9; p=0.02), MG score (1.0±1.2 vs 3.1±1.7; p=0.01), MGYLS (0.0±0.0 vs 0.6±1.0; p=0.50), 
FLBUT (3.13±0.81 vs 3.45±1.03; p=0.53), LOM (0.9±0.9, 1.0±1.0, p=1.00).  
CONCLUSIONS: This pilot study showed that LDS improved symptoms, ocular staining and meibomian 
gland function for the group that received LDS. This indicates that LDS can aid in the management of SS 
dry eye.  
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7.2 Introduction 
 
Dry eye is a multifactorial disease characterized by symptoms, not limited to stinging, grittiness and or 
burning sensation of the eyes.1 The Dry Eye Workshop 2007 defined dry eye as follows1:  “Dry eye is a 
multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual 
disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by 
increased osmolarity of the tear film and inflammation of the ocular surface”.  
Aqueous deficiency is one of two major classifications for dry eye and a major cause for aqueous deficiency 
is Sjӧgren’s Syndrome (SS).1 SS is an autoimmune condition in which lymphocytes infiltrate and attack the 
lacrimal gland, causing damage to the gland tissue.2 The American College of Rheumatology had proposed 
an expert consensus approach to the diagnosis of SS, which communicates a positive diagnosis if two of 
the three following criteria are met3:  
1. Positive serum anti-SSA/Ro and/or/anti-SSB/La (or positive rheumatoid factor and ANA titer ≥ 
1:320),  
2. Labial salivary gland biopsy exhibiting focal lymphocytic sialadenitis with a focus score ≥ 1 
focus/4mm2,  
3. Ocular staining score ≥ 3.  
Recent studies have shown that the meibomian glands (MG) are also affected in SS,4,5 showing functional 
and morphological changes to their structure. One of the primary mechanisms driving obstruction of the 
MGs is hyperkeratinization of the eyelid margin and duct orifices.6 There are various endogenous and 
exogenous factors that influence keratinization of the duct epithelium, including stem cell 
migration/differentiation abnormality, medication use and aging.6 As keratinized material is built up around 
and within the orifice, the gland is obstructed and meibum cannot be delivered from the gland to the tear 
film.6  
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In addition, the flow of meibum from the orifice to the tear film can be hindered with the accumulation of 
debris that is associated with the thickening of the Line of Marx (LOM).7 The positional change to the LOM 
may be due to hyperosmolar changes in the tear film.8,9 A recent study by Korb et al.7 described a novel 
procedure termed “lid debridement-scaling” (LDS) that was shown to increase MG function and reduce 
symptoms by debriding the LOM. This technique works by mechanically removing accumulated debris and 
keratinized cells from the eyelid margin to increase the flow of meibum into the tear film.7  
To date, the aforementioned study7 appears to be the only publication describing the debridement of the 
LOM and the subsequent improvement in symptoms and MG function. It is currently unknown how 
effective this technique is at providing relief for individuals who experience extreme dry eye, which 
typically occurs in SS. Therefore this study aims to determine how effective LDS is at improving clinical 
signs and symptoms, in addition to MG function, in individuals with SS. 
7.3 Methods 
 
7.3.1 Participants 
 
This was a prospective, unmasked, randomized, controlled study that enrolled 14 participants with SS. 
Eligibility was determined at a screening visit. Diagnosis of SS was confirmed as per the criteria outlined 
by the American College of Rheumatology.3 Seven participants were randomly selected to receive LDS, 
and the remainder served as controls. All participants except one returned one month later for follow up 
measurements. This study was conducted in accordance with the ethical principles in the Declaration of 
Helsinki. Ethics clearance was obtained through a University of Waterloo Research Ethics Committee prior 
to commencement of the study. Informed consent was obtained from all participants prior to enrolment in 
the study.  
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7.3.2 Clinical Methods 
 
All measurements were obtained by the same investigator (WN).  
To assess symptoms, the Ocular Surface Disease Index (OSDI)10 and the Symptom Assessment iN Dry Eye 
(SANDE)11 1 & 2 visual analogue scales were used. OSDI and SANDE were conducted at the beginning 
of each appointment, prior to testing.  
Fluorescein break-up time (FLBUT) was conducted by wetting a fluorescein strip (Fluorets, Bausch & 
Lomb Canada Inc., Markham, Ontario, Canada) with a few drops of saline (Bausch & Lomb Sensitive 
Eyes® Saline Plus, Rochester, New York, USA), shaking off any excess dye, and then applying the strip 
to the lower fornix of both eyes. The time for disturbances in the tear film to appear was recorded in seconds 
using a stop-watch. At this point, corneal staining was also assessed. Lissamine green (GreenGlo™, HUB 
pharmaceuticals, Rancho Cucamonga, California, USA) was then instilled by wetting a strip with a few 
drops of saline, shaking off any excess dye, and then applying the strip to the lower fornix of both eyes. 
The combination of corneal and conjunctival staining was graded using the Sjӧgren’s International 
Collaborative Clinical Alliance Ocular Staining Score (SICCA OSS).12 This grading scheme factors in 
additional clinical features such as staining in pupillary area, presence confluent staining, and presence of 
filaments, for a total maximum score of 12 per eye.  
Meibomian gland score (MG score) was obtained by using the Meibomian Gland Evaluator™ (MGE) 
(TearScience, Inc., Morrisville, North Carolina, USA)13  to apply a controlled and constant pressure of 
approximately 1.25g/mm2 to the central 5 glands of the inferior lid margin for 10 seconds.13 The meibum 
expressed was graded based on the following scale, and was scored out of 15 (5 central glands were 
evaluated, with a maximum score of 3 for each gland)13:  
Grade 0: No expression 
Grade 1: Inspissated (toothpaste) 
Grade 2: Cloudy with debris 
 
 
113 
 
Grade 3: Clear 
The Meibomian Glands Yielding Liquid Secretions (MGYLS) measurement is a count of those 5 glands 
with MG score of 2 or higher.13  
LOM position was determined by instilling an additional drop of lissamine green and everting the lower 
eyelid margin for observation. This highlighted the LOM and keratinized debris that accumulated on the 
lid margin. The position of the LOM relative to the MG orifices was graded based on the following scale:14  
Grade 0: LOM mostly (>75%) posterior to the orifices 
Grade 1: LOM mostly bisecting the orifices 
Grade 1: LOM mixed posterior and bisecting the orifices 
Grade 2: LOM mostly anterior 
Grade 2: LOM mixed posterior, bisecting and anterior to the orifices 
Grade 2: LOM mixed bisecting and anterior to the orifices 
 
LDS was conducted by instilling a single drop of proparacaine hydrochloride 0.5% (Alcon, Inc., Fort 
Worth, Texas, USA) in both eyes to reduce lid sensation and any discomfort. The stained cells/debris were 
gently debrided using a stainless steel golf club spud (Hilco Wilson Ophthalmics, Plainville, MA, USA). 
The stained cells/debris were debrided by tracking the head of the golf spud gently across the lid margin in 
both directions (Figure 7-1). In a manner previously described,7 this procedure did not remove any debris 
or cells that could not be removed with merely a mild/gentle force. 
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Figure 7-1: Above, the LOM is shown highlighted with lissamine green. Below, LDS had removed 
stained debris and keratinized cells from the LOM. 
7.3.3 Statistical Analysis 
 
Statistical analyses were conducted with GraphPad Prism 6.05 (GraphPad Software, San Diego, CA, USA) 
and STATISTICA 7.1 (StatSoft, Inc., Tulsa, OK, USA). The normality of distribution was tested using the 
Shapiro-Wilk test, at the level of α=0.05 with STATISTICA 7.1. GraphPad Prism 6.05 was used for the 
remainder of the statistical tests. Paired t-test was used to determine the statistical significance of the 
difference of means in parametric ocular variables. Wilcoxon test was conducted on ocular variables that 
did not pass the normality test. Spearman correlation was examined on all ocular variables and symptoms 
collected from the baseline visit. Data from only the right eye (where applicable) were analyzed. Level of 
statistical significance was set at p < 0.05. 
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7.4 Results 
 
7.4.1 Participants 
 
A total of 13 females completed the study (mean age = 60.0±9.7, from 46.0 to 76.0 years). One participant 
was unable to attend her final visit due to scheduling conflict. Seven participants were randomized to the 
treatment group (mean age = 58.0±8.1 years), and the remaining 6 were randomized to the control group 
(mean age = 62.3±11.6 years). The mean ages of the two groups were not significantly different (p=0.46).  
7.4.2 Clinical Outcomes 
 
The difference in means between the baseline and 1 month visit, along with statistical significance for each 
group is summarized in Table 7-1. The treatment group showed a statistically significant reduction in dry 
eye symptoms and signs with both the OSDI scores (-16.3 points) and in SICCA OSS (-1.6 grade units). 
Also, the MG score improved by +2.1 grade units. Post treatment FLBUT increased, but not significantly. 
There was no significant difference in SANDE analogue scale scores, MGYLS, and LOM placement. The 
control group did not show any significant changes in any of the variables tested.  
The Spearman correlation between each variable is summarized in Table 7-2. FLBUT correlated 
significantly with SICCA OSS and MGYLS. OSDI correlated with SANDE, but this relationship was not 
statistically significant.  
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Table 7-1: Summary of difference in means between visits and level of significance for both treatment 
and control group.  
 Control Group  Treatment Group 
Test Baseline 1 Month p-value  Baseline 1 Month p-value 
SICCA OSS (0-12) 7.0±4.5 8.2±3.5 0.25α  6.6±2.9 5.0±3.9 0.02* 
MG score (0-15) 1.3±1.5 1.0±0.9 0.75α   1.0±1.2 3.1±1.7 0.01* 
MGYLS (0-5) 0.3±0.5 0.0±0.0 0.50α  0.0±0.0 0.6±1.0 0.50α 
FLBUT (seconds) 2.99±1.54 2.85±1.79 0.63  3.13±0.81 3.45±1.03 0.53 
LOM (0-2) 2.0±0.0 2.0±0.0 ----  0.9±0.9 1.0±1.0 1.00α 
OSDI (0-100) 58.3±22.1 48.3±29.0 0.051  63.2±13.3 46.9±19.4 0.04* 
SANDE (0-100) 77.4±22.1 89.6±32.6 0.20  72.6±17.1 77.0±28.0 0.54 
 
Bold and * indicates significant differences. 
α indicates Wilcoxon test. 
 
 
 
Table 7-2: Spearman correlation matrix displaying the linear relationship between each variable. 
 SICCA OSS MGS MGYLS FLBUT LOM SANDE OSDI 
SICCA OSS  0.43 0.35 -0.72 0.28 -0.28 -0.13 
MG score 0.43  0.60 -0.45 0.00 0.37 0.25 
MGYLS 0.35 0.60  -0.34 0.33 0.23 -0.03 
FLBUT -0.72 -0.45 -0.34  -0.24 -0.26 0.06 
LOM 0.28 0.00 0.33 -0.24  0.06 -0.27 
SANDE -0.28 0.37 0.23 -0.26 0.06  0.55 
OSDI -0.13 0.25 -0.03 0.06 -0.27 0.55  
 
bold denotes p ≤ 0.05 
 
7.5 Discussion 
 
This study showed that LDS improved MG function and reduced symptoms in individuals with SS. All 
participants reported the LDS procedure to be relatively painless and reported that the sensation was similar 
to a “mild tickling” sensation. Although this study used proparacaine to reduce and avoid discomfort, it did 
not appear to be necessary and it is possible that many participants would be able to tolerate the procedure 
without it. We did try the procedure without anesthesia on a few volunteers after the study and minimal 
discomfort was reported.  
Hyperkeratinization of the eyelid margin is one mechanism that may drive obstruction of the MGs, 
ultimately leading to atrophy of glandular tissue.6 However, there are other non-obstructive mechanisms 
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that can also lead to atrophy of MGs, for example inflammation and aging. An in vivo confocal imaging 
study of the MGs in SS showed that individuals with SS had larger amounts of periglandular inflammation 
compared to non-SS individuals with MGD,5 and a second in vivo study showed presence of glandular 
atrophy, both in minimal or absent orifice obstruction.15 We may not yet be able to reverse age-related 
changes and LDS does not manage the inflammatory aspect of SS related MGD. Thus, it is possible that 
anti-inflammatory therapy in conjunction with LDS may be helpful in managing MGD in SS.  
Improvement in MG function was modest. The function of the MGs was graded with both MGS and 
MGYLS. The MG score was scored out of 15 (5 central glands were evaluated, with a maximum score of 
3 for each gland). Participants typically presented with a score of 1/15, which can be interpreted as “only 1 
gland out of the 5 expressed meibum, and the meibum coming out of that gland was opaque with a 
toothpaste-like appearance”. After LDS treatment, the MG score increased on average approximately 2 
points, resulting in a total score of 3/15. Thus, it could be interpreted as “of the 5 glands, only 3 expressed 
meibum, but each of the expressing glands had meibum that was still opaque and toothpaste-like in 
consistency”. This is not an inaccurate description of improvement, since the MGYLS count did not change 
significantly post LDS. MGYLS is a count of the glands that secreted liquid secretions. An increase in MG 
score but without an increase in MGYLS suggests that the LDS increased the function of MGs by increasing 
the quantity of meibum expressed, without improving the quality of meibum. This is in accord with the 
mechanism behind the LDS technique – which allows for delivery of the meibum by mechanically 
removing the barrier of keratinized cells and debris obstructing the delivery of meibum onto the ocular 
surface.7 A possible next step would be to determine the rate at which eyelid hyperkeratinization occurs 
and the frequency at which LDS should be conducted.  
Meibum helps stabilize the tear film.16 A previous study showed that it is the quality of meibum, not the 
quantity that affects tear film stability.17 Since this treatment did not aim to improve meibum quality, 
FLBUT was not expected to be significantly different post LDS, and the findings of this study appeared to 
fit this expectation. The statistically significant correlation found between FLBUT and MGYLS may be a 
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false positive result. All of the 13 participants at baseline had an MGYLS count of 0, with the exception of 
2 participants, and those 2 participants each had an MGYLS count of 1. Thus, there is not enough 
information to make a conclusion regarding the correlation between FLBUT and MGYLS.   
This study did find a strong correlation between ocular staining and FLBUT (in both pre and post LDS). In 
previous studies,18,19 the relationship between FLBUT and corneal and conjunctival staining (separately) 
was found to be poor. A possible reason to explain this discrepancy may relate to the nature of the SICCA 
OSS scale. The SICCA OSS grading scale factored in the presence of filaments, which if present would not 
only increase the SICCA OSS score, but would also quickly reduce the stability of the tear film. In this 
study, 4 of 13 participants were positive for filamentary keratitis.  
In addition to the LOM grading scale used in this study14 there is only one other LOM grading scale 
published.9 The grading of LOM position relative to the MG orifices did not change significantly pre and 
post LDS. This was expected, since the thickening and advancement of the LOM is a morphological 
change8,9 of the eyelid and is not likely to be reversed by LDS.  
While the magnitude of change in OSDI (-16.3) was considered to be clinically significant,20 none of the 
symptom assessments correlated significantly with any of the clinical signs. This was not surprising, since 
the relationship between dry eye signs and symptoms is known to be poor.18,19,21,22 The OSDI showed a 
positive correlation with the SANDE severity scores, however this relationship was not statistically 
significant.  
Two major limitations of this study include the small sample size and that the treatment was administered 
without masking of either the subjects or investigators. An issue to note related to this latter point is that 
the control group’s OSDI score also decreased at the 1 month follow-up (Table 7-1). While this reduction 
was not statistically significantly, the 10 point reduction was near the magnitude of that seen in the treatment 
group, which reduced by approximately 16 points. This decrease in symptoms is difficult to explain, but 
could have been due to the “Hawthorne effect”23 in the control group, in which symptoms change due to 
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the mere fact that subjects are being observed, regardless of the fact that no treatment is being undertaken. 
The lack of masking may also have caused the treatment group to have exaggerated their improvement due 
to a placebo-effect. While this study was still able to show significant improvements with MG score and 
OSDI and ocular staining, having a larger sample size may have helped us determine whether or not there 
were improvements in other clinical variables.  
Many participants who had LDS reported that their eyelid margins felt a pleasant “cool” sensation for about 
a week after the procedure, and that their symptoms had improved slightly for a couple of weeks. The 
cooling sensation could be due to the exposure of the debrided eyelid margin to the environment. The 
improvement in symptoms may be due to the belief that the treatment had helped, and may be unrelated to 
whether or not it truly did. One way to control for this factor would have been to administer a placebo 
treatment, in which the LDS treatment was imitated but without actually debriding the eyelid surface and a 
study using such a sham procedure may be worthy.  
7.6 Conclusion 
 
This pilot study was able to show that LDS was effective in improving some clinical signs and symptoms 
in participants with SS who exhibited severe dry eye and may play a helpful role in the management of 
SS dry eye.   
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8 The Relief of Dry Eye Signs and Symptoms Using a Combination of 
Lubricants, Lid Hygiene, and Ocular Nutraceuticals 
 
This chapter is published as follows: 
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This is an open access article under the CC BY-NC-ND license.   
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8.1 Overview 
 
PURPOSE: To determine the combined effect of TheraTears® Lubricant Eye Drops, TheraTears® 
SteriLid Eyelid Cleanser, and TheraTears® Nutrition on dry eye signs and symptoms.  
METHODS: This prospective study enrolled 28 dry eye participants. Participants were instructed to use 
the Lubricant Eye Drops at least 2-4x a day, SteriLid 1-2x a day, and Nutrition 3 gel caps once a day. 
Participants were followed up at baseline, 1 month and 3 months. Outcome variables were the Ocular 
Surface Disease Index (OSDI), Symptom Assessment iN Dry Eye (SANDE) questionnaire, non-invasive 
tear break-up time (NIBUT), osmolarity, number of meibomian glands blocked (#MG blocked), meibum 
quality, eyelid margin features, Schirmer’s test, tear film lipid layer thickness (LLT), meniscus height, 
corneal and conjunctival staining.   
RESULTS: Twenty participants (mean age = 43, from 23 to 66, 17F, 3M) completed the study. Participants 
reported having used, on average, the Lubricant Eye Drop 2.4x/day, the SteriLid 1.1x/day, and the Nutrition 
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3 gel caps 1x/day. There was a significant change over time (p<0.05) for OSDI (-21.2 points), SANDE (-
32.4 points), NIBUT (+0.43s), eyelid margin features (-1.1 grade), meibum quality (-1.0 grade), and #MG 
blocked (-4.0 glands).  
CONCLUSION: By using a combination of TheraTears® Lubricant Eye Drop, SteriLid, and Nutrition, 
patients experience significant relief in both dry eye symptoms and signs.  
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8.2 Introduction 
 
Dry eye is a complex multifactorial condition that was defined by the 2007 Dry Eye Workshop as: 
 “Dry eye is a multifactorial disease of the tears and ocular surface that results in symptoms of 
discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is 
accompanied by increased osmolarity of the tear film and inflammation of the ocular surface”.1  
The two major etiological categories of dry eye are aqueous deficient and evaporative dry eye.1 The former 
consists of a wide variety of conditions that result in a deficiency of the aqueous portion of tears (eg typical 
aqueous deficient dry eye and Sjӧgren’s syndrome).1 The latter category includes a group of tear film and 
adnexa anomalies that quicken the evaporative loss of tears from the surface of the eye (eg meibomian oil 
deficiency).1  
In either case, the symptoms brought about by ocular dryness can severely affect quality of life.2-4 
Individuals suffering from dry eye may feel significant discomfort during certain tasks, including driving, 
reading, computer usage, or simply being in an environment with low humidity.2  
The clinical assessment of dry eye typically include tests that assess subjective symptoms, along with 
various features of the ocular surface, adnexa and accessory tear glands.5 The assessment of symptoms is 
conducted through symptom questionnaires,5 with some assessing purely symptoms,6,7 and others 
combining symptoms with quality of life measures.8,9 The physical signs of dry eye are commonly assessed 
with corneal staining, conjunctival staining, tear breakup time, meibomian gland (MG) function, and by 
undertaking a Schirmer’s test.5 These clinical tests permit determination of the extent of the condition, along 
with monitoring any improvement of symptoms and signs with the administration of dry eye treatment.
1 
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8.3 Methods 
 
8.3.1 Participants 
 
This was a prospective study that enrolled 28 dry eye participants. The key inclusion and exclusion 
criteria is outlined in Table 8-1.  
Table 8-1: Inclusion and exclusion criteria for entry into study 
Inclusion Exclusion 
Between 18-70 years old Has any active ocular disease (other than blepharitis, MGD, dry eye), infection or allergies 
Has read and signed an information consent letter Is participating in any concurrent clinical or research study 
Is willing and able to follow instructions and 
maintain the appointment schedule 
Has known sensitivity to the diagnostic 
pharmaceuticals to be used in the study 
Exhibits symptoms of dry eye for at least 3 
months 
Has a systemic condition or taking medications 
that may affect a study outcome variable 
Ocular Surface Disease Index (OSDI) of ≥ 23 Has worn contact lenses in the past 5 years 
On a non-omega 3 dry eye regimen that consists 
of instilling artificial tears at least 3 times a week 
for the past 3 months 
Is currently on, or have used omega 3 
supplements in the past 3 months 
Has an average non-invasive tear breakup time 
(NIBUT) of ≤5.00s in at least one eye 
Is pregnant, lactating, or planning a pregnancy at 
the time of enrollment as determined verbally 
 Has undergone refractive error surgery 
 Has taken part in another pharmaceutical research study within the last 30 days 
 Has worn contact lenses within the past 5 years 
 Is currently using or have used omega 3 supplements in the past 3 monthsf 
 
The study was conducted at the Centre for Contact Lens Research (CCLR), at the University of Waterloo 
(UW). The study was conducted in conformance with the ethical principles of the Declaration of Helsinki, 
the ICH guidelines for Good Clinical Practice, the UW Guidelines for Research with Human Participants.  
Informed consent was obtained from all participants prior to enrollment in the study. Ethics clearance was 
obtained through a UW Research Ethics Committee prior to commencement of the study.  
All participants were screened at the baseline visit to determine their eligibility. Once eligibility was 
determined, participants were enrolled and baseline measurements were obtained. Participants were then 
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asked to cease their current dry eye treatment and provided with the TheraTears® Lubricant Eye Drop, 
TheraTears® SteriLid, and the TheraTears® Nutrition to use, as per label. Details about the study products 
can be found in Table A.1.  
After leaving the CCLR at the baseline visit, participants were asked to start using the products immediately. 
All participants were contacted at 2 weeks into the study to ensure that adherence to product use was 
maintained, to monitor adverse events, and to measure symptoms. All participants returned at 1 month and 
3 months for follow up measurements.  
8.3.2 Clinical Measurements 
 
At the beginning of each study visit, adherence to product and changes to health or medications was 
documented. 
Symptoms were assessed with the Ocular Surface Disease Index (OSDI),15 and the Symptoms Assessment 
iN Dry Eye (SANDE).6 The OSDI is a dry eye questionnaire that quantified dry eye symptoms in the context 
of visual symptoms, visual tasks, and environmental factors. The SANDE quantified dry eye symptoms by 
combining two visual analogue scales that separately assessed frequency and severity of dry eye 
symptoms.6  
Tear osmolarity was conducted using the TearLab™ Osmolarity System (TearLab™, California, USA).16 
Prior to testing, participants verified that no eye drops were instilled 2 hours prior to arriving at the visit. 
The tip of the pen was gently touched to the tear meniscus on the temporal lid margin to obtain a reading, 
as per manufacturer recommendation.   
The tear film lipid layer thickness (LLT) was assessed using the LipiView (TearScience®, North Carolina, 
USA) in primary gaze.17 The average interferometric color unit (ICU) for each eye was documented.  
Tear meniscus height was measured to 0.01mm accuracy using the Keratograph® 5M (OCULUS Inc, 
Wetzlar, Germany).18 The built-in software ruler was used to conduct the measurement. The ruler was 
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drawn from edge of the tear meniscus at the 6 o’clock position of the pupil vertically downward to the edge 
of the eyelid margin. This was conducted 3 times and the values were averaged.  
Non-invasive tear breakup time was conducted by using a corneal topographer.19 An illuminated placido 
disc was projected onto the cornea and imaged with an infrared CCD camera in the Humphrey Atlas® 
Topographer 991 (Zeiss, California, USA). This was conducted by asking participants to hold their eyes 
open for as long as they could. A stopwatch was used to quantify the time in which distortions began to 
appear in the reflected placido disc. This measurement was measured to 0.01s accuracy, and repeated three 
times and then averaged. 
Eyelid margin features were examined under a slit lamp. The parameters of interest were erythema, edema, 
vascularity and telangiectasia. They were each graded and summed to generate a composite eyelid margin 
score. The grading scale used for each parameter is outlined in Table A.2. 
A strip of fluorescein was wetted with a few drops of saline, and was instilled in each eye to assess corneal 
staining. Corneal staining was assessed using the CCLR scale, which assessed type, depth, and extent of 
staining on a scale of 0 to 100 each.20 After 1 minute had elapsed, fluorescein was instilled once more. After 
waiting for another 3 minutes, the superior eyelid was everted and fluorescein lid wiper epitheliopathy 
(LWE) was assessed.21 A strip of Lissamine green was wetted with a few drops of saline and instilled into 
both eyes to assess conjunctival staining (using the Oxford Scale).22 After 1 minute, Lissamine green was 
instilled again. The eyelids were everted after 3 minutes to assess Lissamine green LWE. Both fluorescein 
and Lissamine green LWE grades were averaged to generate the final LWE grade.21 Table A.3 outlines 
further details on LWE grading.  
Meibomian gland function was assessed by observing the expressibility and quality of meibum in the 
inferior central 8 glands. Meibomian gland expressibility was assessed by applying variable digital pressure 
to the lid margin and estimating the force required to express meibum. Meibum quality was then assessed 
by applying firm digital pressure to the lid margin and assessing the physical characteristics of meibum 
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using a 4 point grading scale previously described.23 The number of blocked glands (out of 8) were defined 
as ones that did not express liquid secretions.  
Meibography was assessed by everting the lower and upper eyelids and imaging the tarsal plate using the 
Keratograph® 5M.24 The amount of MG dropout from the upper and lower eyelids were was quantified 
using a grading scale previously described,25 and summed.  
Schirmer’s test was conducted by inserting a Schirmer strip for 5 minutes in the lateral 1/3 of the eyelid 
margin. Participants’ eyes were closed for the duration of 5 minutes. The amount of wetting after this 
duration was quantified.  
A summary of clinical testing and the order in which they were conducted is summarized in Table 8-2.  
Table 8-2: Summary of procedures and instruments 
Testing order Procedure Instrument 
1 Compliance and adverse event check N/A 
2 Symptoms assessment OSDI and SANDE 
3 Entrance visual acuity Electronic logMAR chart 
 
4 Osmolarity TearLab Osmolarity System 
5 LLT LipiView 
6 Tear meniscus height Keratograph® 5M 
7 NIBUT Atlas® topographer 
 
8 Eyelid margin features 
Slit lamp, fluorescein and Lissamine green.  
9 Corneal staining, conjunctival staining 
10 LWE 
11 MG function (meibum quality, expressibility, 
# glands blocked) 
 
12 Meibography Keratograph® 5M 
13 Schirmer’s test Schirmer’s strips 
14 Exit visual acuity Electronic logMAR chart 
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8.3.3 Statistical Analysis 
 
Statistical analysis was conducted using GraphPad Prism 6.05 (GraphPad Software, California, USA).  
Normal data distribution testing was conducted using the Shapiro-Wilk normality test. Repeated Measures 
ANOVA was conducted on variables that had passed the normality test with a threshold of alpha=0.05. 
Post-hoc Dunnett’s test was used to determine which visit was significantly different from baseline values 
in parametric distributions. Friedman test was conducted on non-parametric variables that did not pass the 
normality test. Dunn’s test was used to determine which visits were significantly different from other visits 
in non-parametric distributions. 
Data from only the left eye were analyzed. Level of statistical significance was set at p < 0.05.  
8.4 Results 
 
8.4.1 Participants 
 
A total of 20 participants (17 female, 3 male) completed the study. The mean age of the participants was 
43 (median 41 years, ranging from 23 to 66 years). All participants had previously used lubricant eye drops 
for at least once a day before switching over to the study products. Participants were not on any dry eye 
medications (e.g. cyclosporine, steroids) and were not using any eyelid hygiene products at the time. With 
a combination of OSDI ≥ 23, NIBUT < 5.0s, significantly altered meibum quality and gland obstruction at 
baseline (Table 8-3), participants in this sample appeared to have moderate to severe dry eye.  
8.4.2 Compliance 
 
Participant adherence to product usage was monitored at every visit. On average, participants had used the 
Lubricant Eye Drops 2.4x per day, SteriLid 1.1x per day, and Nutrition 3 gel caps once daily.  
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8.4.3 Clinical Outcomes 
 
There was a significant improvement in symptoms as measured by the OSDI (Figure 8-1). The net change 
from baseline to week 2 (-19.8), to 1 month (-21.4), and to 3 months (-21.2) were all statistically significant 
(all p<0.01). There was also a significant improvement in SANDE scores. The net change at week 2 (-10.2), 
at 1 month (-21.4), and at 3 months (-32.4) were all statistically significant from baseline (all p<0.01).  
 
Figure 8-1: The OSDI score showed significant change over time, with a total net change of -21.2 points 
over the study duration. 
NIBUT was significantly improved from baseline. A median improvement of +0.63s at 1 month and +0.48s 
at 3 months were both statistically significant (both p<0.05).  
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Figure 8-2: NIBUT significantly improved over the course of the study, with a total net change of +0.48s 
at 3 months. 
Eyelid margin scores showed significant change over the course of the 3 months (Figure 8-3). Although the 
change from baseline to 1 month was not statistically significant (-0.4 grade units, p>0.05), the change from 
baseline to 3 month was significant (-1.1 grade units, p<0.05).  
 
Figure 8-3: Eyelid margin features gradually improved over the course of the 3 months, with a significant 
net change in of -1.1 grade units from baseline. 
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Meibomian gland function was also observed to improve significantly (Figure 8-4). Meibum quality was 
not significantly different than baseline at 1 month, but became significantly different at 3 months (-0.5 
grade units, p=0.16; -1.0 grade units, p=0.01, respectively). The number of glands blocked also reduced 
significantly from baseline to 1 month (-2.0 glands, p=0.04), and to 3 months (-4.0 glands, p<0.01).  
 
Figure 8-4: Summary of changes to MG function over the course of the study. By the end of 3 months 
there was a significant improvement from baseline in meibum quality, number of MGs blocked, and 
expressibility of glands (all p<0.05). 
There was no significant difference in Schirmer’s test, LLT, tear meniscus height, LWE, corneal staining, 
conjunctival staining, meibography, and osmolarity. A summary of the clinical results is listed in Table 8-
3.  
Table 8-3: Summary of clinical changes over time (n=20).  
Ocular Measurement Baseline 2 weeks 1 month 3 month p-value 
Parametric (mean±SD)      
OSDI 44.8 ± 17.0 25.0 ± 15.6* 23.4 ± 15.1* 23.6 ± 17.9* <0.01 
SANDE Global Score 63.0 ± 20.6 52.8 ± 23.2* 41.6 ± 27.3* 30.6 ± 25.1* <0.01 
Eyelid margin score 6.0 ± 3.1 N/A 5.6 ± 2.7 4.9 ± 2.6* 0.02 
LLT 82.2 ± 15.4 N/A 76.6 ± 15.9 79.5 ± 16.7 0.21 
Osmolarity 301 ± 13 N/A 304 ± 11 302 ± 11 0.35 
Non-parametric (Q1, median, Q3)      
NIBUTa 1.75, 2.42, 3.27 N/A 1.97, 3.05, 4.49* 2.22, 2.90, 3.63* 0.02 
Meibum qualitya 2.0, 2.5, 3.0 N/A 2.0, 2.0, 2.0 1.0, 1.5, 2.0* <0.01 
Expressibilitya 2.0, 2.0, 3.0 N/A 1.0, 2.0, 2.0 1.0, 2.0, 2.0* <0.01 
Number of glands blockeda 5.3, 6.0, 7.0 N/A 2.3, 4.0, 6.0* 1.0, 2.0, 4.8* <0.01 
Schirmer’s testa 4.5, 8.5, 14.0 N/A 4.0, 9.0, 13.0 5.3, 11.0, 25.0 0.41 
Meniscus Heighta 0.17, 0.20, 0.26 N/A 0.16, 0.19, 0.27 0.18, 0.22, 0.24 0.78 
LWEa 0.00, 0.00, 0.19 N/A 0.00, 0.00, 0.75 0.00, 0.00, 0.50 0.29 
Corneal Staininga 14, 53, 96 N/A 5, 40, 124 3, 25, 46 0.36 
Conjunctival Staininga 0.2, 1.0, 2.0 N/A 0.0, 1.0, 1.0 0.0, 1.0, 1.0 0.08 
Meibographya 0.2, 2.0, 4.0 N/A 1.0, 2.0, 3.8 1.0, 2.0, 4.0 0.66 
a denotes Friedman test  
* p < 0.05 from baseline 
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A total of 8 participants were prematurely discontinued from the study. There were 2 participants who had 
experienced adverse events related to study product use. One participant experienced dyspepsia after 
ingesting the Nutrition gel caps, and the other participant felt significant eyelid discomfort after using the 
SteriLid. These symptoms were resolved upon cessation of the study product. The remaining 6 participants 
were found to be ineligible at screening. The data from these participants were not used in the analysis.  
8.5 Discussion 
 
This study showed that a combination of lubricant eye drops, lid hygiene, and oral omega-3 supplements 
was effective in improving moderate to severe dry eye.  
Because of the study design, it is not possible to determine from the data how much each separate 
component contributed to the improvement in dry eye. Due to differences in clinical testing and grading 
scales it is also very difficult to compare results to other published studies. For example, the oral omega-3 
supplements used in this study (450mg eicosapentaenoic acid (EPA)/300mg docosahexaenoic acid 
(DHA)/450mg alpha linolenic acid (ALA), total omega-3 content of 1200mg daily) have been shown to be 
effective in reducing dry eye symptoms,26,27 however the methods for symptoms assessment or reporting 
were different from this study. Two previous studies reporting OSDI outcomes using oral omega-3 
supplements showed that OSDI scores improved by 11.6 units (participants taking 6000mg flaxseed oil 
daily),28 and 8.3 units in a separate study (participants taking 360mg EPA, 240 DHA daily).29  
The scenario is similar for the lubricant eye drop and the eyelid hygiene product used in this study. This is 
the first clinical study documenting the effectiveness in relieving symptoms using the TheraTears® 
lubricant eye drop in conjunction with other dry eye treatments.  However, there are no studies with 
TheraTears® lubricant eye drops as a stand-alone product documenting symptom relief.  In other studies 
that have reported OSDI outcomes with other artificial tears, one had reported a change of approximately 
14.0 units with three separate artificial tear drops formulations (used 2-3 times daily) each,30 and another 
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study showed that OSDI improved by approximately 13 units with 4 different formulations (used 3 times 
daily) each.31 Similarly, the only study that reported an OSDI outcome with an eyelid hygiene product 
(Blephaclean twice a day) showed an improvement of 10 units.12  
If we follow the assumption that artificial tears, eyelid hygiene, and omega-3 supplements provide an 
improvement to OSDI of 13, 10, and 10 points respectively, then a complete additive effect of combined 
therapy would yield a theoretical improvement of 33 points to the OSDI. However, the differences between 
reported therapy ingredients, duration of therapy, dosage, population sampling, and study design make it 
very difficult to estimate the true potential improvement for OSDI scores and it is unlikely that these 
benefits are summative in this manner. The total improvement in OSDI score in this study (21.2) suggests 
that combination therapy is approximately twice as effective as reported single therapies in relieving 
symptoms. Although we have not examined the effectiveness of the single therapies in this combination, it 
is unlikely that any single product used here could be responsible for an improvement in OSDI of this 
magnitude. Therefore, an additive effect from at least two of the therapies is likely the case.   
The improvement in eyelid margin scores suggests that the combination therapy had an effect in relieving 
blepharitis. The decrease in clinical inflammation can likely be attributed to the actions of the oral omega-
3 supplements, eyelid hygiene, and even the lubricant eye drops. Oral omega-3 supplements have been 
studied extensively and have been shown to reduce inflammatory biomarkers in the body.32 The 
antimicrobial activity of SteriLid against the eyelid bacteria strains have previously been studied in vitro 
(and compared with povidone iodine).13 A combination of omega-3 supplements and eyelid hygiene 
together have been previously studied,33 and have shown improvements in tear break up time, MG 
expression, eyelid margin inflammation, and symptomatic relief. These findings are mirrored very well by 
our study, as we also found significant improvements in MG function, tear breakup time, eyelid margin 
inflammation and symptoms.  
Despite improvements in MG function, there was no significant change in gland atrophy (meibography) 
over time. This was an expected finding, as MG atrophy occurs at a very slow rate and may take many 
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years for any change to be detectable. A previous study by Arita et al.25 documenting the prevalence of age-
related MG atrophy showed that changes to MG atrophy can take decades to occur. Therefore, any change 
(if present) could not have been detected within the course of this study. However, it would be helpful to 
run a prospective longitudinal study spanning several years to see whether or not adding an intervention 
can impact gland atrophy rates.  
This study was not able to detect any changes in corneal and conjunctival staining. The low amounts of 
corneal and conjunctival staining presenting at baseline could be due to the fact that participants were 
already on drops when they presented for this study. Any improvement (if present) from the treatment effect 
would have been very small, and therefore hard to detect. For future reference, it may be a good idea to 
consider having participants go on a “washout” period prior to beginning a study such as this, to allow them 
to manifest their full corneal and conjunctival staining at baseline.  
Osmolarity also did not change throughout the study period. Osmolarity is considered to be a complex 
aspect of dry eye disease involving the breakdown of homeostatic mechanisms.34 Similar to some of the 
other measures, the osmolarity readings may have been impacted by the participants presenting at baseline 
already on drops.  A “washout” period prior to the baseline osmolarity reading would have been expected 
to provide higher initial readings. The 2007 Dry Eye Workshop defines dry eye as high osmolarity readings 
for participants with dry eye.1 It would be expected that those participants with high osmolarity readings 
using the lubricant eye drop in this study containing a hypo-osmolarity component would have decreased 
osmolarity over time.  A previous study showed that higher variability was attributed to blepharitis and 
Sjӧgren’s syndrome dry eye compared to normals.35 In our study, we had found that the standard deviations 
in our osmolarity measurements remained similar over time (12.6 at baseline, 11.1 at 1 month, 11.1 at 3 
months) even though we observed improvements in many other areas (eg OSDI, NIBUT, eyelid margin 
scores). One possible reason for this is that participants in this sample did not exhibit high osmolarity to 
begin with, therefore making it appear that undergoing treatment had no effect over time.  
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A limitation of this study was that since there were no placebo controls, a placebo effect may be present 
and cannot be ruled out. For future work, implementation of an independent control group would help us 
better understand the findings in this study.  
8.6 Conclusion 
 
The combined therapy of TheraTears® Lubricant Eye Drops, TheraTears® SteriLid, and TheraTears® 
Nutrition improved both symptoms and a variety of signs in participants with moderate to severe dry eye. 
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9 General Discussion and Future Work 
 
9.1 Discussion 
 
The past few decades have seen vast improvements in meibomian gland (MG) imaging technology. 
Meibography initially started with crude eyelid transillumination,1 but has now progressed to the point 
where MGs can be observed with optical coherence tomography (OCT).2 In Chapter 3, only the 
Keratograph 5M (OCULUS, Wetzlar, Germany) was found to successfully image the MGs. The Heidelberg 
Retinal Tomograph 3 with the Rostock Cornea Module (HRT3/RCM) (Heidelberg Engineering GmbH, 
Heidelberg, Germany) confocal microscope imaged structures that resembled dermal structures, and the 
ultra-long OCT was unable to obtain images of MGs. Successful imaging of the MGs with OCT likely 
requires a central wavelength of at least 1300nm, as demonstrated by existing studies.2-5 One of the 
limitations inherent with confocal microscopy is the rapid decrease of signal-to-noise ratio with increasing 
penetration depth. Modifying the microscope with a longer wavelength laser may reduce scattering and 
allow viewing of the MG structures.6   
A comparison between the K5M and the older Keratograph 4 (OCULUS, Wetzlar, Germany) in Chapter 4 
showed that the two devices exhibited a low level of agreement and should not be interchanged. The two 
devices differed in field of view and image contrast outputs, which generated two very different images for 
interpretation. Examining the repeatability of the 4-point scale yielded an agreement rate of 76%, which 
was far above the 37% suggested by Bailey et al.7 for effective clinical grading. In addition, the observers 
graded within -1 to +1 grade units between and against themselves 95% of the time, which suggested that 
repeatability of the scale could be improved. After splitting the 4-point scale into half units, yielding a 7-
point scale, the agreement rate decreased from 76% to 64%, and the concordance correlation coefficient 
increased from 0.78 to 0.92. Although this scale was slightly more repeatable, it was still not considered 
sensitive enough to detect small MG dropout changes. In this chapter, none of the eyelid margin features 
correlated with MG dropout.   
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In Chapter 5, a study controlling for age in a female cohort found that only corneal staining, MG quality, 
number of obstructed MGs, and tear stability were significantly associated with symptoms of dry eye 
disease. The proposed mechanism involved is that the reduction in MG function resulted in a decrease in 
tear film stability,8 which in turn exposed the ocular surface to repeated desiccation. The constant 
desiccation caused ocular staining9 and symptoms of dry eye (DE).10 This mechanism suggested that 
perhaps MG dysfunction (MGD) was associated with discomfort in the symptomatic group. An interesting 
observation is that even after controlling for the two major risk factors of age and sex, DE can still be clearly 
observed in the symptomatic group. Without a complete and entire medical and case history, it was difficult 
to determine what the exact cause of their MGD was. 
Using heat to treat MGD is not a novel idea.11 The MGDRx EyeBag (The EyeBag Company Ltd, Halifax, 
UK) is similar in concept to the warm towel compress that has been advocated for many years, however 
the difference is that the EyeBag can retain heat for a longer period of time.12 In Chapter 6, the MGDRx 
EyeBag was not found to have a significant effect on tear film stability and MG function, but did 
significantly improve long and short term symptoms. It is possible that there was a placebo effect, and that 
cannot be ruled out without enrolling an extra study arm. In an additional in vitro study, the EyeBags were 
heated under the recommended duration and microwave wattage/setting (30 seconds @ 900W, maximum 
power), and found that the maximum temperatures reached was approximately 38ᵒC to 40ᵒC. While this 
was still within the melting range of meibum, it still fell short of the upper melting range of 45ᵒC.13 It is 
possible that the effectiveness of the EyeBag could be improved by heating it for slightly longer than the 
manufacturer suggested time, but further work is required to investigate this.  
Hyperkeratinization of the eyelid margins, leading to stenosis of the MG orifices, is the underlying 
pathophysiology behind obstructive MGD.14 The mechanical removal of the debris on the eyelid margin 
was found to be effective in participants with evaporative DE.15 In Chapter 7, this technique was applied to 
patients with Sjӧgren’s syndrome (SS) and found that it was also effective in relieving DE signs and 
symptoms. This gives clinicians another treatment strategy that can be used to help manage SS DE.  
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Finally, Chapter 8 of the thesis evaluated a combination approach to managing DE. A combination of a 
lubricant eye drop, eyelid hygiene, and omega 3 fatty acids was found to be effective at relieving DE signs 
and symptoms. This combination managed DE in a multi-pronged approach, via lubrication of the ocular 
surface, removal of bacteria (that metabolized tear film components) and reduction in ocular surface toxins, 
and the promotion of anti-inflammation therapy. These products are all commercially available and can be 
readily obtained over-the-counter. However, as there are more products and regimens involved in this 
combination therapy, the cost for therapy will be higher and patients will be required to take more time to 
maintain the therapy. 
Imaging technology (OCT, confocal microscopy) has the potential to play a larger role in the diagnosis and 
management of DE. Being able to visualize the structures primarily involved in the disease process can 
help researchers gain insight into its pathophysiology. Further improving on imaging technology and 
adapting it for clinical use can then allow clinicians to better monitor DE disease or treatment progress. For 
this to happen, the fundamentals and limitations of imaging must be first be understood.  
However, despite the best imaging technology, human interpretation or subjective clinical grading of videos 
and images can be a source of error and variability, resulting in a lack of reliability and repeatability. 
Examining the source of these errors may then help improve or develop grading systems that can accurately 
and precisely describe a feature of DE presentation (e.g. MG atrophy). This in turn, would improve the 
testing and diagnosis for DE disease. Currently, the relationship between symptoms and signs is still not 
understood well. However, by developing better testing methods and technologies, there may be a way to 
help clarify the relationship between symptoms and signs.   
The result of better DE testing would translate to better DE management as well. Smaller variability and 
better reliability would increase confidence in monitoring treatment values. However, due to the 
multifactorial nature of DE disease, it would be unlikely that a single DE test could diagnose and stage DE 
disease alone.  
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Due to its multifactorial etiology, it is also likely that multiple concurrent treatments may be required to 
achieve the best outcomes. Different DE etiologies may co-exist with another, e.g. refractive surgery-
induced DE and MGD both have different etiologies and would require different management strategies. 
The treatments explored in this thesis could be combined together to simultaneously manage multiple 
aspects of DE. The EyeBag could be used in conjunction with lid debridement-scaling to help manage 
MGD, and the combined lubricant drop, lid hygiene, and omega 3 system could be used to help supplement 
the tear film and manage inflammation. The most important aspect of these treatments is that they are easily 
accessible and can be readily used in clinical practice.   
9.2 Future Work 
 
The understanding of DE is constantly evolving, and with the completion of this thesis many more areas 
remain to be explored.  
Meibography and MG imaging technology will likely continue to evolve, but the grading scales will need 
to change to keep up. The grading of MGs with a 4 point scale, or a 7 point scale is still not sensitive enough 
to detect relatively subtle changes in MG structure. The question as to how many units on a scale would be 
suitable should be investigated. A way to increase sensitivity of the scale is to increase the amount of grade 
units on the scale. A researcher may be open to using highly sensitive scales, but they may not be very 
practical in a clinical setting. A clinician may not likely use, for example, a 23-point scale, no matter how 
sensitive it is to grade MG dropout. The trade-off with using scales of increased sensitivity is that it takes 
longer to properly allocate a grade to the clinical feature. Analyzing MG atrophy with imaging processing 
protocols is promising as it removes the subjective nature of grading. However image processing protocols 
usually require a defined set of conditions to function optimally, for example, no reflective spots, and that 
all areas of the eyelid is in focus. Therefore, a development of reliable objective methods will greatly 
enhance the detection of changes in MG structures.  
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A problem that is closely related to this is the numerous grading scales that are currently available for 
grading. For example, there are at least 5 different grading scales for meibum quality,16 and at least 4 
different grading scales for corneal grading.17 In this thesis, a number of different grading systems were 
used across different chapters. The reason for this was purely academic in nature, and was intended to be 
an exercise in learning where experience in using different grading scales could be obtained. While there is 
currently no consensus or any evidence suggesting a single grading scale that is superior to all others, the 
multitude of grading scales may cause several problems. Firstly, clinicians may be overwhelmed when they 
try to find a grading scale to use. Some grading scales call for digital pressure to express the MGs, while 
others require standardized pressure. There are scales that may be clinically unintuitive (e.g. Korb & 
Blackie grading scale increases as clinical presentation improves, whereas Mathers et al. decreases), which 
can make it difficult to adopt. Secondly, the multitude of scales make it difficult to compare results against 
other clinical studies. Therefore, a possible direction for future work could be to establish a standard for 
DE testing and grading.  
As discussed in Chapter 4, one of the biggest challenges facing MG imaging is that the eversion of the 
eyelids is not standardized. If the angle of the everted eyelids is not parallel to the imaging plane, MGs can 
be made to appear or disappear.  Developing an eyelid eversion standard will greatly aid clinical grading, 
but may be difficult to accomplish since eyelids come in many different shapes and forms. There are also 
no studies that have observed the natural history of MG atrophy in humans. This is an important point to 
consider where a participant may present with truncated MGs. It is impossible, without observing over time, 
to know whether this person was born naturally with short MGs, or had developed MG atrophy. Therefore, 
it is technically incorrect to use the term “MG atrophy” to describe areas without glands, without having 
observed them first.  
The current focus of DE management is not to cure the condition, but rather serve to relieve symptoms of 
discomfort. With increasing age, the downregulation and senescence of lacrimal structures18 and associated 
glands make DE almost an inevitability. There will continue to be iterations of lubricant drops and various 
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forms of eyelid warming devices, as they remain a mainstay for treatment, and future work to assess their 
treatment efficacies will be required. Perhaps a different management approach that should be considered 
is the prevention of DE. It would be valuable to know if there are measures that can be taken to delay, or 
even prevent, the onset of DE. An example is to determine if conducting regular eyelid hygiene will exhibit 
any protective effect against developing DE, or if long-term anti-inflammatory supplements are protective 
against tissue aging. However, these studies will be costly, as it can take several years and hundreds of 
participants to find any effects, but the results may be extremely valuable and can potentially shift the focus 
of DE management.   
One management aspect that this thesis did not consider, but is vital for future work, relates to 
environmental stressors (e.g. reduced humidity, pollutants). Environmental factors play a major 
contributory role to DE disease and are considered to be an important aspect in DE management. Some 
patients report their symptoms disappearing during the summer months,19 or as they travel to tropical or 
temperate climates. As a corollary, it could be possible that some DE treatments have reduced efficacy 
because they could not overcome the stresses of the environment. Future work should assess the 
environmental impact on DE treatment efficacy. There could also be studies to determine if there are certain 
substances in the air that are beneficial to reducing DE symptoms. Since DE was shown to impact workplace 
productivity,20 it would be in the employers’ interest to understand the atmospheric conditions in an office 
environment to minimize symptoms of DE and minimize productivity loss. This work can potentially have 
an impact on how workplace policies are developed.  
The use of alternative medicine is becoming increasingly popular, as patients wish to be more actively 
involved in maintaining their health.21 Some studies have demonstrated the effectiveness of acupuncture22,23 
and abdominal breathing exercises as methods to stimulate tear production.24 Although alternative medicine 
is still controversial,25 it would be amiss to discount this concept completely without critically studying 
their influence on symptoms and signs of DE. Future work in this area may see clinical trials that study the 
effectiveness of combined conventional and alternative therapies for the management of DE.  
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Appendices 
 
Appendices from Imaging Meibomian Glands using Optical Coherence Tomography and 
Confocal Microscopy 
 
Appendix 1: 
Experimental spectral domain OCT specifications:   
Spectral domain OCT with ~6μm axial resolution (bandwidth 50nm centered around 840nm) 
Ultra-long scan depth ~7.2mm 
High speed 24k A-line per second  
Width scan = up to 18mm in 3D 
Computer controlled fixation target 
Autofocusing colour camera viewing system with low illumination 
X-Y alignment for scan positioning 
Compact power supply for galvanometer 
Manual adjustment of focal plane 
All-in-one OCT software  
 
The settings used to capture the meibomian glands were:  
Integration time 72 
Line # 12000 
Scan orientation X-scan 
Y-ON YES 
Nominal scan width 4.96 
Nominal scan height 4.93 
Scan type 3D 
Focal plane at 1.0 
Scan pattern 2048 32 x 4mm 
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Appendix 2: 
Specifications for the HRT3/RCM37 
Focus range Max 1500μm 
Image size 400 μm x 400 μm 
Resolution (transversal) ~1 μm/ pixel 
Digital image size  384 x 384 pixels 
Microscope lens 63x 
Light source 670 nm wavelength 
Image acquisition time 0.024 sec per 2D image 
CCD camera image 640 x 480 pixels 
Acquisition modes Section, volume (40 images over 80 μm depth), movie sequence 
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Appendices from Repeatability of Grading Meibomian Gland Dropout using Two 
Infrared Systems 
 
Appendix 1: Summary of clinical tests and grading scales  
 
Clinical tests Grading scale 
Corneal Staining 
 
 
 
 
C NT
S
I  
 
Type: 0 – 100  
0: no staining 
25: micropunctate 
50: macropunctate 
75: coalescence 
100: patch 
 
Extent: 0 – 100 
Number represents total area of staining in that zone (S = superior, T = temporal, N = nasal, I = inferior) 
 
Depth: 0 – 4 
0: none 
1: epithelial 
2: stromal (delayed) 
3: stromal (confined) 
4: stromal (diffuse) 
 
Zone score = Type*Extent*Depth 
Total score = sum of zone score in each zone 
Telangiectasia 0: none 
1: one single telangiectasia 
2: 2-5 telangiectasia 
3: >5 telangiectasia 
4: entire lid involvement 
MG orifice obstruction 
using digital expression 
of ~1.5g over the 
inferior central 8 
orifices 
0: no orifices contain turbid secretions 
1: less than 1/3 of orifices, but at least one contain turbid secretions 
2: between 1/3 and 2/3 of orifices contain turbid secretions 
3: more than 2/3 of orifices contain turbid secretions 
4: all orifices plugged with turbid secretions 
Vascularity 0: none 
1: minimal 
2: mild 
3: moderate 
4: severe 
Lash loss 0: none 
1: minimal 
2: mild 
3: moderate 
4: severe 
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Appendix 2: Raw grading scores for both observers on both days 
 
Image Number 
Day 1 
 
Day 2 
Observer 1 Observer 2 Observer 1 Observer 2 
1 2 2  1 0 
2 0 1  1 2 
3 1 1  1 1 
4 0 0  0 0 
5 0 1  0 0 
6 0 1  0 1 
7 0 1  1 1 
8 1 2  2 2 
9 0 0  0 0 
10 3 2  3 2 
11 2 3  0 0 
12 1 1  2 1 
13 1 2  1 2 
14 0 0  1 1 
15 0 0  1 1 
16 1 0  0 0 
17 0 0  0 0 
18 0 1  1 1 
19 0 0  0 0 
20 1 1  2 0 
21 0 0  0 0 
22 1 1  1 1 
23 1 2  1 1 
24 1 0  0 0 
25 0 1  0 0 
26 1 0  0 0 
27 1 1  0 1 
28 1 0  1 1 
29 1 0  1 1 
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30 3 3  3 3 
31 1 1  0 0 
32 1 2  1 1 
33 0 1  1 1 
34 1 1  1 1 
35 3 3  3 3 
36 1 1  1 1 
37 2 1  1 1 
38 0 0  0 0 
39 2 2  1 2 
40 0 0  0 0 
41 0 0  0 0 
42 0 0  1 2 
43 0 0  0 0 
44 0 0  0 0 
45 0 0  0 0 
46 0 0  0 0 
47 1 1  1 0 
48 0 0  1 1 
49 1 0  1 0 
50 3 2  3 2 
51 1 1  1 1 
52 1 0  1 1 
53 0 0  0 0 
54 0 0  0 0 
55 0 0  0 0 
56 1 0  1 0 
57 1 1  1 1 
58 0 0  0 0 
59 1 1  1 1 
60 1 0  0 0 
61 0 0  0 0 
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62 0 0  0 0 
63 1 0  1 0 
64 0 0  0 0 
65 0 0  1 0 
66 0 0  0 0 
67 1 1  1 0 
68 0 0  0 0 
69 0 0  0 0 
70 3 3  3 3 
71 1 1  0 0 
72 0 0  0 0 
73 1 2  1 2 
74 0 0  0 0 
75 1 1  1 1 
76 0 0  0 0 
77 2 2  2 1 
78 1 2  0 0 
79 2 2  2 2 
80 0 0  0 0 
81 1 1  1 2 
82 1 1  0 0 
83 1 1  1 1 
84 0 0  1 0 
85 0 1  0 0 
86 0 0  1 0 
87 1 0  1 1 
88 1 1  2 1 
89 0 0  0 0 
90 3 3  3 3 
91 1 0  0 0 
92 1 0  1 1 
93 2 2  1 0 
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94 0 0  0 0 
95 0 1  0 0 
96 0 0  0 0 
97 0 1  0 1 
98 1 1  1 0 
99 1 0  1 1 
100 0 0  0 0 
101 0 0  0 0 
102 0 0  0 0 
103 2 1  2 1 
104 0 0  1 0 
105 1 1  2 1 
106 0 1  0 0 
107 1 0  1 0 
108 0 0  0 0 
109 2 1  1 1 
110 3 3  3 3 
111 1 0  1 0 
112 1 1  1 1 
113 1 1  1 1 
114 1 1  1 1 
115 3 3  3 3 
116 1 1  1 1 
117 1 1  0 1 
118 0 0  0 0 
119 1 2  1 1 
120 1 0  0 0 
121 1 0  1 0 
122 2 2  2 2 
123 0 0  0 0 
124 0 0  0 0 
125 0 0  0 0 
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126 0 0  0 0 
127 1 1  1 1 
128 2 1  1 1 
129 0 0  1 0 
130 3 2  2 2 
131 1 1  1 1 
132 1 1  1 1 
133 0 0  0 0 
134 0 0  0 0 
135 0 0  0 0 
136 0 0  1 0 
137 1 1  1 1 
138 1 1  0 0 
139 1 0  1 1 
140 1 1  1 0 
141 1 0  1 1 
142 0 0  0 0 
143 1 0  1 0 
144 1 1  1 0 
145 0 0  0 0 
146 1 1  1 1 
147 0 0  0 0 
148 0 0  0 0 
149 0 0  0 0 
150 3 3  3 3 
151 1 1  0 0 
152 1 0  0 0 
153 2 1  1 1 
154 0 0  0 0 
155 1 1  1 1 
156 0 0  0 0 
157 2 1  2 1 
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158 1 1  0 0 
159 2 2  2 2 
160 0 0  0 0 
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Appendices from A Comparison of Dry Eye Diagnostic Tests between Symptomatic and 
Asymptomatic Age-Matched Females 
 
Table A1: Meibum quality grading scale 
Grade Meibum quality 
0 Normal, clear, may have a few particles 
1 Opaque with normal viscosity 
2 Opaque with increased viscosity 
3 Severe thickening (toothpaste) 
 
Table A2: Eyelid margin score derivation 
Eyelid Margin Feature Grade 
Erythema 
(0 = none, 1 = minimal, 2 = mild, 3 = moderate, 4=severe) 0     1     2     3    4 
Lash Loss 
(0 = none, 1 = minimal, 2 = mild, 3 = moderate, 4= severe) 0     1     2     3    4 
Edema of lid margin 
(0 = absent, 1 = present) 0     1 
Lid Margin Telangiectasia 
(0 = none; 1 = single telangiectasia; 2 = 2 to 5 telangiectasia; 3 = > 5 telangiectasia; 4=severe-entire lid 
involvement) 
0     1     2     3    4 
Table A3: Line of Marx grading scale 
Grade Clinical feature of the Line of Marx 
0 Mostly (>75%) posterior to the orifices 
1 Mostly bisecting the orifices 
1 Mixed posterior and bisecting the orifices 
2 Mostly anterior 
2 Mixed posterior, bisecting and anterior to the orifices 
2 Mixed bisecting and anterior to the orifices 
 
Table A4: Lid wiper epitheliopathy grading scale 
Horizontal length of staining Grade Sagittal width of staining Grade 
<2mm 0 <25% of the width of wiper 0 
2-4mm 1 25% - <50% width of wiper 1 
5-9mm 2 50% - <75% width of wiper 2 
>10mm 3 ≥ 75% of the width of wiper 3 
Fluorescein Grade = (Horizontal + Sagittal) / 2 
Lissamine Green Grade = (Horizontal + Sagittal) / 2 
Final LWE Grade = (Fluorescein Grade + Lissamine Green Grade) / 2 
Table A5: Meibomian gland dropout grading scale 
Grade Meibomian gland dropout 
0 No dropout 
1 Between 0 to 1/3 of the lid 
2 1/3 to 2/3 of the entire lid 
3 More than 2/3 of the entire lid 
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Table A6: Means and standard deviations for the symptomatic and asymptomatic groups for future 
sample size determination.  
 Symptomatic Group Asymptomatic Group 
Age 59.4 ± 8.5 59.8 ± 8.7 
OSDI (0-100) 40.0 ± 20.4 3.6 ± 4.0 
Visual Acuity (logMAR) 0.02 ± 0.10 0.03 ± 0.11 
Ocular staining (0-12) 5.2 ± 2.1 1.1 ± 1.8 
Meibum quality (0-3) 2.8 ± 0.4 2.2 ± 0.7 
Number of glands obstructed (0-8) 6.6 ± 1.8 4.2 ± 2.6 
NIBUT (seconds) 2.4 ± 1.3 3.9 ± 2.3 
Eyelid margin score (0-13) 6.8 ± 2.3 7.2 ± 2.7 
Meiboscore (0-6) 2.5 ± 1.8 1.7 ± 0.9 
Lid wiper epitheliopathy (0-3) 0.52 ± 0.81 0.42 ± 0.85 
Marx’s line placement (0-2) 0.85 ± 0.88 0.40 ± 0.68 
Schirmer’s Test (0-30) 11.5 ± 8.5 11.9 ± 11.0 
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Appendices from The Effect of an Eyelid Warming Device on Meibomian Gland 
Dysfunction 
 
Temperature curve of the EyeBag after heating 
An EyeBag was heated in 900W microwave (RCA, USA) for 30 seconds according to manufacturer 
instructions.32 After removal from the microwave, the EyeBag was lightly shaken to evenly distribute the 
heated seeds. The silver side (silk) was set down flat against a wooden surface and centered on top of a HH-
20A series digital thermometer probe (Omega Engineering, Stamford, Connecticut, USA). The temperature 
of the EyeBag was recorded every 5 seconds for the first 5 minutes and every 30 seconds for the subsequent 
5 minutes, for a total duration of 10 minutes. This was repeated two more times and the mean temperature 
for each time point was recorded. This procedure was repeated with another 2 separate EyeBags 
subsequently (within 5 minutes).  
After removal from the microwave, the temperatures of the EyeBags continued to slowly climb. The peak 
temperature of each EyeBag occurred at approximately 3 minutes before slowly decaying over the course 
of 10 minutes. The maximum for EyeBag 1, 2 and 3 was 38.7°C @ 4:35 mins, 40.4°C @ 2:45 mins, and 
39.2°C @ 3:25 mins, respectively. Mean temperatures for EyeBag 1, 2, and 3 at the end of the 10 minute 
period was 38.2°C, 38.9°C, and 38.2°C respectively.  
A two-way ANOVA with post-hoc Tukey’s multiple comparison test was used to determine the statistical 
significance of the difference between the EyeBags at different time points.  
Prior to microwaving (t = Pre), there was no significant difference between all 3 EyeBags. However, 
EyeBag 1 and EyeBag 2 were significantly different between t = 5s and t = 80s inclusive, with maximum 
difference of 3.3°C occurring at the t = 20s mark. EyeBags 2 and 3 were not significantly different from 
each other at all time points. EyeBags 1 and 3 were not significantly different from each other at all time 
points. Figure 6-4 is a temperature-time curve highlighting the temperature retention of each EyeBag.  
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Figure 6-4: Mean temperature-over-time curves of 3 different EyeBags. Temperatures continued to 
quickly rise for the first 60s before slowly plateauing and decaying slowly. At the end of the 600s 
duration, the temperature of all EyeBags were at least 38.1°C. EyeBag 3 was not significantly different 
than EyeBags 1 or 2 at all time-points. EyeBag 1 and 2 was significantly different only between t=5s and 
t=80s. 
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Appendices from The Relief of Dry Eye Signs and Symptoms Using a Combination of 
Lubricants, Lid Hygiene, and Ocular Nutraceuticals 
 
Table A.1: Product information sheet (all Advanced Vision Research, Inc.) 
Products TheraTears® Lubricant Eye Drop (15mL) 
TheraTears® Nutrition (90 
pack) 
TheraTears® SteriLid Eyelid Cleanser 
(48mL) 
Dosage Ophthalmic, 1 or 2 drops, prn Oral, 3 capsules QD Ophthalmic, 1 or 2 application OU, QD 
Active Ingredients 
0.25% sodium carboxymethylcellulose 
 
1 serving = 3 softgels 
Per serving:  
Omega-3 fatty acids: 
   EPA 450mg 
   DHA 300mg 
Flaxseed Oil (organic): 1000mg 
N/A 
Inactive Ingredients 
Sodium chloride, potassium chloride, 
sodium bicarbonate, calcium chloride, 
magnesium chloride, sodium phosphate, 
borate buffers, Dequest and purified 
water; sodium perborate 
Gelatin, glycerin USP, Vitamin E 
(in soybean oil), purified water 
USP 
Water, PEG 80, Sorbitan Laurate, Sodium 
Trideceth Sulfate, Cocamidopropyl Betaine, 
Sodium Lauroamphoacetate, PEG 150 
Distearate, Sodium Laureth 13 Carboxylate, 
Linalool Oil, Hepes Acetate, Sodium 
Perborate Monohydrate, Panthenol, Allantoin 
(Comfrey Root), Sodium Chloride, Tea Tree 
(Melaleuca Alternifolia) Oil, Tris EDTA, 
Boric Acid, Cocamidopropyl PG Dimonium 
Chloride, Etridronic Acid, Citric Acid for pH 
adjustment, Sodium Hydroxide for pH 
adjustment 
Preservative Sodium perborate None Sodium Perborate , EDTA 
 
Table A.2: Components of the eyelid margin score 
Eyelid Margin Feature Grade 
Erythema 
(0 = none, 1 = minimal, 2 = mild, 3 = moderate, 4=severe) 
0     1     2     3    
4 
Lash Loss 
(0 = none, 1 = minimal, 2 = mild, 3 = moderate, 4= severe) 
0     1     2     3    
4 
Edema of lid margin 
(0 = absent, 1 = present) 0     1 
Lid Margin Telangiectasia 
(0 = none; 1 = single telangiectasia; 2 = 2 to 5 telangiectasia; 3 = > 5 telangiectasia; 4=severe-entire lid involvement) 0     1     2     3    4 
 
Table A.3: Grading components for LWE 
Horizontal length of staining Grade Sagittal width of staining Grade 
<2mm 0 <25% of the width of wiper 0 
2-4mm 1 25% - <50% width of wiper 1 
5-9mm 2 50% - <75% width of wiper 2 
>10mm 3 ≥ 75% of the width of wiper 3 
Fluorescein Grade = (Horizontal + Sagittal) / 2 
Lissamine Green Grade = (Horizontal + Sagittal) / 2 
Final LWE Grade = (Fluorescein Grade + Lissamine Green Grade) / 2 
